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Methotrexate (MTX) was covalently linked to human serum albumin using the 
water soluble carbodiimide reagent l-ethyl-S-CS’-dimethylaminopropyl) 
carbodiimide (ECDI) and also using the N-hydroxysuccinimide active ester 
of MTX, molar conjugation ratios of up to 26 being achieved. MTX was also 
linked (via ECDI) to a poly (L-lysine-L-glutamic acid) copolymer which was 
synthesised by the copolymerisation of the N-carboxyanhydrides of 
carbobenzoxy-lysine and benzyl-glutamate using diethylamine as initiator. 
The molecular weight of the polymer was determined from viscosity 
measurements on the protected copolymer and confirmed by fast protein 
liquid chromatography (FPLC) of the deprotected copolymer. The high 
molecular weight conjugates of.MTX were isolated by Sephadex gel 
filtration chromatography. The in vitro stability of MTX-carrier (HSA or 
copolymer) conjugates in buffer (pH7.4 and 5.6) was determined in the 
presence and absence of enzymes (trypsin and tritosomes) at 37°C. The 
release of free MTX was monitored using an FPLC column (Superose 12 or TSK 
G3000 PWxl) which was also used to determine the molecular weight 
distributions of the samples (by analysis of the output from a UV detector 
using a BBC Master series microcomputer). The stability experiments 
showed that at pH7.4 up to 5% free drug was released from MTX-HSA 
conjugates over a 24 hour period. The MTX-copolymer conjugates were shown 
to be stable-under the same conditions. Incubation with enzymes had 
little effect on the release of free MTX. The presence of drug conjugated 
to the carrier did not prevent the enzymatic degradation of the carrier 
unless drug loading was extremely high. It was found that both enzyme 
systems brought about a reduction in the molecular weight of MTX-HSA 
conjugates into a series of identifiable fractions. Trypsin was found to
have a higher activity at pH7.4 and resulted in an increase in the 
polydispersity index of the drug-carrier conjugate with fragments at high, 
intermediate and low molecular weight. The tritosomes, which were more 
active at the lower pH and were dependent on the presence of reduced 
glutathione, caused a large increase in polydispersity with material being 
either high or low molecular weight (ie MTX-oligopeptides). The 
MTX-L-copolymer conjugates were degraded to lower molecular weight 
derivatives of MTX in a similar manner to MTX-HSA systems however the 
molecular weight distribution of MTX-D-copolymer conjugates was unaffected 
by either enzyme system.
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Origins and scope of this study
HSA has previously been investigated as a carrier system for M TX  and 
has been shown to be cytotoxic to L1210 tumour cells in vitro and in 
vivo (Chu and Whiteley, 1979). Combination of such conjugates with a 
monoclonal antibody also demonstrated selective toxicity against in vitro cell 
lines (Garnett et al, 1983). M TX covalently linked to polyamino acids
(mainly poly-L-lysine) has also been examined as a potential carrier system 
since it has the ability to enhance drug uptake (Shen & Ryser, 1979). The 
potential of such a system is limited due to the cationic nature of the 
polymer which results in indiscriminate cellular binding.
It was the purpose of this study to investigate the factors affecting the 
covalent linking of M TX  to HSA and to monitor the solution stability of 
the conjugates so formed. It was thought important to quantify the release 
of free M T X  since this would affect the in vitro cytotoxicity and conse­
quently any results which have been attributed to the conjugate alone (Chu 
and Whiteley, 1979, Garnett et al, 1983).
Copolymers (of L-lysine- and L-glutamic acid) were synthesised for evalu­
ation as carriers since it was proposed that the net charge on the mol­
ecule would be less than for either homopolymer. The polymer should also 
provide a larger number of sites for linkage of M TX than HSA, in a
lower molecular weight molecule. The presence of both amine and carboxyl 
groups may also provide possible sites for linkage of different types of 
cytotoxic drugs.
The effect of enzymes (ie trypsin and tritosomes) on the release of free 
M TX from the conjugates was assessed along with the breakdown of the
macromolecule into different molecular weight fractions. This was in order 
to discover whether the M TX  would be released in the free form or as 
oligopeptide derivatives.
The in vitro release (in buffer pH7.4 and 5.6) of the drug was deter­
mined using Fast Protein Liquid Chromatography. The data from the U V  
detector was also captured by an Acorn BBC Master series 
microcomputer/Winchester disk and a programme to determine the
molecular weight distributions of the samples following incubation in the 
presence and absence of enzymes.
CHAPTER ONE: INTRODUCTION
1.1 Introduction to site-specific delivery of drugs
The entry of small molecules into a cell may be either by passive 
diffusion or active transport. In the case of cancer chemotherapy the 
cytotoxic drugs can circulate in the blood stream and may be taken up by 
normal and cancerous cells alike, leading to the occurrence of side effects.
The biodistribution and cellular uptake of drugs can be modified by 
increasing their molecular dimensions (eg by incorporation into liposomes 
(Gregoriadis et al, 1982)), incorporation into or linking to particulate 
carriers (eg albumin microspheres (Widder et al, 1981) or cyanoacrylate 
nanoparticles (Couvreur et al, 1980)) or by linking to soluble 
macromolecules. The increase in size restricts cellular uptake to 
pinocytosis (fluid phase or adsorptive) or phagocytosis, in the case of 
the particulate material. Particles over 50nm in diameter are unable to 
leave the vascular system except in organs such as the liver and spleen 
where the blood capillaries have a discontinuous lining of endothelial 
cells. The majority of particulate matter is phagocytosed by the fixed 
macrophages of the reticulo-endothelial system (RES), notably the Kupffer 
cells of the liver. The uptake of such particles is affected by their 
size and surface properties, consequently their fate can be influenced to 
some extent by the adsorption of proteins, sugars or surfactants. In the 
case of soluble carrier systems the macromolecules need to be sufficiently 
large to avoid glomerular filtration (MW c.30,000) but small enough to 
escape from the vascular system ie IgG (MW = 160,000) is extravasated but 
it is unlikely that IgM (MW = 900,000) leaves the circulation (Taylor and 
Granger, 1984).
2Passive targeting (ie linking of a drug to a carrier) may be sufficient to 
increase the therapeutic index alone eg diseases of the macrophage system 
or RES. However active targeting may be necessary to achieve delivery to 
other groups of cells. This approach requires the incorporation of a more 
specific site directing agent which is recognised by cell surface 
receptors (with subsequent rapid uptake by receptor mediated pinocytosis) 
or that attach to cell membrane components (followed by uptake by 
adsorptive pinocytosis). The use of antibodies may be of particular 
importance since they exhibit exquisite specificity and can be raised 
against specific cell surface antigens.
The simplest site specific drug delivery system would thus comprise drug 
linked to an antibody however it has been shown that only a limited number 
of drug molecules can be combined without loss of antibody specificity 
(Ghose and Blair, 1978).
The use of a carrier system is thus implicated to increase the drug 
loading per antibody in order to achieve a therapeutic level 
intracellularly. The delivery system should be as small as possible to 
facilitate extravasation with a high drug loading (avoiding insolubility 
problems).
1.2 Cellular internalisation and fate of macromolecules
The term lysosomotropic agents was adopted by de Duve (de Duve et al,
1974) to describe substances that were selectively taken up into the 
lysosomes, it was further proposed that the phenomenon could also find 
application in the area of drug delivery. The lysosomes themselves are
3cell organelles which are present in all eukaryotic cells; they are
polymorphic in nature (in terms of size, shape and internal structure) and
comprise a variety of acid hydrolases encapsulated in a lipoprotein
membrane (de Duve, 1983). The lysosomal enzymes number in excess of 50
and comprise proteases, nucleases, glycosidases, aryl sulphatases,
lipases, phospholipases and phosphatases (Barrett, 1972). The enzymes
generally have acidic pH optima and are held within the acidic milieu of
the lysosome (pH4 to 5), where they are capable of dismantling a wide
variety of complex materials (mostly naturally occurring macromolecules 
eg. proteins and polypeptides). The integrity of the membrane is
important since it prevents cellular autolysis by the powerful enzymes
although the dilution effect coupled with the elevated pH of the cytosol
would render them less active. Weak bases (eg dyes and chloroquin) are
examples of lysosomotropic (or acidotropic) agents which become trapped
within the lysosomes by the pH-partition effect whereby protonation of the
base renders it incapable of crossing the cell membrane. A further
example is the surfactant Triton WR1339 which also accumulates in the
lysosome, a phenomenon which is employed in order to isolate modified
lysosomes since it reduces their density (Trouet, 1974).
The entry of substances into the cell may be either by permeation or 
endocytosis. In the former case molecules (depending on their molecular 
size and charge) enter the cell by random diffusion unless an active 
transport mechanism exists (eg. folate transporter).
Endocytosis is the process of internalisation of formerly extracellular 
material brought about by the invagination of the plasma membrane followed
4by the formation of a bound vesicle containing extracellular fluid. The 
term encompasses both phagocytosis and pinocytosis. Phagocytosis occurs 
in specialised phagocytic cells eg macrophages. This is the uptake of 
particulate matter (generally > lum in diameter, eg latex beads) and is 
triggered by the interaction between the particle and the plasma membrane 
causing the particle to be engulfed.
Pinocytosis occurs in nearly all cells and may be fluid phase or 
adsorptive in nature, the latter may be further subdivided into selective 
and non-selective mechanisms. Fluid phase pinocytosis is the entrainment 
of solutes (or small particulates up to 50nm in diameter) within fluid 
droplets when the membrane vacuolises to form a pinosome. In the case of 
adsorptive pinocytosis the substrate (eg macromolecules) binds to the 
plasma membrane and is internalised with the pinosome (Lloyd and Williams, 
1984) this results in an increased rate of uptake over the fluid phase 
mediated process (Duncan et al 1984).
Some molecules have specific cell surface receptors and enter the cell via 
receptor mediated (selective) pinocytosis whereby the ligand eg. low 
density lipoprotein, hormones (EGF) or plasma transport proteins 
(trans-cobalamin) occupies a receptor resulting in internalisation of the 
receptor-ligand complex (Figure 1.1). The receptors (transmembrane 
proteins) when occupied by ligands tend to cluster into special membrane 
areas that are invaginated forming coated pits. The clustering process may 
occur by the complex encountering a coated pit whilst randomly diffusing 
through the lipid bilayer (Schlessinger et al, 1978) since the coated pits 
occupy about 2X of the cell surface. The main component of the coating of 
the coated pit is the protein clathrin (Pearse, 1976) which is composed of
5a heavy chain (MW = 180,000) and several light chains (MW 20-40,000). 
Clathrin in its purified form is a three-armed trimer of three heavy and 
three light chains called a triskelion. These units have the ability to 
polymerise and form a cage like structure which may cause the pit to 
expand and pinch off from the membrane (Crowther and Pearse, 1981). It is 
thus possible that all pinosomes are formed from coated pits.
The invaginations eventually form discrete coated vesicles which rapidly 
lose their clathrin coat (15-60 seconds) (Helenius et al, 1983) and may 
fuse to form larger vesicles (endosomes) (Brown et al, 1983). The pH 
within the endosome has been shown, using fluorescein labelled 
ot-2-macroglobulin, to be acidic with the pH dropping to 5-6 after about 
15-20 mins (Tycko and Maxfield, 1982). The drop in pH causes the 
receptor-ligand complex to separate with the receptors tending to 
accumulate in a tubular extension, which has a high surface to volume 
ratio, from the vesicle (called the CURL; compartment of uncoupling of 
receptor and ligand). It is proposed that the tubular portion then splits 
off and returns to the plasma membrane whilst the vesicular portion may 
either fuse with a lysosome forming a secondary lysosome or possibly be 
exocytosed. Evidence for the recycling of receptors has been supplied by 
the fact that ligand internalisation continued for several hours after 
receptor synthesis had been blocked; also raising the endosomal pH with 
NH4CI (brought about a depletion of surface receptors (Goldstein and 
Brown, 1974). In some cases ligand binding initiates clustering (eg EGF) _ 
and in others ie LDL the coated pits/LDL receptors are continuously being 
recycled (Anderson et al, 1982). It is likely that much of the plasma 
membrane is recycled along with the receptors since it has been calculated 
that endocytosis accounts for up to 200% of the cell surface per hour.
6Figure 1.1 Diagram of receptor-mediated pinocytosis and subsequent 
fate of low density lipoprotein
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7The reduced pH within cellular organelles ie. endosomes and lysosomes is 
thought to be due to an active proton pump as opposed to the buffer 
capacity of the vesicular fluid and it has been shown that the pH lowering 
capacity is dependant on the presence of ATP (Harikumar and Reeves, 1984). 
The acidity within the endosome/lysosome is necessary to achieve 
receptor-1igand decoupling and also for some of the enzymes to be active 
but may also cause accumulation of certain substances eg weak bases as 
previously mentioned. In the case of transferrin there is a rapid drop to 
pH 6 followed by a slow decrease to pH 5. The endosomal pH increases 
during recycling (Corley Cain et al, 1989).
The lysosomal membrane is impermeable to macromolecules hence accumulation 
could occur if the molecule cannot be degraded by the enzymes. If the 
macromolecule is degraded (as is likely in the case of peptides) then only 
low molecular weight molecules, eg. amino acids and dipeptides, can cross 
the membrane either by diffusion or possibly an active carrier (Forster 
and Lloyd, 1988). The degradation products may thus accumulate in the 
secondary lysosome, be released into the cytosol or be exocyt'osed.
It is also proposed that the Golgi apparatus may play a part in the 
cellular movement of endosomes and lysosomes (Pastan and Willinghamf 
1983). It is postulated following studies on transferrin and 
alpha-2-macroglobulin, that the receptosomes may fuse with elements of the 
sorting system eg. the trans-reticular elements of the Golgi system which 
rapidly transfers ligands into lysosomes (Goldenthal et al, 1988).
81.3 Macromolecular carriers for site-specific delivery of drugs 
1.3.1. Introduction
The use of many antineoplastic agents has been restricted by their lack of 
ability to discriminate between normal and transformed proliferating 
cells. In an attempt to acquire some site specificity many workers have 
used carrier molecules to transport drugs to target tissues. An effective 
system has the potential to dramatically improve cancer chemotherapy since 
one of the most serious problems with such therapy is the occurrence of 
toxic side effects (Arnold et al, 1983). The requirements of a 
(lysosomotropic) carrier are as follows (de Duve et al, 1974, Ghose and 
Blair, 1978):
i) the binding of the drug to the carrier must be unaffected by 
body fluids but be reversible by lysosomal enzymes yielding an 
active compound. —
ii) the conjugate must exhibit specificity for the target site and 
reach it in vivo.
iii) the conjugate must be internalised by the cell (charge,
molecular size and functional groups present may be important 
to stimulate pinocytosis).
iv) the carrier should be non-toxic (although preferential toxicity 
for the target site may be beneficial).
9v) the conjugate must lack immunogenicity and must not exhibit 
non-specific binding to molecules of the immune system (the 
formation of immune complexes may lead to non-specific uptake 
particularly by the liver and spleen; immunogenic conjugates 
would lead to hypersensitivity reactions on repeated 
administration).
vi) the number of drug molecules per carrier molecule must be high 
enough to achieve cytotoxic concentrations within the target 
cell. —
Several different carriers linked to a variety of compounds have been used 
in vitro and in vivo eg.:
Carrier Drug Reference
Human serum albumin 
Bovine serum albumin 
















Chu and Howell, 1982 
Chu and Whiteley, 1977 
Chu and Whiteley, 1977 
Shen and Ryser, 1979 
Shen and Ryser, 1979 
Fung et al, 1979 
Duncan et al, 1987 
Duncan et al, 1987 
Trouet et al, 1982
(HPMA = N-(2-hydroxypropyl)methacrylamide)
10
In addition to the above carriers the following have also been used: 
hormones (which possess a high degree of specificity for target cells 
(Varga et al, 1977)), lectins (Yamaguchi et al, 1979), liposomes 
(Gregoriadis, 1982) and antibodies (Ghose et al, 1976).
1.3.2 Albumin as a carrier
Chu and Whiteley (1977) proposed that by synthesizing a higher molecular 
weight derivative of MTX, by linking it to bovine serum albumin (BSA) or 
murine serum albumin (MSA), a prodrug could be produced which would retain 
the properties of the carrier summarised below:
i) the conjugate would be retained within the body forming a depot 
of MTX which would be slowly hydrolysed maintaining elevated 
blood levels.
ii) if the conjugate had sufficient molecular weight it may be 
restricted to a body cavity containing a solid tumour.
These authors found that MTX remained covalently bound to the albumin 
carrier in the plasma.
MTX was coupled to BSA, MSA (and dextran) by condensing a terminal 
carboxyl group of the antifolate molecule to reactive €-amino groups in 
lysine residues of the albumins. The reaction was promoted by 
carbodiimide reagents (Mell et al, 1968) and UV analysis was used to 
estimate that an average of 12 moles MTX were linked per mole of albumin.
11
L1210 tumour bearing mice treated with the conjugate were used to 
demonstrate that a higher more prolonged extracellular concentration of 
drug could be achieved when compared to that achieved using free MTX. The 
authors suggested that MTX-albumin conjugates were retained in the serum 
until hydrolysed (90% of free MTX was found to be intracellular). The 
conjugate was found to be superior to free MTX against Lewis Lung 
carcinoma in mice (Chu and Whiteley, 1979).
Chu and Whiteley (1979) showed that MTX was not hydrolysed from a BSA 
carrier at the plasma membrane (evidenced by low serum levels of MTX) 
Radiolabelling experiments showed that hydrolysis occurred within the cell 
and using inhibitors of MTX transport it was shown that carrier-bound drug 
was transported into the cell by a different mechanism to that used by the 
parent compound. From studies using Dextran T70 (which showed no cellular 
binding and low drug binding) the authors suggested that the capacity to 
bind to a membrane surface was one requirement of a carrier and concluded 
that proteins may be useful as carriers for MTX.
The use of HSA as a drug carrier system has been further explored by 
Trouet et al (1982); in this case daunorubicin (DNR) was linked to a 
succinylated derivative of BSA using amino acid spacers ( 0-4 peptides) 
producing molecules of the type shown below:
Album in-NH-CO(CH2 )2-C0-Ala-Leu-Ala-Leu-DNR
The linkage of DNR or one of its derivatives to succinylated BSA was via 
the free amino group on the drug and the succinyl carboxylic acid residue. 
Linkage was achieved using a carbodiimide reagent. Incubation of the
12
conjugates with rat liver tritosomes revealed that in the case of the
tetrapeptide 75% of the bound DNR was released as the free drug after 10
hours. After a similar period only 60% was released from the tripeptide
and only 8% from the dipeptide. When tested against mice which previously
had been injected intraperitoneally with L1210 cells, the chemotherapeutic
effect followed a similar trend to that noted for the DNR release; the
tetrapeptide being the most effective. It was also shown that the
conjugates were less toxic than the free drug. Trouet et al (1982)
concluded that it was necessary to insert a tri- or tetrapeptide 
to enable release of free drug in the lysosomal environment which was
capable of exerting its cytotoxicity. It was proposed that this peptide
spacer could be used to facilitate release of DNR from any suitable
carrier molecule.
1.3.3 Polylysine as a carrier
Polylysine itself has been shown to have cytotoxic properties (Arnold et 
al, 1979) against Hela cells in culture and Ehrlich ascites carcinoma in 
white Swiss mice. The effects were shown to be dependent on both 
molecular weight (increase in MW led to increased cytotoxicity) and dose. 
No antineoplastic activity was evident with L1210 leukaemia in mice. The 
cytotoxicity against the Hela cells probably resulted from direct 
interaction between the cationic polylysine and the overall 
electronegative charge of cell surfaces (Pitha, 1983). The charge arises 
due to glycoproteins present in the plasma membrane and many types of 
malignant cells have been shown to have higher surface negative charge 
than normal cells (Smets, 1980). The cytotoxicity may arise due to an
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increase in the permeability of the membrane due to polycationic 
interaction with electronegative regions causing openings in the lipid 
bilayers as has been shown for erythrocyte membranes (Katchalsky, 1964). 
The in vivo cytotoxicity against Ehrlich ascites carcinoma was probably 
also due to direct interaction between polymer and cell, although the 
possibility exists that the immune response of the animal was stimulated. 
The effects of poly (L-lysine) (PLL) binding to the cells are as follows: 
rapid leakage of small molecules/ions across the cell membrane (Kornguth 
and Stahman, 1961) followed by rapid loss of RNA and DNA resulting in loss 
of protein synthesis leading to cytotoxicity.
Ryser and Hancock (1965) showed that uptake of protein molecules (eg 
albumin) was enhanced by low concentrations of basic polyamino acids. In 
further studies by Ryser (1967) it was found that increasing the molecular 
weight of poly-L-lysine increased the uptake of albumin by S180 cells (200 
fold increase over the range 19,000-1,130,000 Daltons). Poly-D-lysine 
proved to be more effective than poly-L-lysine at promoting uptake. —  
DEAE-Dextran (diethylaminoethyl-dextran), another basic polymer, was also 
shown to increase albumin uptake and it was concluded that attachment of 
a large basic polymer to membrane constituents and the conformational 
changes resulting from this interaction stimulated pinocytosis. Prattca 
et al (1978) and Duncan et al (1979) investigated the stimulation of 
pinocytosis using polyamino acids (of lysine, ornithine and glutamic acid) 
and dextrans using 125I-labelled PVP as a fluid phase marker. The 
adjuvants had little effect on the rate of uptake of radioactivity by 
either rat peritoneal macrophages or the rat yolk visceral sac. Further 
experiments using 198Au(colloidal) and 125I-PVP showed enhanced uptake of 
198Au in the presence of polycations (PLL, poly-D-lysine and
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poly-L-ornithine) by rat macrophages but not by the yolk sac. The 
enhanced uptake was thought to be due to aggregation of the gold and 
increased affinity of the polycation-colloidal gold complex for the 
plasma membrane leading to endocytosis of the complex, although this was 
not the case for all cells. The uptake of 125I-PVP was relatively 
unaffected dismissing the theory that increased pinocytosis can be caused 
by polycations.
Ryser et al (1978) showed that the membrane transport of the enzyme 
horseradish peroxidase was increased by 1000 fold (over 60 minutes in L929 
mouse fibroblasts) by covalently attaching it to PLL (MW 6,700). The fact 
that PLL was an effective transport vector for molecules larger than 
itself led these authors to investigate conjugates with smaller molecules; 
namely MTX (Ryser and Shen, 1978). MTX was linked to PLL (average MW 
70,000) in a carbodiimide-mediated reaction to produce conjugates of 
molar ratios 13:1 (MTX:PLL). The conjugate was shown to be an effective 
toxin against cultured Chinese hamster ovary cells which were 
MTX-resistant due to deficient MTX transport. This suggested a different 
mechanism of cell entry (ie. piggyback endocytosis). The conjugate failed 
to bind to DHFR in vitro: this may have been due to charge density andjiot 
molecular size since polyglutamates still bind DHFR. It has also been 
shown that a MTX/PLL/heparin complex bound to DHFR in vitro (Shen and 
Ryser, 1981a) due to charge reduction by heparin. These data suggested- 
that intracellular hydrolysis must have occurred.after transport of the 
MTX into the cell. If brief trypsin digestion of the MTX-PLL preceded the 
cell culture experiments enhancement was abolished; the same was shown for 
horseradish peroxidase/PLL conjugate (Ryser et al, 1978). These 
experiments supported the view that MTX-PLL entered the cell by adsorptive
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pinocytosis. The fact that intact conjugates were internalised by a route 
other than by the active MTX transporter was confirmed using thiamine 
pyrophosphate which inhibited MTX transport in L1210 cells but had no 
effect on uptake of MTX-PLL (Shen and Ryser, 1981b). Leucovorin however 
protected cells from both MTX and MTX-PLL since it does not affect 
transport mechanisms but alters the intracellular folate pool (Jolivet et 
al, 1983). Intracellular degradation of the internalised MTX-PLL 
conjugate was thought to yield either MTX, MTX-lysyl or MTX oligolysyl 
peptides or a combination thereof (this was inferred due to the lack of 
MTX-PLL DHFR binding in vitro).
MTX coupled to poly-D-lysine (MW 60,000) (Shen and Ryser, 1979) showed no 
inhibitory effect on drug resistant Chinese hamster ovary cells since it 
would not have been broken down by lysosomal enzymes, though 
internalisation presumably occurred at a similar rate to that of MTX-PLL. 
Horseradish peroxidase studies (Ryser et al, 1978) showed that HRP-PLL 
conjugates were present in endosomes.— It seems likely that MTX-PLL 
conjugates follow the same route and are digested within secondary 
lysosomes allowing release of MTX (and possibly lysyl derivatives) into 
the target cell. _
The idea of confining a conjugate to a body compartment was investigated 
using mice containing L1210 tumour treated with MTX-BSA and MTX-PLL (Chu 
and Howell, 1981). Leucovorin was employed to block the toxicity of any 
escaping MTX. MTX-BSA was retained for 48 hours in contrast to MTX-PLL 
which was cleared within 4 hours. This may have be due to the positive 
charge on the PLL at physiological pH and its subsequent affinity for cell 
surfaces, leading to increased cellular uptake and decreased intracavity
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half-life (PLL of MW 40,000-60,000 being cleared more rapidly than PLL of 
MW 3,000). The half-life for MTX was increased by linking to BSA but its 
cellular uptake was poor and blood clearance slow.
Galivan et al (1982) showed, using tritiated MTX, that uptake of MTX-PLL 
was equivalent in both resistant and non-resistant (re. MTX transport) 
hepatoma cells in vitro. MTX-PLL was found to be much more effective at 
inhibiting growth than PLL (MW 35,000) alone (Whiteley et al, 1981) 
whereas the coupling of MTX to poly-D-lysine had no effect on growth. 
Sephadex gel filtration of cell extracts showed that MTX-Poly-D-lysine 
remained conjugated whereas MTX-PLL had been hydrolysed yielding free MTX 
and some higher molecular weight derivatives; either polyglutamates or 
oligolysyl derivatives. DHFR also exhibited radioactivity due to the 
presence of bound 3H-labelled MTX. Leupeptin, an inhibitor of lysosomal 
cathepsins (thiol proteases) in hepatic cells (Seglen et al, 1979), 
prevented the liberation of MTX from PLL indicating that cleavage does in 
fact occur by a lysosomal mechanism. The hydrolysis of MTX-PLL was 
reduced by the addition of NH4CI to (another lysosomal inhibitor (Seglen 
et al, 1979)) to the incubation medium again indicating a lysosomal 
mechanism. Folinic acid (leucovorin).blocked the uptake of MTX but not 
MTX-PLL in H35 non-resistant cells indicating that endocytosis of MTX-PLL 
was the mechanism of its internalisation.
1.3.4 HPMA as a carrier
A model synthetic (biodegradable) macromolecule has been investigated by 
Kopecek and coworkers (1982) based on a non-degradable polymer backbone ie
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N(2-hydroxypropyl)methacrylamide (HPMA). Biodegradability was introduced 
into the system by way of oligopeptides which were used to both cross link 
the polymer chains and also as spacers to incorporate model drugs and 
vectoring agents into the carrier system. The composition (number, type 
and sequence) of these oligopeptides were altered in order to investigate 
the enzymatic degradation of the polymer and release of model drug 
p-nitrophenol. The peptides could be varied to suit enzymes with known 
specificities (eg chymotrypsin and trypsin) and it was found that a 
tetrapeptide spacer (minimum) was necessary to allow maximal cleavage, 
presumably due to steric problems ( and enzyme specificity). The 
tritosomal degradation of a variety of conjugates were also investigated 
(Duncan and Lloyd, 1980) with the result that release of model drug 
occurred; the sequence could thus be tailored either to yield a 
particular release rate or to a particular enzyme within the lysosomes.
The systems were found to be essentially stable in rat plasma/serum 
(Duncan and Lloyd, 1984). It was concluded that this approach could 
enable the mechanism of conjugate action to be discovered and employed to 
improve their efficiency. Cathepsin B was found to be more active against 
a Gly-Phe-Leu-Gly-NAp sequence than cathepsin L or H but not as active as 
total tritosomes (Kopecek, 1984). The cleavage of the cross links in the 
HPMA polymer by tritosomes was investigated (Subr et al, 1986) and 
concluded that the extent of cleavage was dependent on the length and 
composition of the cross linking oligopeptide.
Duncan et al (1979) also demonstrated that the polymers were internalised 
by fluid phase pinocytosis and that the rate of uptake could be increased 
by incorporation of hydrophobic residues or a positive change. The 
oligopeptides were subsequently degraded by lysosomal enzymes (primarily
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the proteases) following internalisation (Duncan and Lloyd, 1981). The 
linkage of HPMA to rat immunoglobulin (IgG) resulted in an increased rate, 
when compared to unmodified HPMA, of pinocytic uptake by the rat visceral 
yolk sac indicating that the antibody could still interact with membrane 
binding sites and had potential as a targeting moiety (Duncan et al, 
1986a). The biodistribution of the delivery system was modified by 
incorporation of galactosamine terminated oligopeptide side chains, this 
resulted in rapid uptake by the liver as compared to the parent 
macromolecule and glucose and mannose terminated conjugates (Duncan et al, 
1983). The blood clearance and liver association of the galactosaminated 
HPMA was found not to increase significantly when the galactosamine 
loading was increased above 4 molX. It was proposed that the HPMA was 
degraded intralysosomally to release low molecular weight material into 
the bulk phase since following injection of radiolabelled HPMA into rats, 
material was detected in isolated liver lysosomes (Duncan et al, 1986b) . 
This effect was thought to be due to the presence of galactose receptors 
on the hepatocyte membranes (Hudgin et al, 1974).
The immunogenicity of the polymers was investigated by determining their 
ability to induce antibody formation in mice (Rihova et al, 1984) the 
polymer itself (HPMA) was non-immunogenic however attachment of the 
oligopeptide side chains provoked a weakly immunogenic reaction.
Daunomycin has been linked to HPMA via a peptide spacer (Gly-Phe-Leu-Gly 
tetrapeptide giving the maximum release rate upon incubation with 
tritosomes) and exhibited reduced toxicity in vitro against leukaemia 
cells when compared to free drug (Duncan et al, 1987). Tn vivo results 
however demonstrated an increased survival time, over the free drug, of
19
mice injected with L1210 cells whilst the conjugate with a non-degradable 
linkage was not significantly different from the untreated controls. This 
would infer that the conjugation resulted in reduced cardiotoxicity 
(Duncan et al, 1988) possibly by altering the pharmacokinetic disposition 
of the drug.
1.3.5 Antibodies as carriers
Antibodies are serum globulins with a wide range of specificities for 
different antigens. The potential use of antibodies as drug carriers for 
site directed therapy was originally suggested by Ehrlich who envisaged 
that.specific antibodies could be produced against antigens.
The specificity of an antibody and its ability to combine with a 
particular antigen is due to the combining site of the Fab portion which 
is a cleft formed in the hypervariable regions of the H and L chains. The 
closer the fit between the combining site and the determinant (a given 
portion) of the antigen, the stronger the binding forces and the higher 
the affinity. Antigen-antibody combining forces are non-covalent (ie Van 
der Waals, electrostatic and hydrophobic interactions) (Roitt, 1980).
The IgG antibodies, and better still their Fab/ or F(ab/)2 portions, have 
the greatest potential due to their low molecular weight (IgG MW is 
approximately 160,000 as opposed to IgM 900,000 (Roitt, 1980) allowing 
extravascular movement) and their abundance. Polyclonal antibodies have 
shown some use as drug carriers (Ghose and Blair, 1978) but they lack 
selectivity. The discovery of tumour-associated cell surface antigens has
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permitted the production of specific antibodies by injection of human 
tumour cells into an animal. Tumour-associated antigens (TAA) arise 
during neoplastic transformation and are not detectable on normal 
untransformed tissue. Examples of TAAs are carcinoembryonic antigen, 
alphafetoprotein, ectopic hormones as well as other embryonic markers and 
non-foetal TAA’s (Ghose and Blair, 1978). Cell surface markers 
(glycoproteins etc) are recognised as foreign and act as antigens leading 
to the production of antibodies. Obtaining an antibody specific for one 
antigen in useable quantities was nearly impossible until 1975 due to 
difficulties in purification and the quantities produced (Obrist, 1983).
Methods for production of monoclonal antibodies (MCA’s) discovered by 
Kohler and Milstein in 1975 has solved this problem by allowing the 
synthesis of potentially unlimited amounts of specific MCA. All the
molecules of a MCA sample are identical in amino acid sequence and hence
in binding properties; the antibody can thus have exceptional specificity 
(Edwards, 1981).
The binding of drugs to antibodies may be achieved by non-covalent or more 
commonly by covalent bonds mediated by a variety of reagents eg. 
glutaraldehyde (Hurwitz et al, 1975), carbodiimides and activated ester 
intermediate (Kulkarni et al, 1981). The problems arising from coupling 
reactions which employ bifunctional reagents are that cross linking and 
polymerisation of the antibody may occur (due to the large number of 
functional groups present) resulting in a loss in specificity. A loss of 
antibody activity may also result from drug substitution at the antigen 
binding site (Gros et al, 1981) or alteration in the tertiary structure of
the antibody arising from multiple substitution. The following are
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examples of cytotoxic agents which have been linked to immunoglobulins.
1.3.5.1 Alkylating agents
Chlorambucil (an aromatic derivative of Nitrogen mustard) has been linked 
to antitumour globulins (by carbodiimide) and has been successfully 
employed in the treatment of tumour inoculated mice (Tai et al, 1979).
1.3.5.2 Intercalating agents
Hurwitz (1983) linked daunomycin either directly to antibody or via a 
dextran bridge. In all cases a drop in antibody activity was observed. 
The reduction was greater when the dextran spacer was incorporated (50% 
activity retained). The spacer also caused a drop in pharmacological 
activity but allowed an increased level of substitution over direct 
linking of drug to the antibody. It was found from in vivo experiments 
that linking the drug to a macromolecular carrier brought about a 
reduction in the toxic side effects, that specific carriers were more 
effective than non-specific carriers in several tumour systems and that 
both were an improvement over the free drug. In contrast to this 
Aboud-Pirak et al (1989) showed that daunorubicin linked (via a 
tetrapeptide spacer) to a monoclonal antibody was inactive even though 
antibody activity was retained and drug was released in the presence of 
lysosomal enzymes in vitro.
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1.3.5.3 Antimetabolites
Initially MTX was linked to antitumour immunoglobulin using a diazo 
reaction and employed successfully to treat inoculated L1210 leukaemia in 
mice (Mathe et al, 1958). Other attempts at diazo-mediated coupling gave 
variable results and often extensive precipitation (De Carvalo et al, 
1964). Robinson et al (1973) demonstrated that diazotisation led to a 
variety of side reactions and concluded that carbodiimide-mediated linking 
gave a superior product exhibiting much better survival rates in animal 
experiments than unconjugated drug/antibody. The link produced using the 
carbodiimide reagent is between the amino groups of the protein and one of 
the carboxylic acid residues on the MTX, this is important since this does 
not interfere with the pteridine moiety of MTX, which is involved in 
binding DHFR (Bertino, 1963).
Kulkarni et al (1981) linked MTX to immunoglobulin using three different 
methods:- —
a) water soluble carbodiimide
b) activated ester (N-hydroxysuccinimide (NHS))
c) raixed anhydride
It was concluded that the NHS method gave the best results since a 
conjugate with an MCR of 10 retained 90% of the antibody activity with 70% 
of the protein being recovered. The carbodiimide-mediated product with an 
MCR of 8 yielded values of 50% in both cases, however aggregation and 
changes in the tertiary structure were thought to be more pronounced. It 
was found that even with high levels of anhydride an MCR of only 2-3 could
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be achieved, although 100% of antibody activity was retained. The ability
of the drug to inhibit dihydrofolate reductase was found to be reduced in
the case of a) and b) but abolished in the case of c). The in vivo
results showed that MTX conjugated to innunoglobulin showed a significant
improvement over free drug. Characterisation of synthetic methods were
confirmed in a later series of experiments reported by Ghosh et al (1989)
who also demonstrated that the rate of release of MTX (by hydrolysis) was
dependent on pH and all conjugates, independent of the method of
synthesis, had a similar pH profile showing minima at pH 7. These data
indicated that the bond formed was similar in each case. Endo et al
(1987a) demonstrated that MTX linked to MCA (via active ester) exhibited
increased selectivity over normal murine immunoglobulin and that lysosomal
degradation was in fact responsible for the activity of the conjugate.
MTX linked to various MCAs showed an increased rate of tumour cell
inhibition over free MTX (Smyth et al, 1987). The authors conclude that
the conjugates bound specifically to their antigens/receptors
(non-specific pinocytosis was minimal). Internalisation was followed by
intralysosomal degradation of the conjugate. The mechanism was
established by use of MTX transport inhibitors, low temperature and
lysosomal inhibitors.
The MCR has been increased by the use of a copolymer intermediate 
(glutamic acid:lysine 4.7:1) where 63-76 moles of MTX were bound per mole 
of immunoglobulin (via carbodiimide) with 80-100% of pharmacological 
activity (inhibition of [3H]-deoxyuridine incorporation) and 50-80% of 
antibody activity being retained (Hurwitz, 1983).
MTX has also been linked to immunoglobulins via an HSA carrier (Garnett et
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al, 1983). Carbodiimide was used to obtain a conjugate with MCR of 32 
MTX/HSA; 1-3 moles of MTX-HSA conjugate were then linked to one mole of 
monoclonal antibody (791T/36) yielding an overall MCR of 32-96. The 
activity of the antibody (as determined by cell cytofluorimetry) was found 
to be reduced to 28% of the unmodified antibody. However the conjugate 
exhibited increased cytotoxicity over MTX with antibody-reactive cell 
lines; this effect was diminished by incubation with excess antibody.
This conjugate was also shown to be more cytotoxic than MTX linked 
directly to the antibody (via active ester) probably due to increased drug 
loading (Baldwin et al, 1987). Selectivity of the conjugate was 
demonstrated since it showed reduced activity with non-reactive cell 
lines. Incubation of conjugate with reactive cell lines with the 
incorporation of a lysosomal inhibitor (ammonium chloride) brought about a 
significant reduction in cytotoxicity inferring that cellular toxicity was 
mediated by lysosomal degradation (Garnett et al, 1984). The results of 
experiments with inhibitors of MTX transport lead the authors to the 
conclusion jthat free MTX released by lysosomal enzymes was transported 
into the cytoplasm by a specific transport mechanism. The lysosomal 
involvement was further supported by the in vitro work of Endo et al 
(1987b) using a different cell line.
1.3.5.4 Natural toxins
A lot of interest in the area of immunoconjugates has been concentrated on 
highly potent toxic glycoproteins eg diphtheria toxin (Thorpe et al,
1978), ricin (Krollick et al, 1983) and abrin (Olsnes et al, 1976). These 
toxins comprise two polypeptide chains (A and B, disulphide bridged, each
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about 30kD) neither of which separately is toxic to cells (Olsnes, 1981). 
The B chain is concerned with binding to the cell surface and 
internalisation of the A-chain into the cytosol where it terminates 
protein synthesis (Thorpe and Ross, 1982). Diphtheria toxin is enzymatic 
in its mode of action (Collier and Kaplan, 1984) catalysing the transfer 
of adenosine diphosphate ribose ( a part of the electron carrier 
nicotinamide adenine dinucleotide) to a protein called elongation factor 
2. The latter is required for synthesis of protein on ribosomes and is 
inactivated by attachment of the ADP ribose group.
Abrin and ricin are glycoproteins which have similar structures and 
mechanisms of action. The B chains bind to any carbohydrate moiety on 
cell-surface glycoproteins .or glycolipids which terminate in non-reducing 
galactose. There are 10® such receptors on human erythrocytes and up to 
3xl07 on Hela cells (Sandvig et al, 1976) although only a few cells are 
able to mediate penetration of the isolated A chains through the cell 
membrane. The binding can be competitively antagonised by galactose or 
lactose thus reducing toxicity. The mechanism of entry of the A chain 
into the cell is unknown, it may involve endocytosis, channel formation in 
the membrane or may be a carbohydrate triggered mechanism (Thorpe et al,
1982). The A chains of ricin -and abrin inhibit protein synthesis by 
inactivating the 60S subunit of the ribosome.
The toxins (or A chains) have been conjugated to either complete 
antibodies (Blythman et al, 1981) or Fab monomers or F(ab)2 dimers (Ross 
et al, 1980). It is safer using the A chain alone since the complete 
molecule may still retain some non-specific action. However some 
antibodies have been conjugated in such a way as to sterically block the
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receptor on the B chain (Foxwell, 1984). Those conjugates still retaining 
non-specific activity can be removed by binding to a column containing 
galactose residues.
The cell-specific cytotoxicity of these conjugates in vitro has been 
impressive, however in vivo results have not lived up to these promising 
results (Thorpe et al, 1982). One possible use of immunotoxins is in bone 
marrow transplantation to eradicate T lymphocytes thereby overcoming 
graft-versus-host disease.
Toxin A-chains have also been attached to other carriers to increase 
specificity eg. lectins (Yamaguchi et al, 1979), hormones (Miskimins and 
Schinizu, 1979) and epidermal growth factor (Cawley et al, 1980).
The aim in cancer chemotherapy is to deliver antineoplastic agents 
selectively to local tumour and more particularly to metastases (Baldwin 
and Pimm, 1983). The advent of monoclonal antibodies has been an 
important step toward achieving this goal providing specific binding to 
tumour associated antigens. The use of radiolabelled antibodies and MCA*s 
(using 123I, 125I, 131I and X11ln) has demonstrated their ability to 
localise ivf nroplastic tissue (using 7 -scintigraphy coupled with computer 
manipulation) in induced tumours in animals (Epenetos et al, 1982). 
Detection of tumours as small as 1 mm in diameter has been achieved. 
However uptake ratios are not 100% leading to accumulation in other 
tissues eg. non-specific accumulation in the liver and the blood (possibly 
due to binding to secreted antigen). Antibody guided irradiation could 
also be useful therapeutically using /^-emitting isotopes (Hammersmith 
Oncology Group, 1984) the radiation from which can penetrate about 2mm
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into tissues causing cell cytotoxicity. Tumour heterogeneity can cause 
problems with localisation (Neville et al, 1984) as morphologically 
identical cells can contain different epitopes. The use of $ -emitters 
may overcome some problems of heterogeneity but at present the 
efficiencies of antibody localisation are insufficient to make this a 
viable approach.
The use of immunotoxins is interesting since they are potentially very 
powerful therapeutic agents (one molecule is said to be sufficient to kill 
a cell). This is useful with regard to the paucity of tumour associated 
antigens (Kishida, 1983). Possible problems with immunotoxins are that 
combination with secreted antigen present in circulating plasma could lead 
to complexes which may be taken up non-specifically by the 
reticuloendothelial system and uptake by normal cells by pinocytosis.
Their potency may thus lead to toxic effects on normal cells. 
Immunogenicity is also likely to be a problem if repeated dosing is 
anticipated.
The use of more conventional drugs linked to monoclonal antibodies will 
accentuate the problems associated with the kinetics of internalisation. 
The possibility exists that antibody conjugates which are attached to the 
cell membrane may not be internalised, therefore the use of a carrier to 
increase drug loading may be essential for adequate therapy. The problem 
of tumour heterogeneity in drug targeting may possibly be overcome by the 
use of a cocktail of MCAs against a variety of tumour associated antigens. 
Non-specific antibody interactions (ie Fc receptors on cells and the fact 
that Fc portions bind complement) can possibly be obviated by using Fab 
fragments, which may also be useful in lowering the MW of the conjugate.
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Polycations may prove to be useful carriers since they have been shown to 
promote internalisation, however due to the electronegativity of cell 
surfaces non-specific binding may occur. The advantage of using a 
conventional drug (such as MTX) over immunotoxins is that side effects of 
free drug are already tolerated in the clinic thus any degree of 




The development and use of folic acid antagonists began only a few years 
after the isolation and synthesis of folic acid itself; aminopterin being 
one of the first used for the treatment of acute lymphoblastic leukaemia 
in 1948 (Farber et al, 1948). Since then methotrexate has become one of 
the most commonly used antineoplastic folate antagonists in the treatment 
of a variety of malignant conditions (Table 1.1).













The folate vitamins are a class of essential cofactors which carry 
one-carbon groups required for the purine and thymidylic acid synthesis 
necessary for DNA production and cell division. Interference with this 
pathway by methotrexate has been exploited as a method of preventing 
cellular proliferation. Circulating folates contain a single terminal 
glutamate residue, however within the cell they are converted to a 
polyglutamated derivative by folate polyglutamate synthetase (Covey, 
1980). The glutamate units are linked by peptide bonds and are retained 
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In order to participate in enzymatic reactions leading to purine synthesis 
the cofactors must be reduced to their tetrahydro form (in the pteridine 




Replacement of the 4-OH group with an amino moiety results in a several 
thousand fold increase in affinity for DHFR, MTX is a further development 









MTX enters the cell via the carrier-mediated transport system for 
naturally occurring reduced folates (FH4 ). In addition to this mechanism 
passive diffusion may be significant at elevated concentrations (above 
20uM) (Warren et al, 1978). After entering the cell MTX binds with and 
competitively inhibits DHFR. This enzyme is responsible for maintaining 
intracellular folate (FH4 ) levels by reducing dihydrofolates (FH2 ) 
produced during thymidylate synthesis. The resulting high levels of FH2 
then compete with MTX to bind with DHFR (White, 1979). NADPH has been 
shown to form a ternary complex with MTX and DHFR exhibiting increased 
affinity (Blakely, 1984); inadequate levels of NADPH render MTX a 
reversible competitive inhibitor of DHFR (Kamen et al, 1983). The net 
result of the inhibition of DHFR is the depletion of FH4 levels.
Consequent reduced levels of N5"1P-methylene-FH4 lead to a cessation of 
thymidylate synthesis; this occurs at MTX concentrations of 10*8M (Chabner 
& Young, 1973). At MTX levels above 10"7M depletion of N10-formyl-FH4 
occurs resulting in the inhibition of purine synthesis (Zaharko et al, 
1977). The lack of either thymidylate or purines leads to a cessation of 
DNA synthesis.
Intracellular folates are converted to polyglutamates primarily by folate 
polyglutamate synthetase with 5-7 extra glutamyl residues predominating 
(Covey, 1980). It has been shown by Mathews (1980) that the 
polyglutamated forms are actually the preferred substrates for folate 
requiring enzymes. Baugh et al (1973) showed that MTX was also a 
substrate for folate polyglutamate synthetase and later 
MTX-polygamma-glutamates were found in human liver (Jacobs et al, 1977). 
These derivatives appear to have at least equal affinity for DHFR (cf.
MTX) (Jacobs et al, 1975) but dissociate at a slower rate suggesting
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Figure 1.2 Mechanism of action of methotrexate (after Jolivet et al, 1983)
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DHFR = dihydrofolate reductase
TS = thymidylate synthetase
FPGS = folate polyglutamate synthetase
FH4 = Tetrahydrofolate dUMP = dioxyuridylate
FH2 = dihydrofolate dTMP = thymidylate
Glu = glutamate
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effectively reduced reversibility of inhibition. The polyglutamated forms 
of the drug also possess an increased intracellular half-life, and 
consequently prolonged inhibition of DHFR (Jolivet et al, 1982), which 
appears to be chain length dependent. In addition to DHFR, 
MTX-poiyglutamates can also inhibit other folate-requiring enzymes eg. 
5-aminoimidazole-4-carboxamide ribotide transformylase and glycinamide 
ribonucleotide transformylase both of which are involved in sie novo purine 
synthesis and naturally utilise 10-methyltetrahydrofolate as a substrate. 
The polyglutamated forms of these folates appear to be preferred 
substrates for these enzymes (Allegra et al, 1985). Similarly MTX 
polyglutamates can competitively inhibit these enzymes as well as a 
thymidylate synthetase (Szeto et al, 1977). De novo purine synthesis can 
also be indirectly affected due to accumulation of oxidised folates caused 
by MTX inhibition of DHFR (Baggott et al, 1986).
1.4.3 Clinical Pharmacology
It is expected from clinical experience, cytotoxicity experiments using 
cultured cells and analysis of receptor-mediated folate/MTX transport 
(Kamen, 1987) that a plasma level exceeding 10*7M would be cytotoxic 
(folate circulates at a concentration of approximately 10"8M). At low 
doses (<50mg/m2) MTX undergoes limited metabolism, however high dose 
therapy results in the formation of 7-OH-MTX (by hepatic aldehyde oxidase) 
which has a longer half-life than the parent compound; 23.8 hours as 
opposed to 2.1 hours (Breithaupt and Kuenzler, 1982). MTX is found to be 
protein-bound in plasma to a level of about 50% (Paxton, 1982) independent
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of concentration (10"4M to 10“9M) inferring a high capacity, low affinity 
binding site. The metabolite, 7-OH-MTX, also binds to serum proteins 
(Lopez et al, 1986) to a level around 65%; Scatchard analysis implies two 
binding sites on human serum albumin, one being partially competitive with 
MTX.
The use of high dose MTX (HDMTX) (l-30g/m2) followed by leucovorin 
(N5-formyl-FH4, folinic acid) rescue has become more frequent. The 
administration of leucovorin is followed by its rapid metabolism in the 
plasma to N5-methyl-FH4, the physiological circulating folate (Hamel et 
al, 1981) which can enter cells and replete the folate pools following 
metabolism by methionine synthetase. The use of HDMTX resulting in high 
plasma levels (10"4 to 10"5M) for prolonged periods (12-36 hours) has a 
number of advantageous effects:,
i) passive diffusion may overcome active transport defects.
ii) increased free intracellular MTX can overcome resistance due to
unusually high levels of DHFR or altered enzyme binding.
iii) sustained, elevated plasma levels can promote increased
polyglutamation.
iv) prolonged administration exposes more cells to MTX during
DNA synthesis.
v) HDMTX may prevent or delay development of resistance which “tends to




MTX resistance may occur due to a variety of effects:
i) Decreased membrane transport.
Tumour cells in culture have been shown to become resistant to drug due to 
decreased affinity of the carrier for MTX in the active uptake system.
ii) Decreased affinity of DHFR for MTX.
Reduced binding affinity has been demonstrated in human cell lines with an 
associated reduction in cytotoxicity (Jackson & Niethammer, 1977)..
iii) Increased levels of DHFR.
Long term exposure of cells to differing levels of MTX has been shown to 
produce higher levels of DHFR possibly due to amplification of genes 
encoded for DHFR (Melera et al, 1980) which may be reversible (Schinke, 
1986).
iv) Decreased polyglutamation
A cancer cell line in which decreased polyglutamation was in part 
causative of drug resistance has been described (Cowan & Jolivet, 1983) 
however it has not been extensively characterised.
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v) Thymidylate synthetase activity.
A reduction in the rate of thymidylate synthesis has been shown to render 
cells less susceptible to MTX (Moran et al, 1979).
As previously outlined some of the mechanisms by which cellular resistance 
is thought to occur may be overcome by high dose MTX therapy followed by 
leucovorin rescue which has the additional benefit of exhibiting reduced 
toxicity.
The toxicity of MTX is associated with its anti-proliferative action 
exerted on growing tissues; mainly the bone marrow and the mucosae of the 
GI tract. In addition MTX is associated with hepatic (Lawrence et al,
1983) and CNS toxicity (Fritsch and Urban, 1984).
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1.5 Human Serum Albumin
1.5.1 General Properties and Biological Function
Human serum albumin (HSA) is a plasma protein present at a level of about 
42g per litre of plasma; this is equivalent to around 150g in the blood of 
a 70kg person. In addition to this circulating component about 230g 
exists in an exchangeable extravascular reservoir within the lymph spaces. 
The half-life of albumin is 19 days in humans; 14g being lost daily and 
replaced by hepatic synthesis.
The main functions of albumin are in the maintenance of fluid balance and 
the binding and transport of endogenous ligands. The former property 
arises from the relatively low molecular weight of HSA and its high 
concentration (60% of the total plasma protein). Albumin contributes 
” about 80% of the colloidal osmotic pressure of plasma, which reduces the 
extravasation of fluid.
HSA is capable of binding a wide variety of ligands. This ability is 
derived in part from its molecular flexibility and also the fact that its 
chemical complexity allows both hydrophobic and ionic interactions with 
other molecules. The general properties of serum albumin have been 




Albumin is a secreted protein which characteristically has low contents 
of tryptophan and methionine and high levels of cysteine and charged amino 
acids (aspartate, glutamate, lysine and arginine) (Table 1.2). This 
results in a large number of ions per molecule at physiological pH and 
yields a net charge of -15 at pH7.
Table 1.2 Amino acid composition of Human Serum Albumin
aspartic acid 36 cysteine 35
asparagine 17 methionine 6
threonine 28 isoleucine 8
serine 24 leucine 61
glutamic acid 62 tyrosine 18
glutamine 20 phenylalanine 31
proline 24 lysine 59
glycine 12 histidine 16
alanine 62 tryptophan 1
valine 41 arginine 24
total number of residues 585
calculated net charge (pH 7) -15
average residue weight 113.57
molecular weight 66241
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Hunter & McDuffe (1959) discovered, by reduction and alkylation, that HSA 
was composed of a single chain. The sequence of the chain was later 
elucidated and published in 1975 (Brown, 1975, Behrens et al, 1975, Meloun 
et al, 1975).
Secondary Structure
Optical rotation measurements show HSA as a typical globular protein (at 
pH7) with an estimated 55% of the molecule as ot -helix and 16% as 
^-pleated sheet. —
Tertiary Structure
The presence of 17 disulphide bridges brings about the organisation of the 
molecule into a series of 9 loops each bound by two such bridges (see 
Figure 1.3). The nine loops are grouped in triplets (large-small-large) 
thus forming three domains; this may have arisen from an evolutionary 
precursor one third or one ninth the size of HSA.
1.5.3 Physical Properties
HSA is an acidic, water-soluble, stable protein which has an 
isoelectric point (with bound fatty acid) at around pH4.8.
Size and Shape
Knowledge of the primary structure of HSA has enabled calculation of the 
precise molecular weight of the protein; ie. 66241. The higher values
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The one-letter code for amino acids is A,Ala; C,Cys; D,Asp; E,Glu; 
F,Phe; G,Gly; H,His; I,lie; K,Lys; L,Leu; M,Met; N,Asn; P,Pro; Q,Gln; 
R,Arg; S,Ser; T,Thr; V,Val; W,Trp; Y,Tyr.
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derived from physical measurements may arise due to the presence of 
adducts eg* fatty acids, carbohydrates, polymers and tightly bound water 
(c. 20 molecules) (Table 1.3).
The shape of HSA in solution is prolate ellipsoid with associated water 
molecules (both tightly and loosely bound) increasing its overall 
dimensions. At neutrality the molecule possesses maximal helical content 
(c. 55%). As pH is lowered (down to pH 1-2) it unfolds and elongates, 
complete unfolding being restricted by the disulphide bonds. At elevated 
pH there is only a slight drop in helical content; however, above pH 10, 
deamidation and disulphide interchange may occur. HSA also exhibits 
thermal stability and can withstand heating to 60°C for 10 hours (in the 
presence of stabilizers). The above effects tend to be reversible thus 
rendering HSA fairly resistant to denaturation. However prolonged or 
repeated heating or exposure to alkali will cause dimerisation, unfolding 
and eventual aggregation. Heating a solution at pH9 to 65°C causes 
polymerisation and loss of helix within one minute.
1.5.4 Metabolism 
Biosynthesis
Albumin is synthesised in the liver and during this phase 19 ribosome 
units attach to one albumin mRNA forming a large polysome. A signal 
peptide is the first translated sequence and this is responsible for 
guiding the polysome to the endoplasmic reticulum (ER) and inserting the 
growing peptide chain through the ER membrane. The signal peptide is
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Table 1.3 The physical properties of
Molecular weight
i) from composition
ii) from physical data
Sedimentation constant, S20W .
i) monomer
ii) dimer
Diffusion constant, D20W 
Intrinsic viscosity 
Overall dimensions 
Optical absorbance, El%/lcm, 279nm
(a) Charlwood, 1961
(b) Oncley et al, 1947
(c) Hughes, 1954




4.6 x 108 (b)
6.7 x 1013 (b)
6.1 x 107 (b)
0.042 dl/g (a)
38 x 150 A (c)
5.31 (d)
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cleaved off prior to completion of translation of the mRNA and detachment 
of the peptide chain from the ribosome, which is then followed by the 
linking of cysteine residues. This produces the peptide known as 
proalbumin (Judah et al, 1973) which differs from albumin in that it has a 
basic hexapeptide attached to the amino terminus. This peptide remains 
intact during the molecule’s transit from the rough through the smooth 
endoplasmic reticulum to the Golgi apparatus. The hexapeptide is then 
cleaved prior to the release of albumin into the circulation; the entire 
secretory process taking 20-30 minutes.
The rate of albumin synthesis, maximal during periods of good health and 
nutrition, diminishes rapidly in malnutrition and disease states when the 
liver synthesises other proteins, eg. fibrinogen and orosomucoid.
The liver can increase albumin production by up to 100X during 
protein-losing enteropathy and nephrosis or following protein deprivation. 
The production of albumin can be stimulated by the anabolic hormones 
insulin and somatotropin (growth hormone).
Catabolism
The disappearance of albumin from the circulation is first order, a small 
quantity leaks into the GI tract from where its amino acids can be made 
available for reuse. Studies using bound radiolabelled oligosacharides 
(Yedgar et al, 1983, Baynes & Thorpe, 1981) show that albumin molecules 
are taken up by pinocytosis in cells throughout the body and degraded in 
the lysosomes. The rate of catabolism is directly related to the albumin 
plasma levels and may be increased by adrenal stress hormones. Mego
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(1984) has suggested that modified albumin is degraded following 
pinocytosis, conversely unmodified molecules are released back into the 
circulation. It has also been suggested (Dammacco, 1980) that bound fatty 




The carbodiimides are a group of bifunctional condensing reagents which 
were originally prepared about a century ago. A resurgence of interest in 
these compounds followed a review of their chemical and physical 
properties by Khorana (1953). The general structure of carbodiimides is 
as follows:
where R and R ’ may be aromatic or aliphatic. Carbodiimide compounds may 
be soluble in organic solvents eg. dicyclohexylcarbodiimide (DCC)
or may be soluble in aqueous systems eg. l-ethyl-3-(3-dimethylaj«.ino- 
propyl) carbodiimide hydrochloride (ECDI).
R - N = C = N - R
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The versatility of carbodiimides as reagents for organic synthesis 
involves them in coupling reactions between such functional groups as 
carboxylic acids, phenols, amines, phosphates, alcohols and thiols 
resulting in the formation of amides, esters etc. They are particularly 
useful in the synthesis of peptides and nucleotides.
1.6.2 Synthesis
Carbodiimides themselves are synthesised from a variety of compounds 
including thioureas, ureas and isocyanates; the carbodiimides being formed 
by techniques such as dehydration or desulphurisation (Sheehan, 1961).
1.6.3 Reactions
Carbodiimides can, under the correct conditions, react with a variety of 
substances including alcohols, phenols, sulphonic acids, phosphate esters, 
inorganic acids, carboxylic acids and amino compounds (Kurzer and 
Douraghi-Zadeh, 1967). Carbodiimides undergo an addition reaction with 
water to form the corresponding urea; the reaction may be catalysed by 
both acid and alkali conditions (Scheme 1.1).
1.6.4 Peptide Bond Formation
One of the more useful attributes of the carbodiimides is their ability to 
unite free carboxyl and amino groups to form a peptide bond. This is a
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Scheae 1.1 Reaction of carbodiiaide reagents with water
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one step synthesis which may be performed at room temperature with 
subsequent high yields (Sheehan and Hess, 1955). The latter authors 
reported that no racemisation occurred using an optically active dipeptide 
as the acylating agent.
The general scheme of the reaction is as outlined in scheme 1.2. The 
formation of peptide bonds occurs via a 1,2 addition reaction due to the 
twinned double bonds of the carbodiimide. The first step is the addition 
of a proton to form compound (III) which is subsequently susceptible to 
attack by the acid anion forming the O-acylisourea (IV). The formation of 
a peptide bond could then proceed by one of three routes (Scheme 1.2):
a) a proton is attached to (IV) forming the cation (VI) which is 
then subject to attack by the acid anion forming the urea 
(VII) (corresponding to the carbodiimide (II)) and an 
anhydride (VIII). The latter is then open to nucleophillic 
attack by an amine; the symmetrical anhydride thus acts as 
the acylating agent resulting in the formation of a peptide 
bond, accompanied by the liberation of the free carboxylic 
acid.
b) The peptide link results from the direct nucleophillic attack 
upon the O-acylisourea (IV) by the primary amine with the 
concomitant formation of the appropriate urea (VII).
c) The O-acylisourea (IV) undergoes intramolecular rearrangement 
to form the N-acylurea (V) which could be attacked by an amine 
to produce the amide and urea derivatives.
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Scheae 1.2 Peptide bond foriation using carbodiiaide reagents
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The formation of peptides via the stable N-acylurea (path c)) has been 
excluded by reaction kinetics experiments described by De Tar (1966).
Evidence in support of pathway b) was provided by Weetall and Weliky
preventing anhydride formation. Conversely Rebek and Feitter (1974) 
concluded that the anhydride is the acylating agent following solid phase 
peptide synthesis experiments with polymer-bound amines. They proposed 
that in solution the O-acylisourea is the acylating group, ie. path b), 
whereas it is the anhydride which acylates in the solid phase, ie. path
Dicarboxylic acids, eg. glutaric acid, can react with carbodiimides to 
form a cyclic anhydride and the disubstituted urea via pathway a) 
(Khorana, 1953). Cyclisation may occur following the first 1,2-addition 
(IV); the reaction being facilitated by the proximity of the second 
carboxylate group.
(1964) who linked amines to polymer bound carboxylic acids using DCC; thus
a).
C O O H ( C H 2) c o o h  c n + Rr N=C = N - R 2
O
II
(CH2)n O + R N H C O N H R 2
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The anhydride thus forned would then be subject to nucleophillic attack 
(by an amine) as would intermediate VIII. The molecular rearrangement to 
the N-acylurea (V) predominates at elevated temperature; the production of 
this side product may be reduced by lowering the reaction temperature and 
by the presence of an amino group during the reaction (Bauminger and 
Wilcheck, 1980).
The use of insoluble carbodiimides eg. DCC, diethylcarbodiimide and 
diphenyl carbodiimide has become popular in non-aqueous peptide synthesis 
since the urea by-products tend to be insoluble and are readily removed liy 
filtration. (Sheehan and Hess, 1955).
Water-soluble carbodiimides first developed by Sheehan and-Hlakva (1956) 
also find applications in aqueous and non-aqueous peptide synthesis. This 
class of carbodiimides include tertiary and quaternary amine substituents 
being soluble in dilute acid and water respectively. These reagents give 
rise to water soluble ureas during peptide synthesis which can be removed 
from an organic environment by aqueous extraction; this can prove useful 
if the product and side product (urea) are both insoluble using 
water-insoluble CDI*s (eg. as might occur during DCC coupling of high 
molecular weight peptides).
In addition to their uses in peptide synthesis, carbodiimide reagents have 
been used in the preparation of immunizing conjugates. The purpose of 
these systems is to enable antibodies to be elicited against small 
molecules (haptens) of molecular weight less than 1000. These haptens, 
which are not normally antigenic, are rendered so by covalently linking 
them to proteins or synthetic polypeptides (Erlanger, 1980). Serum
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albumins have commonly been used as the carrier proteins in such systems, 
eg. bradykinin and angiotensin linked to rabbit serum albumin (Goodfriend, 
1964), steroidal hormones (progesterone) linked to bovine serum albumin 
(Erlanger et al, 1959), a -melanocyte stimulating hormone linked to 
albumin (McGure, 1965) and prostaglandins bound to poly-L-lysine (Levine & 
Van Vunakis, 1970).
The use of water-soluble carbodiimides in such systems enables separation 
of the product from uncoupled hapten and urea by-products by dialysis or 
gel filtration (Bauminger & Wilchek, 1980). The amountof conjugated 
hapten can be estimated, following separation, by various techniques 
depending on the nature and pretreatment of the hapten, eg. 
spectrophotometry, radioactive tracer assay or quantitative analysis of 
the carrier, eg. amino acid analysis. As has been previously described 
carbodiimide reagents can react with a variety of functional groups (such 
as those present in albumins) and they have been shown to react with 
protein-tyrosine residues (Carraway & Koshland, 1968) and sulphydryl 
groups (Carraway and Triplett, 1970) which may affect the antigenic 
potential of the product.
Carbodiimides have also found application in the determination of carboxyl 
groups in proteins by conjugating them with radiolabelled 14C-glycinamide 
(Carraway & Koshland, 1972). This procedure also yielded information on 
the accessibility of carboxyl groups by reaction in the presence and 
absence of high concentrations of urea or guanidine (denaturing reagents).
The desired reaction in conjugation procedures involving hapten, 
carbodiimide and protein results in the formation of an amide bond, ie. a
54
hapten molecule containing a carboxylic acid residue may combine with one 
of the lysine residues of the protein (which have pendant amine groups).
In addition to such amide bonds, ester linkages may also be formed between 
hapten carboxyl groups and hydroxyl groups present in serine and threonine 
residues of the protein. Esterification may occur via the O-acylisourea 
(IV) or the anhydride (VIII) (March) (Scheme 1.3). ii) Alcoholysis of 
anhydrides
The panoply of amino acid residues present in proteins, with their 
associated free functional groups, render inter & intramolecular 
cross-linking a distinct possibility in carbodiimide-mediated reactions. 
Timkovich (1977) has reported polymerisation in four different proteins; 
the extent of the polymerisation was significantly reduced by the presence 
of a nucleophile at high concentration. The amino acid residues which are 
proposed to be involved in cross-linking reactions (with 0-acylisoureas) 
are tyrosine, serine or threonine (hydroxyl residues forming esters), 
glutamic acid (carboxylic acid residues forming anhydrides) and lysine 
(amine residues forming amide bonds). It was concluded that the polymers 
formed in this experiment (as detected by gel electrophoresis) could be 
readily separated by gel filtration and using this technique a level of 
20% polymerisation was determined in the absence of nucleophile. The 
addition of nucleophile significantly reduced the level of polymerisation 
in the case of myoglobin & cytochrome C (down to 6%) and prevented 
polymerisation in the lysozyme & ribonuclease reactions.
Scheie 1.3 Fonation of esters
i) esterification via O-acylisourea
c
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ii) alcoholysis of the anhydride
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1.6.5 Peptide bond formation by activated esters
The formation of peptide bonds has also been achieved using carbodiimide 
reagents via an activated intermediate. Anderson et al (1964) used esters 
of N-hydroxysuccinimide (NHS) in peptide synthesis; the esters are the 
product of a carbodiimide-mediated reaction between a carboxylic acid and 
NHS (NHS may be produced by the fusion of succinic anhydride and 
hydroxylamine HC1) (Scheme 1.4).
Scheme 1.4 Peptide bond formation using N-hydroxysuccinimide
R-COOH + DCC +
O
II
R - C - N - R
l
H
p e pt i d e
DMF
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The reaction is performed in a non-aqueous environment, eg. DMF (Kulkarni 
et al 1981), and proceeds via the O-acylisourea with the insoluble urea 
derivative of DCC ultimately being precipitated permitting its removal by 
filtration. The peptide link with a free amine could subsequently be 
effected by reaction with the activated ester in a semi-aqueous 
environment.
CHAPTER TWO: SYNTHESIS AND CHARACTERISATION OF MTX-HSA CONJUGATES
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2.1 Introduction
2.1.1 Gel Permeation Chromatography
2.1.1.1 Introduction
Gel permeation chromatography (GPC) is a term which was proposed by Moore 
in 1964 to describe the separation and characterisation of protein
components using porous gel matrices. A number of workers have used a
variety of terms to describe the same phenomenon i.e. gel filtration 
(Porath and Flodin, 1959), molecular sieve filtration (Fasold, 1975), 
restricted diffusion chromatography (Steere and Ackers, 1962), molecular 
sieve chromatography (Hjerten and Mosbach, 1962) exclusion chromatography 
(Pedersen, 1962) and simply gel chromatography (Determann, 1964).
The main component of a GPC system is a swollen gel matrix through which a
liquid mobile phase is pumped. The system is capable of separation 
according to molecular size. Molecules with a larger hydrodynamic volume 
being eluted before those occupying a smaller volume. The primary process 
involved is the diffusional partitioning of solute molecules between a 
mobile solvent phase and the interior solvent spaces within the porous 
particles comprising the stationary phase; large molecules are sterically 
excluded from the matrix pores and permeate more rapidly through the 
column with the mobile phase.
A GPC system comprises the following:
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i) a column containing the swollen gel matrix
ii) mobile phase pumped at a constant rate through the column
iii) flow detector and/or fraction collector
The gel is composed of a 3-dimensional cross-linked matrix which is in a
swollen state in the mobile phase. Ideally the gel should possess the
following properties:-
i) Inert character
chemical interaction between solute and matrix~may lead to
irreversible binding or to modification of labile
substances.
ii) Chemical stability
gels need to be stable over a range of pH and 
temperature without leaching material and should be capable 
~of being used repeatedly over an extended time period.
iii) Low content of ionic groups
to avoid ion exchange effects
iv) Narrow particle size distribution
particle size should be carefully controlled; small 
particles with a narrow size distribution give better 
resolution.
v) Mechanical rigidity
softer gels may be deformed and thus limit flow rates.
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The volume of the chromatographic bed, Vt, consists of the following 
components.
Vt = Vo + Vi + Vg .................  (1)
where Vt = total volume of the column, Vo = void volume, Vi = internal 
volume and Vg = gel matrix volume. Vi + Vg = Vt - Vo (see Figure 2.1)





The void volume (Vo) represents the elution volume of a solute which is 
totally excluded from the gel matrix (ie. elutes with the solvent front) 
and is equivalent to the volume of liquid in the interstitial spaces 
between the particles.
In a chromatographic experiment a sample is applied to the gel column and 
the concentration of solute in the effluent is monitored. When this is 
plotted against the volume of eluant collected it yields the elution curve 
(Figure 2.2).
61




The elution volume (Ve) can be used to characterise the behaviour of a 
given solute in a given system under controlled conditions and should 
ideally be independent of flow rate.
The solute in a gel/solvent system is distributed by diffusion between 
solvent regions inside and outside the gel. At equilibrium a partition 
isotherm can be deduced defining the relationship between the weight of 
solute (Qi) inside the gel and the solute concentration (C) in the void
space.
Qi = f(C) .......................... (2)
The distribution coefficient (partition coefficient) referred to internal 
solvent volume, Kd, is a ratio of the mass of solvent in the gel phase per 
unit volume and the concentration in the external phase.
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Qi/Vi = Kd.C ......................  (3)
Or, Kd = Qi/Vi.C .......................  (4)
Kd is thus a dimensionless measure of the extent of solute penetration
within the available interior solvent region of the gel.
Kd = Vp/Vi ...........................  (5)
where Vp = penetrable volume occupied by solute molecules at equilibrium.
Therefore, Kd = (Ve - Vo)/Vi ....................  (6)
An alternative distribution coefficient, Kav, can be calculated with - 
reference to the total volume of the gel. In this case Vx is considered 
as the stationary phase where
Vx = Vt - Vo = Vi + Vg ...........  (7)
Then, Qi = Kav.Vx.C
therefore, Kd.Vi = Kav.Vx
or, Kd/Kav = Vx/Vi
which is a constant independent of solute concentration.
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Therefore, Kav = (Ve - Vo)/(Vt - Vo) .........  (8)
Kav can thus be used to characterise the elution of solutes in GPC and 
indicates the fraction of the stationary phase that is available to the 
solute. It is not a true distribution coefficient since it incorporates 
the volume of impenetrable gel matrix, it is however more convenient to 
derive since determination of Vi is difficult. Kav can be calculated from 
knowledge of the total column volume, the void volume and the elution 
volume (Figure 2.3).
Figure 2.3 Relationship between expressions used for normalising 
elution behaviour
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2.1.1.2 Solute - matrix interaction
The matrix material is selected to be inert, however some substances may 
still interact. In aqueous systems the main types of interaction are 
ion-ion interactions and Van der Waals interactions. Van der Waals 
interactions lead to common phenomena known as hydrogen bonding and 
hydrophobic bonding. In organic solvents hydrogen bonding and hydrophilic 
interactions may occur.
Two types of ionic interactions are encountered
i) Direct interaction with trace amounts of charged groups 
present on the matrix - mainly carboxyl but
also sulphate groups on agarose columns. ~
ii) Donnan effect. A potential builds up due to partitioning of 
low molecular weight counter-ions into the gel from an eluant 
containing a charged macromolecule.
The effects of both types of ionic binding decrease with increasing ionic 
strength. In practice ionic strengths greater than 0.02M minimise the 
effects of ionic binding.
Hydrophobic interactions were initially noted in relation to aromatic 
substances by Gelotte in 1960. However aliphatic compounds have also
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been shown to interact with the matrix (Marsden, 1965). All gel matrices 
have potential sites for hydrophobic interaction and these sites have been 
identified in some cases, eg. the cross-linking bridges in Sephadex 
(Determann and Walter, 1968). The extent of the hydrophobic interaction 
tends to increase with increasing ionic strength.
Hydrophobic interaction can only occur between accessible sites of the 
solute and the gel matrix. In the case of proteins hydrophobic regions 
tend to be within the interior of their tertiary structure and 
consequently cannot bind with hydrophobic gel sites. The primary 
hydrophobic binding site of Sephadex and Sepharose gels are the 
cross-linking bridges which are surrounded by matrix chains and are 
consequently inaccessible to compact, sterically excluded molecules, eg. 
proteins. The interaction and adsorption of intact proteins is thus 
rarely observed. However the probability of such phenomena occurring with 
low molecular weight compounds is much greater. Molecules which interact 
are often eluted as sharp, well defined peaks; thus the effect can be used 
to separate molecules which may be difficult to resolve. The interaction 
of purines with Sephadex has been employed in the separation of folic acid 
and derivatives (including polyglutamates) using Sephadex G10 (Kas and 
Cerna, 1976).
2.1.1.3 Measurement of column efficiency
An indication of the performance of a column can be obtained by 
determining the number of theoretical plates, which is a measure of the 
amount of zone broadening caused by the column. The height equivalent to 
a theoretical plate (HETP) can be determined by calculating the number of
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theoretical plates (N) (Figure 2.4).
HETP = L/N where L = length of column in cm.
HETP is a measure of column efficiency allowing comparison between columns 
of differing length.







where a = distance from injection to peak maximum and b = length of 
baseline limited by tangents to the peak.
Plate number is a measure of the amount of zone broadening caused by a 
column and is dependant upon column length.
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2.1.1.4 Determination of molecular weight
One of the most important applications of GPC is molecular weight 
determination, particularly of proteins. The results obtained are 
reliable, accurate and compare favourably with other techniques eg. 
viscosity, diffusion and light scattering. A number of workers (eg 
Whitaker, 1963, Determann and Michel, 1966) have indicated that for most 
proteins there is a close correlation between molecular weight (molecular 
radius) and elution behaviour as determined by Kav values. The partition 
coefficient (Kav) corresponds to the distribution of solute within the gel 
matrix at thermodynamic equilibrium, this is representative of the steric 
constraints leading to exclusion which are determined by molecular size 
and shape. A GPC system can be used for molecular weight determinations 
following calibration of the columns using suitable materials of defined 
physical properties. Molecular weight determinations have also been 
performed in the presence of denaturing agents such as urea, guanidine 
hydrochloride or sodium dodecyl sulphate (Fish et al, 1969, Hung et al, 
1977) thus minimizing the effects of tertiary or quaternary protein 
structure on elution.
Andrews (1965) showed using Sephadex G200, that a relationship existed 
between the partition coefficient and the molecular weight of a number of 
proteins (Figure 2.5).
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The following relationship was discovered empirically using 
semi-logarithmic plots:
Kav = -A. log M + B
where A and B are constants and M is the molecular weight.
This equation/calibration is particularly applicable for the molecular 
weight determination of proteins having a similar structure to those used 
for the column calibration.
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Number and weight averages can be calculated from a normalised GPC 
chromatogram using definitions which were developed for polymer chains.
Mi = molecular weight of polymer chain having a degree of
Calculation of Molecular Weight Averages
weight averages can a 
using definitions developed polymer cha
If i = degree of polymerisation
Na = Avogadro’s number
 
polymerisation i
Ni = number of molecules with degree of polymerisation i
ni = number fraction = Ni/ ^ N i  ..................  (9)
Wi = weight of molecules with degree of polymerisation i
wi = weight fraction = W i / ^ W i  ..................  (10)
Then Wi = Ni.Mi/Na ................................  (11)
A chromatogram is essentially a plot of detector response (which is 
proportional to the number of molecules) against the retention volume 
(proportional to the molecular weight) (Figure 2.6).
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retention volume (or log M)
The chromatogram can be converted into a series of vertical lines and 
digitised. The amount of polymer can be expressed by number or by weight; 
if the data are converted to number or weight fractions then the 
chromatogram is said to have been normalised and is independent of the 
absolute amount. Normalisation can be achieved by dividing the digitised 
heights by the total area under the curve.
Nuab^r average molecular weight, (Mn)
Mn = the sum of the products of the molecular weight of each 
fraction multiplied by its mole fraction
ie. Mn = ^  ni.Mi
then Mn = ^  Ni.Mi/ Ni
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Weight average molecular weight, (Mw)
Mw = sum of the products of the molecular weight of each 
fraction multiplied by its weight fraction
ie. Mw = wi.Mi
since wi = Ni.Mi/ ^  Ni.Mi
then Mw = ^  Ni.Mi2/ Ni.Mi
The relationship between Mn and Mw can be defined from the variance of 
the number distribution:
a 2 = $  Ni (Mi - Mn)2/ ^  Ni
This may be rearranged to
c 2 = (Mw.Mn) - Mn2 = Mn2(Mw/Mn - 1)
therefore Mw/Mn = 1 + a 2/Mn2
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Since <J can only be zero or positive then the ratio Mw/Mn must be 
greater or equal to unity. When a is zero then the polymer is 
monodisperse. The ratio of Mw/Mn is thus a measure of the spread of the 
molecular range within the polymer and is termed the polydispersity index. 
Mw by definition is always greater than Mn. The lower value produced by 
the number distribution arises from the fact that a given weight fraction 
of small molecules contains a large number of molecules whereas the same 
weight fraction of large molecules contains a smaller number of 
molecules.
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2.2 Synthesis of MTX-HSA Conjugates
2.2.1 Introduction
The reaction used to conjugate MTX to HSA in this series of experiments 
was similar to that used by Kulkarni et al (1981) and Chu and Whiteley 
(1977). The reaction was performed in phosphate-buffered saline (PBS) pH
7.4 (I = 0.29 or 0.15M, 0.05M total phosphate). This pH was chosen as a 
compromise since the ECDI link to the acid residue is promoted by hydrogen 
ions and the lysine residues (on HSA) are more reactive at elevated pH 
where unprotonated amine groups occur (pKa = 9.8). The reaction was 
terminated by fractionation on a GPC column. The molar conjugation ratio 
(MCR) of MTX to HSA was determined by spectrophotometry and subsequently 
the stability of MTX-HSA conjugates was assayed by FPLC.
The reaction mixture was prepared by taking aliquots of concentrated 
reactant solutions (in PB&) and making up to the desired volume with PBS. 
Solutions of HSA (20mg/ml) and MTX (20mg/ml free acid) were either freshly 
produced or recently produced and stored at -20°C. The ECDI solution was 
prepared immediately before use. The reaction was allowed to proceed for 
up to 24 hours prior to termination.
The separation of the high molecular weight conjugate from the low 
molecular weight reactants (MTX, ECDI) and by-products (urea derivatives) 
was achieved using GPC. The gels employed were Sephadex G15, G25 & G50 
(exclusion limits 1,500, 5,000 & 30,000 Daltons respectively (Pharmacia)) 
packed into 1.6cm x 75cm or 2.6cm x 35cm columns. The eluent (PBS pH7.4) 
was pumped using a peristaltic pump at a flow rate dependant on the column
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and the eluate monitored by flow UV spectrophotometry at 254 or 280mm. 
The reaction mixture was applied to the column via a calibrated loop (1 or 
5ml) and the conjugate, which eluted as a yellow band with the void 
volume, was collected into either a 25 or 100ml volumetric flask.
The molar conjugation ratio (MCR) was determined by UV assay at 376nm to 
estimate the amount of MTX present; from this and the known amount of HSA 
applied to the column the MCR was calculated, assuming 100% recovery from 
the column (see section 2.2.3).
2.2.2 Loop Calibration
The application of sample to a gel column may be achieved either directly 
onto the column using a syringe or via a loop system as was used in this 
study. The advantages of the latter method are:
i) the sample can be applied without significantly interrupting 
the flow of mobile phase.
ii) a knownvolume of sample can be applied using a calibrated 
loop.
The injection system was based around two four-way valves with two loops 
operating on the same apparatus. The approximate volumes of the loops (ie 
1 & 5 ml) were determined from the internal dimension of the tubing and 
its length; the loops were then calibrated iji situ in the following 
manner:
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i) a solution of MTX (0.5mg/ml in PBS) was injected into the 
appropriate loop in the load position.
ii) the valves were turned to the inject position and the loops 
flushed out with mobile phase and collected directly into an 
appropriate volumetric flask; the loop having been flushed 
with 15-20 loop volumes of PBS.
iii) standards were produced by pipetting the appropriate volume 
of MTX solution into a volumetric flask.
iv) the solutions were assayed by UV spectrophotometry at 370nm, 
sufficient replicates being determined until successive 
readings were + 0.002 absorbance units (typically 3-4 
readings)
Table 2.1 Calibration of injection loops used with Sephadex columns
Nominal loop 
volume









0.3475 ± 0.0054(4) 0.3334 ± 0.0042(2) 1.04 ml
5ml (diluted 
to 100ml)
0.4128 ± 0.0022(6) 0.4014 ± 0.0031(3) 5.13 ml
76
2.2.3 The yield of HSA from Sephadex columns
The determination of the yield of HSA from Sephadex columns was important 
since the MCR calculation was based on the assumption that all of the 
applied conjugate was separated from the free MTX and was subsequently 
collected for assay. The experiment was conducted using two columns in 
series, the first containing Sephadex G15 (70cm x 1.6cm) and the second 
Sephadex G50 (20cm x 1.6cm). The gels had been used previously but had 
been flushed with at least three column volumes of 0.2M NaOH and then 
equilibrated with distilled water. Water was used as the mobile phase in 
order to encourage binding (ionic interaction being reduced with 
increasing ionic strength). Flow spectrophotometers were placed in line 
between the two columns and after the second column thus enabling 
monitoring of the eluant from both columns.
The elution characteristics of HSA solution (lmg/ml) were compared to that 
of a blue dextran solution with the result that both compounds eluted from 
both columns with identical retention volumes. Since blue dextran has a 
molecular weight of 2,000,000 and is used to determine the void volume in 
GPC it confirmed that HSA eluted with the void volume from both grades of 
Sephadex.
In the adsorption experiments 1ml samples of HSA solutions (5 & lOmg/ml) 
were applied to the column (flow rate 2.55ml/min, H2O) and samples of the 
effluent were collected. 6 x 10ml samples prior to the HSA peak were 
collected and then the peak (baseline to baseline) was collected in a 25ml 
volumetric flask (test sample) followed by further 10ml samples. The 
samples were the analysed at 279nm against water. Standard samples were
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prepared by pipetting 1ml of sample solution and making up to 25ml in 
volumetric flasks (standard sample) and also by flushing the contents of 
the loaded 1ml loop directly into a 25ml volumetric flask (loop sample).
Recovery of HSA (4.9mg/ml) from a Sephadex G-15 column (duplicate samples)
mean test sample reading = 0.110 (+0.002)
mean loop sample reading = 0.111 (+0.001) (1.04ml)
mean standard reading (1ml) = 0.108 (+0.001) corr. to 1.04ml = 0.112 
yield of HSA as % of loop sample = 99.1%
The absorbances of the other samples were found not to differ
significantly from the blank.
The experiment was repeated using HSA at a concentration of 9.9mg/ml with 
the following results:-
mean test sample reading = 0.218 (+0.001)
mean loop sample reading = 0.224 (+0.001) (1.04ml)
mean standard reading (1ml) = 0.213 (+0.001) corr. to 1.04ml = 0.222
yield of HSA as % of loop sample = 97.3%.
The results indicated that the yield of HSA from the column was virtually
100% of that applied. However the accuracy of the experiment was limited 
by the sensitivity of the assay. It was thought reasonable to assume a 
yield of 100% for calculation of the molar conjugation ratios.
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2.2.4 Experiment to determine the separation efficiency of a Sephadex 
column
Since the conjugation of MTX to HSA requires an excess of drug it was 
important to ensure that the GPC column employed to separate the high 
molecular weight conjugate from the low molecular weight drug and 
by-products did so efficiently. The following reaction mixtures were
| . I n
consequently set up (Table 2.2):
Table 2.2
Reactant Concentration Volume' (ml)
A B C D
HSA 20mg/ml 1.5 1.5 1.5 -
MTX 20mg/ml 0.6 0.6 - 0.6
ECDI 25mg/ml 0.6 - 0.6 0.6
PBS - 0.3 0.9 0.9 1.8
Total volume 3.0 3.0 3.0 3.0
Molar ratio 
HSA:MTX:ECDI 1:58.3:174.9 1:58.3:0 1:0:174.9 0:58.3:174.9
The samples were incubated at ambient temperature overnight and then 
1.04ml aliquots were fractionated on a Sephadex G50 column (2.6cm x 38cm) 
the output being monitored at 254nm. The following fractions were 
collected as indicated on the chromatogram obtained for sample A (Figure 2.7).
79




20  25 1054838
25ml 20ml 50  ml 2 5 0 m l
Time(mins) and Volume collected (ml)
The fractions were all assayed using a scanning spectrophotometer and 
absorbance readings taken at specific wavelengths ie. 230, 262, 279, 306 
and 376nm thus enabling identification of each fraction from the 
differences in UV spectra (Table 2.3).
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Table 2.3 Retention times (min) and UV absorption maxima (nm) of
fractions taken from Sephadex fractionation experiment
Fraction number
Sample 1 2 3 4
A 15.5 min 65.5 min
236,262,306,376 223,262,303,373 226 226,258,303,373
B 15.9 min - - 66.0 min
231,279 223,279 - 223,259,303,370
C 15.5 min - 46.5 min -
231,279 223,279 252 -
D - - 47.5 min 64.5 min
- - 233 226,259,303,370
Fraction 1 corresponded to material eluting with the void volume (ie with 
blue dextran) and represented substances with a molecular weight above 
around 50,000, (Kav = 0) ie. excluded material.
The retention time of fraction 3 corresponded to that of ECDI (or its urea 
derivative) and had a Kav of 0.8. The final fraction (4) whose
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chromatographic characteristics corresponded to MTX had a Kav value of 1.2 
which indicated some column interaction which was advantageous in a 
separation of this nature.
The UV analysis from sample A (ie. HSA/ECDI/MTX) fraction 1 showed that it 
had a fairly high content of MTX; this was not pure MTX since there was a 
slight shoulder on the absorption spectrum close to 280nm and also a 
spectral shift of the A max values. The absorbance ratio (306nm/376nm) 
value of 3.5, as opposed to 3.1 for MTX, further suggested that this 
fraction was a high molecular weight derivative of MTX, ie. MTX-HSA. The 
MCR of this conjugate was calculated as 14.2 moles MTX per mole HSA. 
Fraction 2 from sample A yielded a similar spectrum but at a much lower 
concentration and showed that slightly over 98% of the MTX-HSA conjugate 
was collected in the first 25ml sample (ie. fraction 1). Fraction 3 
yielded a spectrum with a A max at 230nm with no detectable MTX present; 
this was presumed to be the urea derivative of ECDI. The final fraction 
(4) had a UV spectrum which was concordant with that of MTX ie. 303/373 
ration of 3.1 with no bathochromic shift indicating that it was unmodified 
MTX. The total yield of MTX from the column was 96% indicating that very 
little had been adsorbed (the slight deviation from 100% could be 
accounted for by the method of determination).
Sample B (ie. HSA/MTX) separated as two discrete peaks, fractions 1 & 2 
corresponding to HSA alone (no MTX detectable) and fraction 4 as MTX 
(symmetrical peak) with 303/373 ratio = 3.1. The yield of HSA was 105%, 
99% of which was collected in fraction 1. The yield of MTX was 102% all 
of which was in fraction 4 which was collected in a volume of 250ml.
The fractionation of sample C (ie HSA/ECDI) resulted in two peaks, the
82
first being identified as HSA (fraction 1 & 2) (110% yield) and the second 
(fraction 3) eluting at the appropriate time (ie 47 mins) and giving the
appropriate spectrum of ECDI in buffer. The eluant collected at times
corresponding to the retention time of MTX showed only a baseline when 
analysed by UV was not significantly different from the blank indicating 
that no material eluted in this fraction.
The chromatogram produced for sample D (ie. ECDI/MTX) gave one large peak 
corresponding to MTX. Fractions 1 & 2 contained nothing detectable by UV; 
fraction 3 (a shoulder on the main peak) comprised mainly ECDI and 
fraction 4 was confirmed to be MTX. (yield 99%).
The resolution (Rs) of the peaks was calculated using the following 
formula:
Rs = 2 X (tr 2 - tr1)/(W2 + WI)
where tr is the retention time and w the width of the peak at baseline.
The following values for resolution were obtained:
Rs HSA/ECDI 3.5
Rs HSA/MTX = 2.9
Rs ECDI/MTX = 1.0
Rs Conj/ECDI = 2.8
Rs Conj/MTX = 2.6
A resolution value exceeding 1.25 indicates that baseline separation has
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been achieved; the above results thus confirmed that the Sephadex 
fractionation system was capable efficiently of separating HSA or 
conjugated MTX-HSA from ECDI and free MTX.
2.2.5 Typical synthesis and isolation of MTX-HSA
A typical conjugation reaction was performed as follows:
The reactants were weighed directly into clean, dry volumetric flasks and 
made up to volume using phosphate-buffered saline (pH7.4, I = 0.29). The 
required volumes of each solution were then placed in a clean, dry 
reaction vessel using Gilson automatic pipettes. The sealed vessel was 
then swirled to mix (Vortex Shaker) and then left in the dark in a water 
bath at 25°C + 1°C for 24 hours (Table 2.4).
Table 2.4 Components of a typical conjugation reaction
Substance Concentration (mg/ml) Volume added (ml) Molar ratio
HSA 20.0 3.0 1
ECDI 50.0 0.6 173
MTX 20.2 (as free acid! 2.4 118
The final concentration of HSA in the reaction mixture was lOmg/ml 
Fractionation of the reaction mix was performed under ambient conditions
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using a GPC column which had been pre-equilibrated with mobile phase. The 
conjugated material eluting with the void volume was collected in a clean 









The collected conjugate solution was then assayed by lTV at 376nm following 
a 1 in 2 dilution with PBS.
The molar conjugation ratio (MCR) was then calculated from the following 
data.
Final HSA concentration (MW 66,241) = 51.34 mg in 100ml Absorbance due 
to MTX (MW 454.4) at 373nm = 0.598 (El%/lcm = 162.4)
Therefore, MCR = absorbance x 2 x 1000 x 66241
162.4 x 454.4 x 51.34
MCR = 20.9 moles MTX per mole HSA
Sephadex G15, 1.6 x 68.5 cm




10.4 - 21.25 min
39.6 ml (then made up to 100ml with PBS)








Fig.2.8 Effect of reaction time on the MCR of 
MTX-HSA conjugates at different temperatures
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-□  Ambient, pH7.45 PBS (HSA: MTX: ECDI=1: 29.2: 43.2)
•A  25°C, pH7 .35 PBS (HSA: MTX: ECDI = 1: 58.3: 43.2)
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sufficient determinations were made until a reproducible reading was 
obtained (I + 0.002); typically 3 readings.
Batches of lyophilised HSA obtained from Sigma contained water estimated 
at 5% (Mitsubishi moisture meter). Determination of water content was not 
routinely available therefore no attempt has been made to correct for the 
water content of the lyophilised protein.
2.2.6 The effect of reaction time on the molar conjugation ratio
2.2.6.1 Under ambient conditions (18-20°C, dropping to 13-15°C overnight
The reaction was performed as outlined in section 2.2.3 with an HSA :MTX : 
ECDI ratio of 1:29.2:43.2 (HSA concentration = 10 mg/ml) at a measured pH 
of 7.45 and left at ambient conditions. 1ml aliquots were removed at 
different times and fractionated as previously described; each 
determination was performed at least in duplicate. Results are plotted in 
Figure 2.8 and tabulated in Appendix 8 (Table A8.2.1)
2.2.6.2 Controlled temperature
The reaction mixtures at pH7.35 (HSA:MTX:ECDI = 1:58.3:43.2 (and 
1:29.2:43.2), HSA concentration = 10 mg/ml) were set up in a water bath 
at 25°C + 0.5°C and fractionated after various storage times. The results 
(Figure 2.8, Table A8.2.2) demonstrated that the coupling reaction had 
virtually ceased after 24 hours. The initial rapid rate of linkage 
tailed off after 4 hours and the reaction had proceeded to 90% completion
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after 9 hours (at 25°C). It was therefore decided to allow subsequent 
conjugation reactions to proceed overnight, ie. for 12-24 hours, at 25°C 
prior to termination by GPC.
2.2.7 The effect of the molar ratio of MTX in the reaction mixture on the
molar conjugation ratio
The reaction was performed using a fixed mass of ECDI but adding varying 
amounts of MTX solution and buffer to yield the desired molar ratios. The 
reaction was carried out overnight at 25°C and a measured pH of 7.35, HSA 
lOmg/ml, as previously described. Results are plotted in Figure 2.9 and 
tabulated in Appendix A8 (Table A8.2.3)
2.2.8 The effect of the molar ratio of ECDI in the reaction mixture on
the molar conjugation ratio
The experimental procedure in this case was as for experiment 2.2.7 —  
except that the mass of MTX was constant (except in the absence of ECDI) 
and the amount of ECDI was varied. Data is plotted in Figure 2.10 and 
shown in Table A8.2.4
2.2.9 The effect of increasing the concentration of both MTX and ECDI in
the reaction mixture relative to that of HSA
The reaction mixtures were set up as before with the exception that the 
concentration of MTX and ECDI were both increased whilst maintaining a 





Fig.2.9 Effect of MTX concentration on the MCR 
of MTX-HSA conjugates (25°C, PBS pH7.35)
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Fig.2.10 Effect of ECDI concentration on the MCR
of MTX-HSA conjugates (25°C, PBS pH7.35)
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in Figure 2.11 and tabulated in Appendix A8 (Table A8.2.5).
The results from this series of experiments (2.2.7 - 2.2.9) indicated that 
the MCR was dependent upon the concentrations of both MTX and ECDI.
Figures 2.9 - 2.11 demonstrate that as the concentrations of either MTX or 
ECDI were increased (relative to each other) the conjugation efficiency 
was reduced, presumably due to an insufficiency of the reactant present at 
the lower concentration. This was to be expected since the carbodiimide 
reaction was thought to proceed via the O-acylisourea formed between ECDI 
and MTX. The curves tended to be linear at lower concentrations, 
deviating from linearity at higher concentrations.
2.2.10 The effect of pH on the MCR of MTX-HSA
In this experiment the reaction mixtures were produced as before 
(HSA:MTX:ECDI = 1:58.3:86.4, HSA at lOmg/ml) except that the reactants 
were initially dissolved in distilled water and the appropriate quantity 
of double strength phosphate buffer was added to yield final reaction 
mixtures with the following theoretical pH values: 5.76, 6.12, 6.35, 6.54, 
6.72, 6.89, 7.40, 8.10. Ionic strengths was constant at 0.232M. The 
results (Figure 2.12, Table A8.2.6) are means of two determinations. 
Figure 2.12 shows that the MCR was reduced with increasing pH between pH 6 
and 7 with a subsequent flat portion of the curve. It might be expected 
that the MCR would increase with a further rise in the pH, as the pKa of 
lysine -NH2 is approached, yielding more free amine groups. The 
improved efficiency at low pH was thought to be due to the fact that the 





Fig.2.11 Effect of the concentration of MTX and
ECDI on the MCR of MTX-HSA conjugates
(25°C, PBS pH7 . 35)
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Fig.2.12 Effect of pH on the MCR of MTX-HSA 
conjugates (25°C)
Molar Ratio HSA: MTX: ECDI (1:58.3:86.4) 
HSA concentration=10mg/ml
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protonation). Further experiments were conducted at lower pH employing 
citrate buffers however problems were encountered due to:
i) visible precipitation of MTX below pH5 (ie. as the pKa of 
COOH was approached).
ii) possible interaction between the carbodiimide and citric 
acid.
The overall results of the latter experiments were conjugation ratios of 
less than 1.5 at pH values below 5.9.
Since the intention was to produce conjugates with a reasonable degree of 
reproducibility and predictability it was decided to conduct all further 
experiments within the flat region of the curve. This had the advantage 
that any slight changes in the reaction pH would not have significantly 
affected the reaction efficiency. To this end a phosphate buffeT of pH
7.4 was selected.
2.2.11 Conjugation of MTX to HSA via the active ester
This method involved two steps; the first being the preparation and 
isolation of the active ester of MTX in a non-aqueous environment, 
followed secondly by its reaction with HSA in an aqueous environment.
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Synthesis of active ester solution
In a typical reaction the following were mixed:-
1. 45.4mg of MTX (as free acid) in 1ml DMF (100 micromoles)
2. 11.5mg N-hydroxysuccinimide in~0.5ml DMF (100 micromoles)
3. 20.6g of DCC in 0.5ml DMF tl00 micromoles)
The mixture was stirred at room temperature for 1 hour and then left at
4°C for 18 hours in the dark (under anhydrous conditions). The 
precipitate which formed was removed either by filtration or removal of 
the supernatant which was then sealed in vials and stored at 4°C prior to 
use. Affigel 102 (Bio-Rad) binding experiments indicated that the 
solution contained about 50% active ester after two months storage; 
initial experiments on fresh samples showed about 60% active ester, the 
remainder being free MTX. _ ~
Conjugation of activated MTX to HSA
30mg of HSA were dissolved in 2ml of PBS. The appropriate quantities of 
active ester solution (in DMF) and DMF were added to produce a total 
volume of 3ml. The samples were left for 4 hours or overnight prior to 
separation. 1ml aliquots were fractionated on a Sephadex column-using PBS 
as the eluant, the conjugate fraction being collected in 25ml containers. 
The chromatogram from the separation revealed a second peak eluting close 
to the high molecular weight conjugate peak; this was confirmed by UV 
analysis to be DMF. The conjugate fractions were assayed by UV to 
determine the MCR as described previously.
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MCR’s were calculated assuming 100% yield of HSA from the Sephadex column 
ie. HSA = 6.28 x 10“6M (1.04ml of a lOmg/ml solution diluted to 25ml). 
Figure 2.13 (see also Table A8.2.7) shows the relationship between MCR and 





Fig.2.13 Effect of active ester ratio on the MCR
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2.2.12 Discussion
The conjugation of MTX to soluble macromolecular carriers (HSA and 
synthetic polypeptides) has been achieved using a simple one step 
procedure employing ECDI to create an amide bond between the carboxylic 
acid residue on the drug and an amine group on the carrier. This reaction 
has been documented previously with separation of product and reactants 
being achieved by GPC and dialysis (Halbert, 1983 and 1987). In this 
study GPC was used extensively to isolate the conjugates and to assess 
their stability in buffer solutions.
Sephadex gels were used to terminate the conjugation reaction by 
separating the reactants and by-products from the covalently linked 
drug-carrier conjugate. The grades of gels (G15, G25 and G50) were 
selected so as to allow the high molecular weight conjugate to be eluted 
with the void volume (confirmed using blue dextran, MW 2,000,000) and 
subsequently collected rapidly in a minimal volume. The globular protein 
exclusion limit of these columns is 1,500 (G15), 5,000 (G25) and 30,000 
(G50) (Pharmacia) thus MTX-HSA conjugates with a molecular weight in 
excess of 65,000 were excluded and eluted with the void volume, being too 
large to enter the pores. The grades of Sephadex available are coarse, 
medium, fine and extra fine; the fine grades afforded better resolution 
but tended to create excessive back pressures, coarse grades could be run 
at high flow rates but gave poor resolution. The medium grades were found 
to offer a good compromise between resolution and flow rate for this type 
of preparatory work.
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The calculation of the molar conjugation ratio (MCR) of MTX to HSA of the 
isolated conjugate relied upon the following:
1. A known amount of macromolecule applied to the column.
2. The yield of macromolecule/conjugate from the column was 100%.
3. The MTX was covalently bound to the macromolecule.
4. The MTX assay was valid when the drug was conjugated.
5. Molecular weight of the macromolecule.
Each of these points will be“considered in turn.
1. The calculation of MCR was not corrected to allow for the water 
content of lyophilised HSA. A moisture determination was carried out on 
one batch of HSA by an outside laboratory and found to be approximately 
5%w/w. A correction for water content in the calculation of MCR was not 
applied since batch to batch variation was expected and it was anticipated 
that the water content of a single batch would have changed upon storage. 
It was not possible to determine water content routinely at Bath therefore 
a rigorous correction could not be used. The error introduced into the 
calculation was expected to be approximately 5% on the basis of the data 
available. The use of calibrated loops ensured that set volumes of
reaction mix were applied to the column each time. A possible problem was
adsorption of protein to the plastic tubing and meshes but this was not 
expected to affect results seriously. Indeed tubing may well have been 
aged since numerous samples were applied using the same tubing loops.
2. It was shown that virtually 100% of HSA (in aqueous solution .at normal 
concentration) applied to a Sephadex column was eluted as determined by UV
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spectrophotometry. The experiment was performed on a freshly cleaned 
column using distilled water as the mobile phase to maximise the 
likelihood of binding (low ionic strength increases the chance of ionic 
interactions although it would reduce hydrophobic interactions). A more 
sensitive assay could have been employed to determine the level of protein 
using the Lowry method however, since this method is essentially the UV 
assay of derivatised proteins, similar errors would have been introduced. 
Moreover in this case the levels of HSA used gave a significantly high 
absorbance with which to compare sample and standards (Beer-Lambert 
linear).
Binding of MTX-HSA conjugates to the column was expected to be very low by 
inference from refractionation experiments where, following a second 
separation, the MTX concentration was 97.1% + 2.9% of that of the first 
separation indicating that only a small amount of conjugate was retained 
by the column. Garnett et al (1984) has attempted to determine conjugate 
binding to a similar column by radiolabelling both HSA and MTX 
individually but encountered assay errors which were too large to 
precisely determine the extent of binding.
3. The calculation of MCR assumed that any MTX eluting with the void 
volume was covalently bound to the HSA and that none of this material was 
physically adsorbed on to the macromolecule (protein binding). The 
binding of MTX to albumin is a well documented phenomenon (Steele et al, 
1979).
The ability of the Sephadex column to separate high molecular weight 
molecules from low molecular weight material (ECDI and MTX) was
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demonstrated with baseline resolution being achieved between HSA/MTX-HSA 
and MTX/ECDI derivatives. The high molecular weight material was eluted 
with the void volume (Kav = 0) with minimal sample dilution. The ECDI 
derivative was eluted with a Kav = 0.8 as a shoulder on the broad MTX peak 
(Kav = 1.2), the high Kav value of the latter peak infers that a degree of 
column interaction occurred. This could have been due to either ionic 
interactions of the ionised carboxylic acid residues (however this should 
be minimised by the high ionic strength of the mobile phase) or 
hydrophobic interactions involving the aromatic rings on the drug 
molecule. The covalent linking of MTX to Sephadex (mediated by ECDI) was 
unlikely since ECDI is inactivated in aqueous solution and following a 
reaction time in excess of 12 hours would only have had a limited ability 
to cause either cross linking of the gel or binding of MTX to the gel. In 
support of this view it was observed that samples which omitted either HSA 
or ECDI still gave the same Kav for MTX suggesting that the interaction 
was not covalent in nature; this was confirmed by the 100% yield of MTX 
from the column over a reasonable time scale. A covalent link would have 
been slowly hydrolysed under the relevant conditions of pH and 
temperature. The lack of physical binding of MTX to HSA was confirmed by 
UV analysis of HSA following incubation with MTX and separation on a 
Sephadex column. The spectrum of the high molecular weight fraction was 
not significantly different from that of the standard HSA solution. The 
absence of MTX in this sample was confirmed by FPLC analysis showing 
little difference between peak areas of the separated HSA sample and the 
standard, neither exhibiting the presence of free MTX either initially nor 
after incubation at 37°C for 24 hours.
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4. The assay to calculate MCR involves determination of the MTX 
concentration using its El%/lcm at its A aax at 370nm. However a 
bathochromic shift occurs altering the A  max to 376nm. This phenomenon 
is not observed in binary mixtures of HSA and MTX (although the spectrum 
is essentially the same) which also implied that the linkage between the 
HSA and MTX is covalent in nature. It is assumed that the use of ElX/lcm 
at 370nm is valid in calculating the MTX concentration since the peak is 
fairly broad and induced errors would be minimal (see Appendix A6).
5. The molecular weight of HSA has been variously reported to be between 
66,000 and 69,000 however the value used in these calculations is 
determined from its composition as given in the Atlas of Protein Sequence 
and Structure ie. 66,241. The conjugation reaction proceeded to virtual 
completion after 24 hours at 25°C (from MCR calculations) with 
approximately 80% of this value being reached after 4 hours. Higher 
activities of MTX or an increase in temperature resulted in faster initial 
rates of reaction. The inclusion of temperature control during the 
reaction yielded MCR with lower standard deviations implying a more 
controlled reaction. The slowing of the reaction is due to the 
consumption of one of the reactants; this is unlikely to be the MTX since 
it is generally present at a large excess (linking efficiency in this case 
being around 10% ie number of moles of MTX conjugated expressed as 
percentage of the number of moles in the reaction mixture). The drop-in 
rate could either be due to all the accessible linkage sites on HSA being 
occupied (however increased levels of MTX/ECDI result in higher MCR’s) or 
the ECDI being consumed either by reaction with MTX/HSA or the buffer 
solution. It has been demonstrated that ECDI solutions (in PBS pH7.4) 
stored overnight (2-8°C) resulted in MCR’s only 13% of those produced
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using fresh ECDI solutions. This suggests that the drop in reaction rate 
is due to the ECDI reacting with water. As a consequence of this the 
buffer solution was added to the dry ECDI reagent immediately before 
aliquots were added to the mixtures of HSA and MTX solutions. Higher 
reaction efficiency could be achieved by adding the HSA/MTX solution to 
the dry carbodiimide reagent, Tiowever this technique proved less accurate 
due to the small amounts (by weight) of the reagent involved.
The effect of varying the level of MTX (HSA and ECDI constant) showed that 
increasing the level of MTX resulted in an increase in the MCR; this was 
however accompanied by a drop in MTX linking efficiency from 12.4%
(HSArMTX = 14.6) to 6.8% (at 116.5). A similar experiment varying the 
relative level of ECDI (HSA:MTX = l:58.3:x) gave the expected increase, in 
MCR with an associated increase in MTX linking efficiency from 5.0% (at 
HSAiECDI = 21.6) to 23.3.% (at 173.0). The graphs of both experiments 
(Figures 2.9 and 2.10) exhibited a curvilinear relationship suggesting 
that the reaction can be limited by levels of either reactants. The 
increasing efficiency with increasing amount of ECDI implies that this had 
more influence on the resultant MCR than did MTX, provided a certain level 
of MTX was present. A more linear relationship was obtained when the 
ratio of MTX:ECDI was kept constant and their concentrations relative to 
HSA were increased. The MTX linking efficiency increased from 10 to 15% 
as the amount of MTX was increased but stabilised at~16-17% for the three 
higher levels. The line fitted to the points tails off at higher levels 
(Figure 2.11) suggesting that there are a limited number of binding sites 
on HSA. If it is assumed that MTX only binds to lysine residues then the 
maximum MCR is 59. It is unlikely that all these residues will be 
accessible although they will tend to be located on the surface of the
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molecule due to their hydrophilic nature. The regression line (r = 0.997) 
does not pass through the origin (intercepts the x axis at c.10 molar 
ratio MTX) it may be concluded from this that a certain level of MTX is 
necessary otherwise side reactions could predominate (ie with H2O or HSA).
The conjugation reaction when conducted in a range of phosphate buffers 
(pH.6-8) showed that a plateau region between pH.6.9 and 8.1 (ie no 
significant difference between the MCRs) corresponding to minimum 
efficiency (15%). At lower pH the MCR increased (as did the efficiency) 
however this was limited by precipitation of the product below pH6 (and 
interaction with the buffer). The increase in linking efficiency at lower 
pH may be accounted for by the acid catalysis of the carbodiimide 
reaction. It is also suggested that the MCR may increase once more at high 
pH as the pKa of lysine is approached thus increasing the number of 
unprotonated residues (Garnett et al, 1984).
This series of experiments indicates that provided the temperature and pH 
of the reaction mixture are controlled and that a freshly prepared 
solution of ECDI is used then a MTX-HSA conjugate of a particular MCR can 
be prepared by selecting the appropriate proportions of each reactant.
The linking of MTX to HSA via the activated ester provided a much more 
efficient reaction with 30-45% of the input MTX being conjugated to HSA. 
The conjugation had reached 90-100% of the 24 hour MCR value after 5.5 
hours. The separation of the conjugate from the MTX/ECDI derivative is as 
efficient as previously observed for carbodiimide-mediated reaction 
however it was noted that the separation of the conjugate from the DMF was 
not as good as might have been expected leading to possible contamination
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of the conjugate solution by the solvent.
The active ester method of conjugation has the advantage over the ECDI 
reaction in that it is more efficient, however the procedure is more 
complex in that it involves two steps and an intermediate assay. The 
presence of DMF may also present a separation problem as described above 
and also affects the solubility of HSA limiting the ultimate degree of 
conjugation.
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2.3 FPLC analysis of MTX-HSA conjugates
2.3.1 Introduction
Halbert et al (1983) demonstrated using dialysis experiments that MTX-BSA 
conjugates were unstable in buffer solutions. It was decided in this 
study to assess the stability of MTX-HSA conjugates using fast protein 
liquid chromatography (FPLC). This technique allows rapid, high resolution 
GPC enabling analytical separation of materials according to molecular 
weight. The analytical system (similar to that of a conventional HPLC) 
was as follows (Figure 2.14):











Mobile phase: as used for isolation of MTX-HSA
PBS pH 7.4, I = 0.29M, filtered (0.45um), degassed
Pump: LDC Constametric II with pressure monitor
Injector: Rheodyne 7132
Autosampler: ACS
Column: Superose 12 (Pharmacia) or TSK G3000PWxl
Detector: Gilson 113
Chart recorder: BBC Servogor 212, dual pen
Microcomputer: Acorn BBC Master linked to Winchester hard disc
via an Econet network
2.3.2 Sample preparation and application
The conjugates were prepared as previously outlined (section 2.2.5) and 
then desalted on a Sephadex GPC column. The samples were then filtered 
(sterile 0.2um) into sterile vials for storage under specified conditions. 
Samples were applied to FPLC columns using one of the following methods:
i) multiple sampling from a solution held at 37°C using a 
modified autosampler injection valve.
ii) samples removed from 37°C storage and injected using the 
autosampler.
iii) samples injected manually using the autosampler to trigger 
data capture (by the microcomputer).
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Samples stored in vials for methods ii) and iii) were either applied 
immediately upon removal from 37°C storage or held at -18°C prior to
assay. The volume of sample applied depended upon the column ie. 200
microlitres for Superose 12 and 20 microlitres for TSK.
2.3.3 Columns
The columns used were either
i) Superose 12 HR 10/30 10mm x 30 cm which contained 
cross-linked agarose beads of diameter 1 0 + 2  urn. This was 
suitable for proteins of molecular weight up to 300,000 
daltons.
ii) TSK G3000PWxL 7.8mm x 30cm
+ TSK guard column PWH 7.5mm x 7.5cm
The flow rates were selected to enable rapid analysis whilst still 
providing good resolution
Column Flow Rate Analysis time
Superose 12 0.5ml/min 60 min
TSK G3000PWxl 0.75ml/min 30 min
108
2.3.4 Temperature control
The temperature of the column was maintained at 25°C + 0.5°C by either 
immersing the column in a water bath (TSK) or using a column jacket 
(Superose). A heat exchanging coil was used to control the temperature of 
the mobile phase and the valve/loop was also immersed in the water bath.
2.3.5 Detection and data capture
The detectors used were a Pye Unicam UV20 (fixed wavelength 254 & 280),
Pye Unicam UV3 (variable wavelength), LDC Spectromonitor (variable) and, 
more routinely, a Gilson 113. The Gilson 113 was a variable wavelength 
detector which could be used as a single wavelength detector with two 
outputs at different sensitivities or a dual wavelength detector and could 
also be used to scan peaks of particular interest. The two outputs were 
monitored using a dual channel chart recorder; one of the outputs also 
being digitised using an Acorn BBC computer. Data was logged on to a 
Winchester hard disc for subsequent analysis; to generate information on 
retention times, peak areas and for computation of molecular weight 
distributions. The autosampler was used remotely to trigger the computer 
data capture system thus enabling retention times to be calculated more 
precisely. _
2.3.6 Column calibration
It was intended to use the FPLC system to investigate the stability of the
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conjugates, release of free MTX and also to study the effects of enzymes 
on the carrier system. Therefore it was necessary to calibrate the 
columns with proteins of known molecular weight to enable the molecular 
weight distributions to be determined and also to calibrate with MTX and 
HSA in order to quantify the release of MTX from the conjugates. Details 
of calibration procedures and the data obtained are described in Appendix 
A2. In summary both columns could be calibrated for molecular weight in 
accordance with theory. When log molecular weight was plotted against Kav 
both columns gave a linear fit over a limited range. The Superose column 
was effective over a wider molecular weight range (1 - 100 kD) than the 
TSK G3000 column (2 - 70 kD) but the latter column was more robust and 
less variable in day to day use. The Superose column compressed during 
use such that its total volume varied during a series of assays. Regular 
calibration was thus necessary to obtain accurate data but this 
disadvantage was outweighed by its superior resolution, particularly of_ 
HSA and aggregates of HSA. MTX interacted weakly with both columns which 
resulted in Kav values slightly greater than unity (Kav MTX was 1.2 and
1.1 on the Superose and TSK columns respectively). Both columns could be 
calibrated for MTX or HSA concentrations giving linear plots against peak 
height or peak area over the relevant concentration range -studied,
2.3.7 Resolution of HSA and MTX by FPLC columns
2.3.7.1 The ability of the Superose 12 column to separate HSA and MTX
The purpose of this experiment was to determine whether or not the 
Superose 12 column was capable of separating MTX from HSA under routine 
operating conditions.
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Samples were prepared by taking aliquots from stock solutions of HSA and 
MTX to obtain a range of MTX and HSA concentrations which were equivalent 
to those present in conjugates following synthesis and fractionation 
(molar ratios of MTX:HSA 0.03 to 21.3) Samples were then placed in vials 
and injected soon after preparation using the autosampler. Other samples 
were stored at ambient temperature and injected after a period of at least 
12 hours storage. Chromatograms-were compared with those of HSA and MTX 
standards to calculate the relative concentration either by peak height or 
area (Cl10 integration) at 300nm. Data obtained is shown in Table 2.5.
The results from this experiment indicated that Superose 12 chromatography 
could be used to analyse both HSA and MTX in the same sample, good 
correlations being achieved in both calibration exercises. The system was 
capable of separating physical mixtures of HSA and MTX with- good baseline 
separation being achieved at all concentrations studied (Rs > 2.4). The 
separated HSA fraction did not contain any physically bound MTX since at 
300nm this would have had a significant affect on UV absorption. 
Statistical analysis (t test) showed that the standard and test sample 
peak heights of HSA were not significantly different. The mean retention 
times were 25.3 (+ 0.1)min and 49.6 (+D.4)min for HSA and MTX 
respectively. —
2.3.7.2 The ability of the TSK column to separate HSA and MTX
Samples were prepared from stock solutions of HSA (5mg/ml) and MTX 
(0.137mg/ml) in PBS pH7.4. The required amounts were mixed and made up to 
volume with PBS to produce the following molar ratios (MTX:HSA) 1,5,10 and 
20. MTX and HSA standard solutions were also prepared with the same 
concentrations as the mixed samples. Samples were stored at ambient
Table 2.5:
The separation of physical mixtures of MTX and HSA using the Superose 12 column 
(detection at 300 run) (HSA - 0.513 mg/ml) (PBS, pH 7.4, 25°C, 0.5 ml/min)
Sample Molar ratio 
MTX : 1 HSA
Rs HSA % of 
input by 
peak height
HSA % of 
input by 
peak area
MTX % of 
input by 
peak height
MTX % of input by 
peak area




RM13/1 0.028 5.5 99.2 (±0.5) 99.7 (±0.4) 100.5 (±0.5) poor integration -
RM13/2 0.057 4.9 99.0 (±0.3) 99.1 (±0.1) 99.3 (±0.3) poor integration -
RM13/3 0.085 4.5 100.0 (±0.3) 101.1 (±1.5) 98.5 (±0.2) poor integration -
RM13/4 0.114 4.3 99.9 (±0.2) 97.8 99.7 (±0.7) 99.4 (±1.9) -
RM13/5 0.142 4.1 99.6 (±0.2) 99.5 (±0.2) 100.2 (±0.2) 102.1 (±0.3) -
RM15 C 0.85 3.5 101.8 (±0.5) 101.2 99.5 (±2.5) 101.0 100.7
RM15 B 5.4 2.7 102.1 (±0.8) 99.1 100.3 (±4.0) 97.9 102.2
RM15 A 21.3 2.4 101.4 (±1.1) 100.7 (±0.2) 99.2 99.9 104.1
(±sd)
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temperature (for up to 30 hours) and then injected onto the TSK column 
with detection at 279 and^303nm. The mobile phase was PBS pH7.4 at 25°C; 
flow rate 0.746ml/min. Data is shown in Tables 2.6 and 2.7.
The mean retention times were:
HSA = 11.47 (±0.05)min, Kav = 0.145
MTX = 24.93 (±0.07)min, Kav = 1.090
The resolution values were calculated giving Rs > 3.4 which indicated a 
good baseline separation. The results showed that the TSK column could be 
used to assay both MTX and HSA and that it was capable of separating 
mixtures efficiently (with 100% yield). The baseline resolution was aided 
by the weak interaction of MTX with the support material.
2.3.8 Discussion
The stability of drug/macromolecular conjugates has previously been 
examined by way of dialysis experiments (Halbert, 1983). In this study 
MTX-HSA stability was examined using FPLC which had the potential to assay 
for free MTX and also check the molecular weight integrity of the carrier 
system simultaneously. This also overcomes any problems associated with 
dialysis experiments eg adsorption, microbial contamination, time delay to 
equilibrium and any inconsistencies due to poor mixing in the bulk phase.
The mobile phase used in the FPLC analyses was prepared as for that used 
in fractionation experiments ie recently prepared, sterile filtered PBS
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Table 2.6:
Separation of physical mixes of HSA and MTX on the TSK column: MTX 







303 nm 279 nm
Sample 
peak 










RM25/1 2.74 X 10-3 100.8 102.6 100.0
RM25/5 1.37 x 10-2 99.3 99.8 100.0
RM25/10 2.74 x 10-2 100.0 99.4 100.0
RM25/20 5.48 x 10-2 100.0 101.2 100.4
Table 2.7:
Separation of physical mixes of HSA and MTX
on the TSK column: HSA assay at 279 nm
(HSA - 6.0 x 10*3M) (PBS, pH 7.4, 25°C, (0.75 ml/min)
Sample Sample peak 
height as % 
std
Sample peak 







pH7.4. This was to prevent microbial spoilage of the columns since 
although a low level of contamination was unlikely to alter the conjugate 
itself, due to the short run times involved, it may have altered the 
chromatographic characteristics of the separation systems (eg reduce the 
plate number). In order to minimise the risk of contamination 0.02% w/v 
sodium azide was incorporated into the mobile phase and the eluant was 
kept flowing through the column continuously. The high ionic strength was 
employed to minimise ionic interactions.
The sample preparation was performed under clean laboratory conditions in 
order to minimise the risk of sample contamination. The Sephadex columns 
were regularly cleaned according to manufacturers instructions ie with 
NaOH and 70% ethanol and were left in ethanolic solution if stored for 
long periods of time. The buffer solutions were recently or freshly 
prepared filtered 0.2um sterile filter and stored in clean/sterile sealed 
Duran bottles at 2-8°C. In later experiments 0.02% w/v sodium azide was 
incorporated into the mobile phase to reduce the probability of microbial 
spoilage of either the column or conjugate solution. All glassware used 
in sample preparation and collection was cleaned, dried and foil wrapped 
before sterilisation in a dry oven at 160°C for a minimum of 2 hours (more 
routinely overnight). Vial caps were soaked in 70% ethanol solution then 
dried briefly at 80-100°C. The sample solution following collection from 
the Sephadex column was immediately sterile filtered (0.2um) into vials. 
The columns were selected on the basis of their claimed separation range 
for proteins which in the case of the Superose 12 was up to 300,000 
Daltons and for TSK was 100,000 Daltons. The required molecular weight 
separation range was 1,000-70,000 Daltons. The Superose 12 column had the 
advantage that it was capable of separating the dimer of HSA but was
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however prone to column compression during a run and periodical blocking. 
The TSK which was slightly inferior in terms of its range of separation 
but did not suffer from the aforementioned problems and had an analysis 
time of only 30 minutes (as opposed to 60 minutes for the Superose 12).
The use of temperature control of the FPLC system was possibly not 
absolutely necessary but helped to prevent baseline drift due to the 
detector which was observed during overnight analysis. The more 
controlled conditions also resulted in more consistent retention times due 
to the mobile phase viscosity remaining constant. The analogue output 
from the detector was digitised and the data captured by an Acorn BBC 
microcomputer. The data was stored on a 30Mbyte hard disc, which was 
necessitated by the large amount of. data and subsequently analysed. The 
analysis of molecular weight programme (see Appendix A7) enabled the 
precise calculation of retention times. The programme also enabled 
determination of area under the curve (AUC) and molecular weight 
distributions (from the MW calibration) either overall or of particular 
peaks. The analysis of specific peaks could be achieved either by 
skimming (a) or by dropping a perpendicular to a preset baseline (b) from 
a particular point (Figure 2.15). The molecular weight distribution being 
determined by normalisation of the peak area and MW calibration (see
section 2.2.2.). The chromatogram (Figure 2.15) shows the smaller dimer . 
peak of HSA (c. 137,000) eluting prior to the larger monomer peak (c.
67,000). These are referred to as the dimer peak and monomer peak.
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Figure 2.15 Chromatogram of MTX-HSA conjugate from Superose 12 showing 
peak area analysis
The molecular weight calibration of the columns was achieved using a 
Pharmacia protein calibration kit. The Superose 12 gave a good regression 
line over the MW range 6,500-134,000 however it may be observed that the 
slope of the lines obtained were not consistent which may arise due to 
changes in the condition of the column (although it was regularly cleaned 
according to the manufacturers instructions). In order to ensure accurate 
results calibration standards were employed during each assay where 
molecular weights were to be determined (at least at the beginning and end 
of each run) and these results used in the calculation of molecular weight 
distributions.
The calibration of the TSK G3000 PWxl column proved more reproducible 
however calibration standards were employed routinely as for the Superose
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column. The regression line fitted to the calibration points from MW 1353 
to 67,000 gave a reasonable straight line however it can be seen from 
Figure A2.5 which includes the BSA dimer that the line is the classical 
sigmoid shape expected in GPC. It shows that the column is linear between 
6,500 and 43,000 implying a useful range between about 5,000-50,000. A 
non-linear regression line would be more appropriate in this case however
since this was unavailable it was thought acceptable to rely upon the
linear regression analysis to calculate the molecular weights. It is
known that this would give slightly erroneous values in some cases but it
was thought the system would still prove valuable since the molecular 
weights were to be determined over the width of a normalised peak fraction 
as opposed to a one point determination.
The calibrations with MTX proved linear over a wide range of 
concentrations at the wavelengths employed on both columns. The method of 
quantification (peak height or area) had no effect on the fit of the 
regression line. The retention^times were also very reproducible with Kav 
values at 1.1 for the TSK column and 1.2 for the Superose 12 column 
suggesting an interaction with the stationary phase in both cases.
The HSA calibration at 279nm for the TSK and 280nm for the Superose 12 
both yielded good calibration lines and reproducible retention times. A 
similar situation was observed with the diluted~conjugate solution on the 
Superose column which showed a linear response for both conjugate and MTX 
using dilutions of 33.3% to 100%. It is concluded from this that no 
significant levels of adsorption occur over the range studied since if 
this were the case then a deviation from linearity may be expected at the 
lower concentrations. The ability of the columns to separate physical
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mixtures of MTX and HSA was demonstrated using a range of MTX:HSA molar 
ratios from 1 to 20 (and as low as 0.03 in the case of the Superose based 
system). In both systems complete separation of both components was 
achieved (ie 100% of standard solutions) with Rs > 2.4 for the Superose 
and Rs > 3.4 for the TSK. This confirms that any MTX that might be 
physically bound to HSA would be separated on the first pass through the 
FPLC column even down to molar ratios of 0.03 moles MTX to 1 mole of HSA. 
Even at this level of adsorption a 10% increase in peak areas would be 
observed at 300nm. This is important to confirm that any release that may 
occur is not due to physically bound MTX. —
2.4 The stability of MTX-HSA conjugates in buffer solution
2.4.1 Effect of MCR on stability of MTX-HSA conjugates
The purpose of the experiments described in section 2.4 was to investigate 
whether MTX-HSA conjugates maintained their integrity when stored in 
solution at elevated temperature. Preliminary experiments indicated that 
the conjugates released free MTX upon storage in buffer solutions at 37°C, 
which confirmed the findings of Halbert (1983).
The preparation of the samples was as outlined in section 2.2.5; ie. 24hr 
conjugation at 25°C followed by Sephadex fractionation (PBS pH7.4 as 
eluant) and sterile filtration. The sample was repeatedly injected on to 
the Superose column from a container held at 37°C using the autosampler. 
The concentration of MTX present in the sample was determined by UV assay 
at 376nm and the MCR calculated (section 2.2.5). Stability test samples
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were interspersed with suitable MTX standards. The amount of free MTX 
released was determined and expressed as a percentage of the total MTX 
concentration.
The conjugate peak was observed to elute first with a similar peak shape 
to HSA alone, the major difference being an increased proportion of dimer 
in the conjugated sample. Dimer and monomer peak shape did not alter 
during a 60 hour run indicating that the tertiary structure of the 
conjugate was unaffected by storage. An example of a MTX-HSA conjugate 
peak (on the Superose column) is shown in Figure 2.15. Conjugate samples 
injected immediately following fractionation showed very low levels, or 
non-detectable amounts, of free MTX. Low levels of free MTX arose due to 
a limited amount of degradation occurring during sample processing after 
fractionation, since the first possible sample point was 30 minutes from 
application to the Sephadex column and 10-15 minutes after emergence of 
MTX-HSA conjugate. Results obtained for release of MTX from conjugates 
with low and high MCR’s are shown in Table A8.2.8 and plotted in Figure 
2.16. Each result was the mean of two separate experiments.
It was concluded from this experiment that the amount of MTX released from 
the conjugates, when expressed as a percent, was not dependent on the MCR 
of the carrier system. The amount of cleavable bonds produced by the 







Fig.2.16 Release of free MTX from MTX-HSA conjugates 
of different MCR (37°C, PBS pH7.4)
HSA concentration^. 513mg/ml5. Ot
1 .0"
0.0
0 2 6 8 104 12 14 16 18 20 22 2 4 2 6
Time (hours)
— A—  Mean MCR = 4 . 7 (+0 . 9) 
Mean MCR = 19.5 (±0.8)
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2.4.2 The effect of the reaction tine on conjugate stability
In this experiment the conjugation reactions were performed in the usual 
manner except that for runs 3, 4 and 5 the ECDI solution had been prepared
about 2 hours prior to use, thus resulting in a lower conjugation ratio
than would have been expected from the 1: 116.5:43.2 ratios employed.- 
However they could be used for comparative purposes (runs 1 and 2 were 
produced using fresh ECDI using a 1:58.3:43.2 ratio).
The results suggested that a shorter reaction time was associated with a 
faster release of free MTX from the conjugate following fractionation 
(Table A8.2.9 and Figure 2.17). This may be explained with reference to 
the experiment described previously relating MCR to reaction time which 
showed that the conjugation reaction was 80% complete at 4 hours. Further
storage time could have resulted in cleavage of less stable bonds which
would not have been replaced as the ECDI reagent was exhausted. The MTX 
cleaved after extended reaction time at 25°C would have been removed by 
fractionation on the Sephadex column resulting in less release of free 
drug upon subsequent storage at 37°C.
2.4.3 The effect of refractionating a degraded MTX-HSA conjugate
The purpose of this experiment was to investigate whether a conjugate that 
had been held at 37°C for a substantial period of time could be 
refractionated to yield a more stable sample.







Fig.2.17 Release of free MTX from MTX-HSA 
conjugates with different conjugation 
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Sephadex column, stored at 37°C and then repeatedly injected on to a 
Superose 12 column. The sample was held at 37°C for approximately 65 
hours and was then refractionated on the Sephadex column (5.13ml injected, 
100ml collected). Its stability was reassessed using the Superose 12 
system, Detection in both cases being either at 300 or 370na. Samples 
*1’ and *2* represented the freshly fractionated sample and the 
refractionated samples respectively. The experiment was repeated on a 
conjugate with a similar MCR. The second fractionation was performed 
following storage at 37°C for 60 hours on a short Sephadex column (5.13ml 
injected, 20ml collected). Data is shown in Table A8.2.10 and Figure 
2.18.
The MTX-HSA peak was found to be smaller following the second 
fractionation due to the dilution effect but its shape was essentially 
unaltered. It was demonstrated that refractionation of a degraded sample 
drastically reduced the rate of release of free MTX but did not prevent it 
completely, implying that MTX-HSA bonds remained which^were hydrolysed at 
a slower rate.
2.4.4 The effect of pH on the release of MTX
The purpose of this experiment was to determine whether the pH of the 
buffer affected the rate of release of MTX from the conjugate. Conjugate 
solutions were prepared by fractionating a 1ml sample of reaction mixture 
(allowed to react at 25°C for 24 hours and then frozen at -18°C until 
required) using distilled water as the eluant. Aliquots of the conjugate 
fraction (MCR = 9.92) were then mixed with an equivalent volume of double
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Fig.2.18 Effect of refractionation on the release 
of free MTX from MTX-HSA conjugates.
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strength buffer, incubated at 37°C for the required period of time and 
then frozen prior to assay on the TSK column. Data are^listed in Table 
A8.2.11 and plotted in Figure 2.19. A pH 4 sample was also produced, 
however this pH caused precipitation of MTX-HSA from solution and the 
sample was not subsequently assayed.
The buffer solutions alone were chromatographed with the result that pH 
5, 6 and 7 produced a deflection at 300nm but only at a low level. The 
retention time of the solvent was found to be between that of the 
conjugate and free MTX and consequently would not have interfered with the 
assay. The peak heights, shape and area were similar at all pH conditions 
except at pH12 which produced a much broader peak for MTX-HSA with a 
slightly reduced area (mainly accounted for by the large release of MTX). 
The change in peak shape at pH 12 was thought to be due to an alteration 
in the tertiary structure of HSA.
The results demonstrated that an increase in pH brought about a more rapid 
and extensive release of MTX up to a limit of about 8% at pH12. The rapid 
plateauing at pH12 inferred that 8% was the maximum amount released after 
the conjugation had been allowed to proceed for 24 hours at 25°C. The 
samples stored at other pH values tended towards this limit after longer 
incubation at 37°C (Figure 2.19). This implied that the hydrolytic 
degradation of MTX-HSA conjugates was~base-catalysed.
In an attempt to synthesise a stable product (using ECDI) the conjugation 
reaction (MCR = 10) was performed in water, stored at 4°C for at least 24 
hours, then the pH raised to 11. The solution was stored at pH 11 and 4°C 








Fig.2.19 Effect of pH on the release of free MTX 
from MTX-HSA conjugates (37°C)
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were then incubated at 37°C and the release of free MTX analysed by HPLC 
(Table 2.8). The increase in pH had no effect on the shape of the 
chromatogram.
Table 2.8 Release of free MTX from conjugates following storage at pH 11 
prior to fractionation
% release of free MTX
Incubation time Storage time at pH 11, 4<5C (hours)
at pH 7.4, 37°C 0 1 2 3 4 6 23
0 5.2 3.7 1.7 0.0 0.0 0.0 0.0
2 6.2 3.8 1.9 0.2 0.2 0.2 0.3
4 6.9 3.8 1.9 0.0 0.3 0.3 0.3
24 9.8 6.8 5.4 0.5 0.7 0.6 0.7
It can be seen from Table 2.8 that incubation at pH 11 for 3 hours and 
more drastically reduced the release of free MTX to approximately 0.5% 
over 24 hours at pH 7.4 and 37°C.
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2.4.5 Stability of MTX-HSA conjugates produced using the active ester
MTX-HSA conjugates were prepared using the active ester derivative of MTX 
and separated as previously described. The stability of these conjugates 
in buffer (PBS, pH 7.4) at 37°C was assessed using Superose 12 column.
Data is shown in Table A8.2.12 and plotted in Figure 2.20.
2.4.6 Discussion
Initial experiments with MTX-HSA conjugates, where the reaction mixture 
was separated on the GPC column and then dialysed against buffer at 
ambient temperature and lyophilised, showed upon FPLC analysis that there 
was a significant level of free MTX present in the reconstituted sample. 
Further investigations revealed that the conjugate solution immediately 
post column contained no free MTX; additional storage at elevated 
temperature revealed the instability of the conjugate. It was decided to 
use the FPLC systems to quantify the release of MTX from the conjugate at 
37°C (dialysis would remove any free MTX and also variable amounts of 
hydrolysed MTX depending on temperature and time).
The samples were collected from the Sephadex column and further processed 
as quickly as possible in order to minimise the time between the start of
I
collection and application to the FPLC column. This finite amount of time 
(15-30 minutes) resulted in a small amount of free MTX being present in 







Fig.2.20 Release of free MTX from ester conjugated 
MTX-HSA conjugates (37°C. PBS pH7.4)
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A comparison of high (MCR = 20) and low (MCR = 5) strength conjugates at 
pH7.4 and 37°C reveals that a similar level of free MTX (expressed as a 
percentage of total MTX) was released from both conjugates. The release 
of MTX (3.5 - 4.0%) was not dependant upon the MCR of the conjugate. It 
may be noted from the shape of the curves that there is an initial fast 
rate of release which starts to tail off after about four hours to result 
in a slower residual rate of release after about 16 hours (Figure 2.16). 
This would imply that there are two populations of hydrolysable bonds 
formed between MTX and HSA, one group which degrades faster than the other 
giving rise to the initial faster rate of release. It would appear that 
the more labile bonds tend to form as a fixed proportion of the total MCR 
(overall percent release is similar) and are dependent on the relative 
levels of ECDI and MTX. The chromatograms show that the conjugate peak 
maintains its characteristic shape during the degradation experiments and 
release was not due to break down of the molecule or deterioration of the 
tertiary structure (see Figure 3.6).
The results from the shorter reaction mixture incubation time experiment 
(4 hours) show a higher level of release (7%) than those reaction mixtures 
left for 24 hours (Figure 2.17). The fact that the ECDI solution was not 
freshly prepared for runs 3,4, and 5 resulted in reduced MCR’s, as 
expected, but this has had no effect on the release of free MTX. The 25 
hour sample had the same release profile as other conjugates produced with 
freshly prepared ECDI solutions and incubated for a similar period. The 
increase in release observed with the 4 hour reaction time sample may in 
part be explained by the decreased reactivity of the carbodiimide with 
storage time in aqueous solution. In the reaction mixture the labile 
bonds will be formed and then slowly hydrolysed, as the carbodiimide
becomes exhausted these links will not be reformed (since there is excess 
MTX). Consequently at longer incubation times more of the labile bonds 
will have been hydrolysed and a lower rate of release will be detected 
from the isolated conjugate. It can be seen from this that the storage 
time and temperature will have a profound effect on the stability of the 
conjugate post-fractionation.
The samples which had been fractionated then stored at 37°C for 65 hours 
prior to refractionation on a Sephadex column showed a much slower rate of 
release than samples from the initial fractionation (Figure 2.18). The 
rate of release of drug was faster than in the later stages of the first 
part of the experiment. This may be due to a disturbance in the 
equilibrium or possibly a dilution effect, however similar release rates 
were observed for refractionations A and B where B was 5 times the 
concentration of A. It would suggest that the bonds being broken are the 
less labile ones.
The effect of altering the pH of the buffer brought about changes in the 
release profile. The results demonstrate that an increase in pH brings 
about a more rapid and extensive release of MTX up to a limit of about 8% 
at pHI2. This implies that the hydrolytic degradation of the more labile 
bonds of MTX-HSA conjugates was base catalysed. Acid catalysis could not 
be examined due to insolubility. Incubation of the reaction~mixture at pH 
11 prior to fractionation (pH 7.4) reduced the level of release of the 
resulting conjugate solution to about 0.5% (free MTX after 24 hours at 
37°C. This was similar to that observed for refractionated samples and 
conjugates produced by the active ester method.
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Release experiments from active ester mediated conjugates revealed a much 
slower release rate after a reaction time of only 5.5 hours indicating a 
more stable product (Figure 2.20). The release profile was similar to 
those observed following refractionation of the carbodiimide-mediated 
conjugate (Figure 2.18) indicating a lack of the more labile bonds.
CHAPTER THREE: ENZYMATIC DEGRADATION OF MTX-HSA CONJUGATES
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3.1 Introduction
The release of drugs from macromolecular carrier systems in the presence 
of enzymes has previously been examined however little attention has been 
focused on the integrity of the carrier itself following exposure to 
enzymes (Trouet et al, 1982).-
In this study it was decided to analyse the release of MTX from the 
carrier system and also the molecular weight distribution of the carrier 
itself following incubation with trypsin and tritosomal enzymes. Trypsin 
was examined as a model enzyme since from its known specificity (Keil,
1971) it should have been capable of breaking down the carrier systems it 
was proposed to use ie HSA and glutamic acid/lysine copolymer. It was 
thought that this would provide useful information as to whether the 
attachment of MTX prevented the degradation of the carrier peptide and if 
the breakdown of the conjugate resulted in an increase in the release of 
MTX as the free drug. —
The question as to whether the conjugate would be degraded by lysosomal 
enzymes were it to be a lysosomotropic agent was addressed by incubation 
with tritosomes.
The tritosomes used in this series of experiments were isolated from rat 
liver according to the method_of Trouet et al (1974), these comprise a 
plethora of enzymes with pH optima varying between 2 and 8 (Barrett,
1972). The lysosomes themselves contain a number of enzymes including 
nucleases, glycosidases, aryl sulphatases, lipases, phospholipases, 
phosphatases and and proteases. The latter are capable of dismantling
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proteins and polypeptides; they comprise the cathepsins and also acrosin 
which is an endopeptidase with a specificity similar to trypsin. It was 
hoped to discover using FPLC whether MTX was released as free drug or 
linked to an oligopeptide unit following tritosomal degradation. It has 
previously been suggested that spacer units may be necessary to enable 
enzymatic hydrolysis and release of the free drug (Trouet et al, 1982); 
this may be required for drugs such as DNR but MTX has been shown to be 
active in the polyglutamated form and even when bound to a polypeptide.
Trypsin —
Trypsin is a serine protease which preferentially catalyses the hydrolysis 
of ester and peptide bonds involving lysine and arginine (basic amino 
acids). The inactive precursor, trypsinogen, is synthesized and 
subsequently converted to trypsin in pancreatic cells. Trypsinogen is 
converted to the active enzyme by limited proteolysis at pH8 (catalysed by 
small amounts of trypsin, enterokinase or thrombin), autocatalysis also 
occurs under mildly alkaline conditions.
\
The molecular weight of the enzyme has been calculated as 23,985 (from 
known structure of bovine trypsinogen) and 23,560-23,700 by 
physicochemical measurements; the extinction coefficient El%/lcm is 15.4 
at 280nm. _
The solution stability was determined by Wang and Carpenter (1967) who 
showed that after 2 hours at pH 8 trypsin retained 100% of its original 
activity (on N<*-benzoyl-L-arginine ethyl ester as substrate) and 92% 
after 20 hours.
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The catalytic site itself is dependent on particular serine and histidine 
residues whereas it is assumed that negatively charged residues are 
present in the specificity site enabling electrostatic binding of 
positively charged substrate groups. As previously mentioned the trypsin 
specifically cleaves bonds involving the carboxyl group of lysine or 
arginine with a pH optimum lying between pH7 and 9. It is suggested that 
the enzyme exhibits increased activity towards the arginine residues but 
this may be attributed to the adjacent residues (Wang and Carpenter,
1967). The rate of catalysis may be reduced by removal of the positive 
charge on the lysine either by altering the pH (pKa of the guadinium group 
on arginine is much higher) or by a substituent on the €-amino group. 
Other factors which may affect the hydrolysis are the tertiary structure 
of the substrate (although positively charged groups are normally located 
on the surface of native proteins) and the presence of negatively charged 
groups in the vicinity of the labile bond.
3.2 The effect of trypsin on the release of MTX from MTX-HSA conjugates
In this experiment the conjugation reaction was set up as previously 
described (section 2.2.5) using a (1:118:173 ratio, pH 7.4) and then 
fractionated on a Sephadex column (mobile phase PBS, pH 7.4) after 24 
hours at 25°C. A -50ml aliquot of the conjugate solution was taken and 1ml 
of a trypsin solution (c. 2.5mg/ml) was added to it prior to incubation at 
37°C. The samples were then analysed on a calibrated Superose 12 column 
at time intervals up to 24 hours.
136
The conjugate peak was found to be degraded into a series of lower 
molecular weight peaks as well as free MTX which eluted separately from 
the other peptide peaks, the retention time of which was identified from 
MTX calibration samples (Figure 3.3). Data are shown in Table A8.3.1 and 
plotted in Figure 3.1. The experiment was performed at least in duplicate.
The results from this experiment demonstrated that the release of MTX from 
the conjugates was not greatly affected by incubation with trypsin 
although the rate appeared to be increased slightly by the addition of 
enzyme. The extent of the release was not affected by the enzyme since 
following 45 hour incubation at 37°C the same conjugate solution was found
to contain 5.4% free MTX both in the presence and absence of enzyme.
A further experiment was performed by exposing a conjugate solution to 
different levels of trypsin and monitoring the release of MTX. The 
conjugate (MCR = 22.1) was produced as normal and following fractionation 
in PBS pH 7.4 had the following added to 25ml aliquots:
A - 13.0mg trypsin, HSA conc. = 7.752 x 10"6M,
Try:HSA molar ratio = 2.82:1
B - 1ml of a 13.5mg/ml solution of trypsin in PBS pH 7.4 giving
—  HSA conc. = 7.454 x 10"$M, molar ratio = 0.29:1
C - 0.1ml of 13.5g/ml solution of trypsin in PBS pH 7.4 giving
HSA conc = 7.721 x 10"6M, molar ratio = 0.028:1
NT - conjugate sample with no trypsin added, HSA conc = 7.752 x 10"6M
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Fig.3.1 Effect of trypsin on the release of free 
MTX from MTX-HSA conjugates (37°C,PBS pH7.4)
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Subsamples were placed in sterile vials, sealed and incubated at 37°C 
prior to assay on the Superose column at 300nm. The release of MTX was 
calculated from the peak heights compared to standard samples.
The data (Table A8.3.2, Figure 3.2) confirmed the previous result that the 
addition of trypsin had little effect on the release of MTX from the-  
conjugates in that all the points lay on virtually the same curve. The
addition of further enzyme at the end of the run had no effect on the
release of MTX from either A,B or C.
The release of MTX in this case was slightly less than previously observed
possibly due to the reaction conditions which were 24 hours at 25°C 
followed by storage at -18°C for 24 hours prior to thawing and 
fractionation.
3.3 The effect of trypsin on the molecular weight distribution of HSA
In order to investigate the digestion of HSA by trypsin, suitable enzyme 
solutions were produced in PBS pH 7.4 and added to an HSA solution {PBS pH 
7.4) in order to produce molar ratios of HSA/trypsin of 1/2.81 (high 
level) and 1/0.28 (low level). The final HSA concentration was 0.45mg/ml. 
Blank solutions were also prepared of HSA and trypsin alone in PBS pH7.4. 
The samples were incubated at 37°C for 20 hours and then frozen along with 
the initial samples prior to assay using a TSK column with detection by UV 
at 279nm. The chromatograms were analysed for molecular weight 







Fig.3.2 Effect of different levels of trypsin on the 
release of free MTX from MTX-HSA conjugates 
(37°C, PBS pH7 . 4)
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chromatogram subtraction program. This was necessary since the trypsin 
chromatogram interfered with that for HSA, the effect being quite marked 
at the elevated level of trypsin. The blanks employed for subtraction were 
the relevant level of trypsin both initially and following 20 hour 
incubation. The efficiency of the subtraction procedure can be 
demonstrated by the reduction in total area (since the trypsin especially 
at the higher level had a significant effect on the area under the curve).
AUC as % of HSA control
Trypsin concn. before subtraction after subtraction
high level 341 103
low level 122 100
Analysis of the trypsin samples revealed that autodigestion had occurred 
after 20 hours, the effect being far more pronounced at the higher 
concentration of enzyme.
The results of the HSA degradation experiment, displayed in Table A8.3.3 
and Figure 3.3, showed that trypsin was capable of dismantling the protein 
molecule into a series of discrete peaks of lower molecular weight. The 
higher level of enzyme predictably resulted in a larger percentage of 
lower molecular weight material during the fixed reaction time. It is 
interesting to note that about 5% of the material was retained by the 
column with a Kav > 1 indicating that some degree of interaction was 
occurring between the peptidic fragments and the column support material.
Fig.3.3 Effect of trypsin on the molecular weight 
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The HSA control samples exhibited little alteration in the shape of the 
chromatogram upon storage with the monomer peak remaining at around 85% 
of the total AUC. It may be noted that levels of the monomer are lower 
than this for the initial analyses of low and high level trypsin which is 
proposed to be due to the finite amount of time between the addition of 
the trypsin solution and the injection time (or time of freezing) 
resulting in partial degradation (lower dimer and monomer peaks).
3.4 The effect of trypsin on molecular weight distribution of MTX-HSA
The samples analysed in this experiment were those analysed in section 3.2 
which are summarised below:
MCR = 22.1 in PBS pH 7.4 
Molar ratio Try/HSA A: 2.82/1
B: 0.29/1 
C: 0.028/1 
_  NT: 0/1
The signal from one of the channels was logged onto the microcomputer to 
enable subsequent analysis of the molecular weight distribution employing 
calibration values generated throughout the analysis period.
The chromatograms were analysed without subtracting the trypsin 
chromatogram since the absorbance due to the enzyme at 300nm was very low 
and would not have had a significant effect on the output from the
Table 3.1: The effect of varying levels of trypsin on the molecular weight distribution of MTX-HSA conjugates at pH 7.4 (37°C)
Values expressed as a percentage of the total area under the curve
Sample A (2.82)* Sample B (0.29)* Sample C (0.03)* NT
Time Peak No Time Peak No Time Peak no Time Peak No
(Hours) 1 2 3 4 5 (Hours) 1 2 3 4 5 (Hours) 1 2 3 4 5 (Hours) 1 2 3 4 5
1.6 5.5 49.5 27.2 10.5 3.7 2.7 8.9 60.4 17.8 8.1 3.3 4.0 12.1 69.1 10.8 5.3 1.5 5.2 21.8 75.8 - -
7.4 2.0 21.6 32.8 17.7 13.0 8.5 6.0 51.9 24.1 10.5 5.1 9.8 11.9 65.7 12.2 6.5 2.5 10.8 22.6 74.6 - -
29.0 0.5 10.9 33.5 20.8 20.8 30.1 3.1 29.6 28.8 14.4 11.5 31.2 8.0 54.7 20.0 8.6 6.5 32.3 19.7 72.0 - - I
42.0 0.2 8.8 32.2 22.3 23.4 43.1 1.9 24.5 30.6 15.7 13.2 44.2 6.1 45.0 25.5 9.8 8.1 45.2 19.1 73.2 - -
- - - - - - 56.5 1.9 20.0 30.8 17.0 16.4 54.2 5.6 39.4 21.8 11.8 10.3 - - - -
Peak No 1 - HSA dimer MW = 140-160,000 * = molar ratio of trypsin to HSA
2 - HSA monomer MW = 60-70,000 (initially) NT = No trypsin
3 - MW = 15-20,000
4 - MW = 4,000
5 - MW = <1,500
HSA Concentration Sample A = 7.75 x 10_6M
Sample B = 7.45 x 1 0*^
Sample C = 7.72 x 1 0*^




detector. A trypsin sample (1.35mg/ml) gave a barely detectable peak.





The samples were incubated at 37°C and were assayed (without further 
storage) at various time points over a 60 hour period.
The addition of trypsin to the conjugate resulted breakdown of the main 
MTX-HSA peak to a series of lower molecular weight fragments (up to about 
7) clearly distinguishable as separate peaks on the chromatogram. This 
was not the case for the sample without trypsin in which the only 
alteration over 45 hours was the expected increase in the level of free 
MTX. The results are displayed in Table 3.1.
The action of the enzyme brought about a reduction in the molecular weight
of the carrier protein. The high molecular weight dimer and monomer being
broken down into peptides approximately equivalent to 15,000 and 4,000
with a significant amount being retained after B12 and having a Kav in 
excess of 1. This suggests that low molecular weight material (less than
c.1,500) was being adsorbed by the column in a similar manner to free MTX.
The extent of degradation to below MW 1,500 can be illustrated from sample
A which after 42 hours was composed of 23% peptidic MTX in this fraction
with only 9% remaining as monomer.
145
The addition of further trypsin and incubation for an extra 30 hours 
resulted in more extensive degradation, 43% of which was below MW 1,500.
It was found that trypsin digested the protein into lower molecular weight 
fragments whose molecular weight also diminished with incubation time, for 
example the monomer peak changed from 67,000 to 54,000 after 42 hours 
(Sample A).
The degradation pattern was similar at all levels of trypsin but as 
expected the rate was greater as the Try:HSA ratio was increased. The 
peaks from a degraded sample (A) were analysed using the detector in 
scanning mode which showed peaks in the spectrum corresponding to those of 
MTX. The fractions (7) were also collected and then analysed using a 
scanning spectrophotometer. All fractions exhibited a peak at 370nm 
indicating that all contained MTX at one level or another. An 
investigation of the absorbance ratio 370/280nm revealed the following:
Table 3.2 UV analysis of trypsin-degraded fragments of MTX-HSA
Fraction Retention time Molecular weight ratio 370/280nm
1 26.0 50,000 0.32
2 32.5 25,000 0.32
3 34.0 7,000 0.18
4 38.0 3,400 0.36
5 39.5 1,700 0.28
6 45.0 1,000 0.36
7 50.0 MTX 0.42
MTX 50.0 - 0.40
MTX-HSA 24.3 - 0.39
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The higher ratios ie. approaching 0.4 suggest a high loading of MTX eg the 
conjugate value of 0.39. Those with a lower ratio have a relatively 
higher absorbance at 280nm inferring the presence of more peptide than 
MTX.
A repeat of this experiment was performed by adding HSA and MTX solutions 
(PBS pH 7.4) to undissolved ECDI. The reaction mixture was left at 
ambient for 2 hours followed by refrigeration overnight prior to 
fractionation. This had the effect of producing a conjugate with a high 
MCR (25), an increased degree of dimerisation and which released a high 
level of free MTX.
A solution of trypsin (0.5ml of 25.3mg/ml, PBS pH 7.4)) was added to 25ml 
of the conjugate solution (molar ratio Try:HSA = 2.74) and the sample 
filtered (0.2um) into sterile vials; the conjugate solution alone was 
also filtered into sterile vials and both stored at 37°C prior to assay on 
the Superose 12 column. A trypsin blank was also produced using-0.5ml 
trypsin solution and 25ml of buffer. The initial and early trypsinised 
samples (up to 8 hours) were run at the time point, the remainder of the 
samples were frozen prior to assay along with calibration standards.
The enzymatically degraded samples had the trypsin chromatrogram 
subtracted from them prior to computer analysis. The mean area under the 
curve for the samples with trypsin was found to be 59.27 (+1.88) which was 
103% of that for samples without trypsin 56.67 (+1.33). The results are 
shown in Table 3.3 and Figure 3.4.
Table 3.3:
The molecular weight distribution of MTX-HSA conjugates in the presence and absence of trypsin in buffer 
solutions (pH 7.4) at 37°C
TRYPSIN NO TRYPSIN
Peak No 1 2 3 4 5 1 2
Time
(Hours)
% MW x 
103
% MW x 
103
% MW x 
103
% MW x 
103
% MW x 
103
% MW x 
103
% MW x 
103
Initial 21.4 215 65.2 67 8.2 20 3.1 3 1.3 <1.5 26.1 190 71.2 69
1 7.2 204 51.3 58 22.1 15 9.7 2.8 7.1 <1.5 26.9 219 66.2 71
2 6.5 182 40.4 56 28.2 15.8 12.1 2.8 9.2 <1.5 27.2 223 66.0 71
4 4.5 190 30.8 56.5 32.9 16 12.3 3 13.0 <1.5 25.6 217 67.9 73
8 4.1 187 23.9 54.5 33.8 15.5 13.6 3 16.3 <1.5 25.0 209 65.7 72
18 3.1 166 17.0 53 34.2 14.5 15.4 3 20.1 <1.5 24.3 213 66.4 72
26 3.1 153 14.3 53.5 34.6 15 14.2 3.8 21.8 <1.5 25.2 219 63.9 72
49 1.7 132 11.2 48.5 31.6 12.3 16.4 3 25.4 <1.5 24.5 215 64.0 72
75 2.2 143 5.7 54.5 30.5 13 16.3 4 26.3 <1.5 24.2 221 63.8 74
results expressed as % of total area
Molar ratio Try:HSA - 2.74 











Fig.3.4 Effect of trypsin on the molecular weight 
distribution of MTX-HSA conjugates 
(37°C. PBS pH7 .4)
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The release of free MTX (calculated by peak area) was 6.8% after 26 hours, 
with the release in the presence of trypsin being slightly higher at 8.3% 
after the same incubation period.
The results from the non-trypsinised sample show that the main MTX-HSA 
peak which constitutes 65-70% of the total area is relatively unaffected 
by storage in solution at 37°C. The slight reduction in area being 
brought about by hydrolysis of MTX with the molecular weight remaining 
fairly constant at around 72,000. The high molecular weight calculated 
for the dimer (ie above 140,000) is due to the width of the fraction used 
to calculate the area under the curve and the molecular weight; it is 
however at a fairly consistent level (24-27%).
The addition of trypsin to the sample caused a significant reduction in 
the level of MTX-HSA (dimer and monomer) associated with an increase in 
material of around 15,000 and 4,000 Daltons. In a similar manner to the 
previous experiment after 49 hours at 37°C a fairly large proportion of 
the MTX-peptide fragments were below around MW 1,500 ie. 25% with only 11% 
remaining as MTX-HSA(monomer).
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3.5 The effect of pH on the degradation of MTX-HSA in the presence and 
absence of trypsin _
The conjugate reaction mixtures were prepared as normal and then 
fractionated using either PBS pH7.4 or Mcllvaines buffer pH5.6 as the 
mobile phase. The degradation experiments were performed in duplicate, 
the reaction mixtures being stored at -18°C prior to fractionation in the 
appropriate buffer system; the mean MCR’s were found to be 9.3 (±0.2) at 
pH 7.4 and 9.9 (+0.3) at pH5.6. Aliquots of the fractionated samples were 
taken and volumes of either buffer or trypsin solutions were added to
yield a final concentration of HSA of lmg/lml (4.19 x 10~6M). The molar
ratio of trypsin to HSA was 0.73:1.
Samples of these solutions were either frozen immediately after 
preparation or incubated at 37°C for 24 hours and then stored at -18°C 
prior to analysis using the TSK column. The samples were analysed in 
duplicate and calibration standards were used to determine the molecular 
weight distributions and MTX release; analysis of blank samples enabled 
chromatrogram subtraction. The results are displayed in Table A8.3.4 and 
Figure 3.5. An example of the chromatograms from an experiment at pH 7.4 
is shown in Figure 3.6.
The MTX-HSA which eluted at the expected retention time (ie c.13.4 mins)
was determined as one peak (the dimer not separating as well as on the
Superose column) resulting in the initial values approaching 100%. The 
molecular weight of 59,000 was due to the width of the cut used to 
determine the area/molecular weight. It has been shown previously that a 








Fig.3.5 Effect of trypsin on the molecular weight 
distribution of MTX-HSA conjugates following 
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this was confirmed in this experiment with the level of free MTX at pH5.6 
being about a third that released at the higher pH.
The addition of trypsin brought about the expected change in the molecular 
weight distribution with a reduction in the level of intact HSA-MTX and 
the appearance of low molecular weight MTX-oligopeptides. The lower pH - 
environment resulted in a less extensive dismantling of the conjugate with 
very little material below about MW 1,500 ie 1.7% as opposed to 16.7% at 
the higher pH. The digestion of the conjugates at both pH conditions 
resulted in fragments of a similar molecular weight, the major difference 
being the extent of the degradation.
3.6 The effect of tritosomes on the release of MTX
3.6.1 Release of MTX at pH 5.6 in the presence and absence of tritosomes
A reaction mixture (7.5ml) was produced (HSA:MTX:ECDI = 1:58.3:86.5) in 
PBS pH7.4 and left for 26 hours at 25°C before being split into 5 x 1.5ml 
samples and frozen. One of these samples was then thawed and fractionated 
on a Sephadex G25 column (2.6 x 70cm) using pH5.6 buffer (Mcllvaines) as 
the mobile phase; the more acidic conditions being chosen to mimic the 
lysosomal environment. The pH of the high molecular weight fraction 
collected in 25ml was measured at pH = 5.61 and its MCR was found to be
8.9.
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The conjugate solution was filtered through a sterile 0.2um filter and 











200 ul samples of the mixtures were pipetted into 800ul vials and sealed; 
the vials were then incubated at 37°C for the appropriate length of time 
and then stored at -18°C prior to assay on the Superose 12 system 
(detection at 300nm).
The amounts of reduced glutathione and EDTA were selected to give a 
concentration of 5mM and ImM respectively in the conjugate solution (ie 1 
+ 2 + 3 )  which equates to 3.9mM and 0.8mM overall. The surfactant 
solution (final concentration 0.02% w/v) was Synperonic OP10 and was at a 
sufficient level to clear the turbid tritosome solution inferring that the 
surfactant had solubilised the vesicle allowing release of the enzymes.
The sucrose solution was added to blank B since this was the medium in 
which the tritosomes were isolated.
1. Conjugate in buffer (HSA = 0.416mg/ml)
2. Reduced glutathione (73.5mM)
3. EDTA (14.8mM)
4. 1% (w/v) Synperonic OP10 solution
5. H2O
6. Tritosome solution
7. Sucrose solution 2%w/v
Total volume
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The amount of free MTX was calculated from the peak height compared to 
standards and expressed as a percentage (Table 3.4).
Table 3.4 Release of free MTX at pH 5.6 in the presence of tritosomes
Time
% free MTX determined by assay
Tritosomal Sample (A) Blank (B)
Initial 0.0 0.0
1 hour 0.0 0.0
2 hours 0.05 0.0
4 hours 0.06 0.03
8 hours 0.18 0.06
16 hours 0.48 0.07
32 hours 0.80 0.12
o.6.2 Release of MTX in the presence and absence of tritosomes at 
pH 5.6 and pH 7.4
The release experiment was repeated using two separate reaction mixes 
(HSA:MTX:ECDI 1:58:87, PBS pH 7.4) which were left at room temperature for 
22 hours before freezing prior to fractionation in pH5.6 and pH 7.4 
buffers. The resulting MCR’s were 9.9 (+0.3) and 9.3 (+0.2) respectively. 
The samples for incubation were produced as before with the exception that
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higher levels of surfactant solution and sucrose solution were employed 
10% and 20% w/v respectively. A blank was also produced which possessed 
conjugate at the same concentration as the other samples in buffer 
solution only.
The samples were incubated at 37°C for 0, 10 and/or 24 hours then frozen 
prior to assay using the TSK system (pH7.4). The peak heights of free MTX 
were measured and expressed as a percent of the total MTX; the results are 
means of duplicate injections of both sets of samples (Table 3.5).
Table 3.5 Release of free MTX in the presence of tritosomes
Sample incubation 
time (h) and pH
% free MTX (+sd) released
tritosomes blank (surfactant) blank (buffer)
0






















3.7 The effect of tritosomes on the molecular weight distribution of the 
conjugates —
The chromatograms from the experiment detailed in section 3.6 were also 
analysed using the molecular weight determination programme following 
subtraction of the relevant blank. The results are shown in Tables 3.6 
and 3.7 and the former data are represented graphically in Figure 3.7.
The samples from 3.6.2 were also analysed for molecular weight 
distributions at 0, 10 and 24 hours using the calibrated TSK system. A 
tritosome blank was produced using the formula detailed in section 3.6.1 
but replacing the conjugate with buffer alone (NB. surfactant 10% w/v and 
sucrose 20% w/v) this was also run on the TSK column and the results 
subtracted from the samples. The blank was found to have peaks eluting 
with the void volume and after about 14 minutes, this was probably due to 
the surfactants (eg Triton X-100) used to extract the tritosomes, the 
enzymes themselves and also the pH5.6 buffer used in the incubation 
mixture. The results are displayed in Table 3.8 and Figure 3.8. A 
typical example of a chromatogram from this experiment is shown in Figure
3.9.
The calculation of the overall molecular weight can be achieved using 
analysis B of the integration programme; this also yields information 
about the polydispersity of the samples (Table 3.9).
The results are means of two different samples except where indicated 
(standard deviations in brackets). A comparison of samples 1, 2 and 3 at 
pH7.4 shows that incubation at 37°C for 24 hours brought about a decrease
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Table 3.6:
The molecular weight distribution of MTX-HSA conjugates in the 
presence of tritosomal enzymes in buffer solution (pH 5.6) at 37°C
Peak No
Incubation 1 2 3 4 5
Time
(Hours)
































































Results expressed as % total area
MW x 1000 in parentheses 
RT= Retention time (mins)
MW= Molecular Weight
HSA Concentration - 0.28 mg/ml
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Table 3.7:
The molecular weight distribution of MTX-HSA conjugates in the 
absence of tritosomal enzymes in buffer solution (pH 5.6) at 37°C
Peak No
Incubation 1 2 3 4 5
Time
(Hours)























































Results expressed as % total area
MW x 1000 in parentheses 
RT= Retention time (mins)
MW= Molecular Weight










Fig.3.7 Effect of tritosomes on the molecular 
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Table 3.8:
The molecular weight distribution of MTX-HSA conjugates in the 
presence and absence of tritosomes in buffer solutions 




58,000 55,000 50,000 18,000 MTX <1500
Initiall 97.7
(±0.8)
- - - - -

















pH 5.6 buffer only
Initial^ 98.3
(±0.2)
- - - - -
24 hours^ 96.5
(±0.6)
- - - 1.0
(±0.2)
-
Results expressed as % of total area 
(sd) n - 4 except * n = 2
1 -* with tritosomes
2 = without tritosomes






Fig.3.8 Effect of tritosomal enzymes on the molecular weight 
distribution of MTX-HSA conjugates in buffer solutions of
different pH (37°C, 24 hours)
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The overall molecular weight distribution of MTX-HSA conjugates, 
using a fixed baseline, in the presence and absence of enzymes 
in buffer solutions (pH 7.4 and 5.6) at 37°C
Sample PH Mw x 10^ Mw/Mn
1-0H [1] 7.4 55.00 0.72*
1-24H [1] 7.4 39.24 8.55
2 - OH 7.4 48.81 (±0.27) 2.96 (±1.37)
2-10H [1] 7.4 26.53 14.21
2-24H 7.4 24.38 (±0.81) 13.96 (±0.35)
3-OH 7.4 43.98 3.77
3-24H 7.4 16.40 12.04
4-OH 7.4 51.33 (±0.71) 2.77 (±0.75)
4-24H 7.4 49.61 (±0.11) 2.60 (±0.05)
6-OH 7.4 59.46 (±0.71) 3.75
6-24H 7.4 56.06 (±0.98) 6.78 (±0.87)
2-OH [1] 5.6 55.18 3.03
2-10H [1] 5.6 33.26 7.52
2-24H [3] 5.6 34.13 (±1.62) 7.31 (±4.04)
4-OH 5.6 52.42 (±0.49) 2.28
4-10H [1] 5.6 38.79 28.00
4-24H [3] 5.6 25.09 (±1.10) 60.03 (±12.40)
6 - OH 5.6 57.07 (±0.41) 3.77 (±2.23)
6-24H [1] 5.6 55.72 3.80
* Below baseline
1 - Trypsin + sample 0.07:1 (Try:HSA)
2 = Trypsin + sample 0.73:1 (Try:HSA)
3 - Trypsin + sample 7.30:1 (Try:HSA)
4 - Sample + tritosomes 
6 = Sample + buffer
OH - initial
10H - 10 hours at 37°C
24H = 24 hours at 37°C
Mw/Mn = polydispersity index 
n - 2 except where indicated [n]
(±sd)
165
in molecular weight and an associated increase in the polydispersity. The 
higher the level of trypsin the greater the reduction in molecular weight. 
The trypsin sample (2) at pH 5.6 also exhibited a reduction in molecular 
weight and increase in polydispersity; however this is not as pronounced 
as at pH7.4 confirming the greater efficiency of the enzyme at the higher 
pH. A similar pH dependency was observed with the tritosomal samples with 
very little change at pH7.4 but a significant reduction in molecular 
weight occurring at pH5.6. The large polydispersity index infers that the 
tritosomal enzymes are capable of more complete dismantling of the MTX-HSA 
molecule at pH5.6 than is trypsin at pH7.4.
The deviation of the initial molecular weight of the samples from that of 
conjugate in buffer alone (6) arises due to the interference from the 
enzymes themselves since the chromatograms have not been subtracted.
3.8 The effect of reduced glutathione on the tritosomal degradation of 
MTX-HSA conjugates
Conjugates (MCE = 10, HSA concentration 0.416mg/ml) were isolated and the
tritosomal solutions produced as described previously (Section 3.6.1),
except that the buffer used was citrate-phosphate at pH 5 and one of the 
samples lacked reduced glutathione. The samples were incubated at 37°C
prior to analysis on the Superose 12 column. The results are displayed in
Table 3.10 and were determined from chromatograms following subtraction of
the tritosome blank.
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Table 3.10: The effect of reduced glutathione on the tritosomal
degradation of MTX-HSA conjugates (37°C, pH 5)
No GSH GSH
Peak No 1 2 5 1 2 5

























7 day - 21.9
(61.3)
50.6 - - 95.2
Results expressed as % of total area
MW = molecular weight x 1000 (in parentheses) 
















Fig.3.10 The tritosomal degradation of MTX-HSA 
conjugates in the presence and absence of reduced 
glutathione (in buffer pH5, 37°C)
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3.9 Discussion
The addition of trypsin to the conjugate solution did not significantly 
affect the release profile of free MTX from the carrier; if anything the 
rate of release was slightly higher from the trypsinised samples. It is 
unlikely that the presence of trypsin would cause the release of more MTX 
since the enzyme cleaves peptide bonds on the carboxyl side of lysine or” 
arginine residues within a polypeptide. Since the MTX is linked via an 
amide bond (section 3.2) the enzyme would not be expected to cause the 
release of free MTX. This result was further confirmed by an experiment 
where three different levels of trypsin were added to the same conjugate 
and release of free MTX at 37°C determined over a period of time; the 
resulting release profile (Figure 3.2) showed that all points could be 
fitted on the same curve. It is reasonable to conclude that there is no 
increase in the release of free MTX upon the addition of trypsin and that 
breakdown of the molecule into smaller units does not allow increased 
hydrolysis of the MTX peptide bond. —
The addition of trypsin caused the HSA molecule to be broken down as was 
demonstrated by FPLC. The analysis of the degradation was problematical 
due to the interference of the trypsin molecule itself since the assay was 
at 279nm and at the high level of trypsin any absorbance was due mainly to 
the trypsin (AUC = 341% of control). This problem was alleviated to some 
extent by the use of the chromatogram subtraction programme-which enabled 
subtraction of a trypsin control chromatogram (either initial or following 
incubation as appropriate) from an HSA/trypsin chromatogram. This 
permitted subsequent molecular weight analysis having reduced the AUC to 
103% of that of the standard. In order to ensure that the results were
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valid the data capture programme had to be initiated at precisely the same 
point for each sample. This was achieved by way of the autosampler which 
automatically started the programme when the injector valve was rotated. 
The efficiency of this method was confirmed by the reproducibility of the 
retention times of both HSA and MTX. The chromatograms for incubated 
enzyme show that at the higher level autodigestion occurred; very little 
breakdown was seen at the lower level although a 20% reduction in the area 
of the main peak was observed.
The addition of trypsin resulted in a reduction in the relative level of 
HSA (dimer and monomer, and an increase in lower molecular weight material 
at approximately 10, 20, 30 and 40,000 Daltons. The total amount of 
material below 1,500 Daltons was approximately 15% at the high level of 
trypsin after 24 hours although this tended to be as a broad distribution 
of material as opposed to specific peaks. The information presented 
(Table 3.3) demonstrated that trypsin was capable of dismantling the HSA 
molecule perhaps by way of intermediate molecular-weight polypeptides. An 
alternative explanation for the observed pattern of degradation is that 
there exist portions of the molecule that are more resistant to enzymatic 
degradation than are others. It was clear that the trypsin did not 
directly cleave the HSA into low molecular weight derivatives as could 
possibly have happened, if all sites were equally accessible, due to the 
fairly random distribution of lysine and arginine residues. This—would 
have resulted in a broad distribution of low molecular weight material due 
to the variable length of peptides between lysine and arginine residues.
It should be pointed out that the assay at 279nm will only detect those 
residues or bonds absorbing at that particular wavelength (essentially 
they must contain a tyrosine residue). Thus the profile obtained using
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this method may not be a complete reflection of the true degradation 
products.
The effect of the autodigestion of trypsin on the resulting chromatogram 
is difficult to evaluate since the addition of substrate to enzyme in 
solution is likely to reduce the extent of autodigestion. Consequently at 
the higher enzyme concentration the subtraction of the chromatograms 
following incubation may have resulted in a distorted molecular weight 
distribution for degraded HSA. This did not pose a problem at lower enzyme 
levels since its effect on the chromatogram was minimal. If this was the 
case then part of the peak occurring at around MW 30,000 may have been due 
to trypsin and there could possibly have been a greater proportion of low 
molecular weight material released on digestion of HSA.
The trypsinisation of MTX-HSA conjugates brought about a similar 
dismantling of the macromolecule although the molecular weight fractions 
were not identical. In this case the assay was performed at 300nm thus 
the presence of the enzyme had very little effect on absorption and the 
assay was in fact monitoring peptide fragments with MTX as a marker. The 
presence of MTX on the HSA molecule did not appear to prevent the 
digestion of the eiacromolecule and. if anything the rate of disappearance 
of the HSA monomer was more rapid than for unconjugated HSA with trypsin. 
The decrease in the area of the monomer peak was-accompanied by a decrease 
in its apparent molecular weight. This was probably explained by removal 
of terminal oligopeptides from some conjugate molecules. Differing levels 
of trypsin resulted in different rates of degradation and appearance of 
low molecular weight material. The low molecular weight material (ie 
below MW c.1,500) included any free MTX and also material with a Kav
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exceeding 1 implying some degree of column interaction similar to MTX.
This was probably MTX-lysyl-oligopeptide derivatives.
The UV analyses of the fractions collected from a degradation run (section 
3.4) all revealed the MTX type spectrum, however when the ratio of 370/280 
was calculated it showed that some fractions contained proportionately 
more MTX in relation to the amount of peptide (or tyrosine) present. The 
apparent release of free MTX was higher when calculated by peak area as a 
percent of total area, rather than by assaying the MTX using the peak 
height of an MTX standard. This may be due to slight shift in A max 
encountered upon conjugation although it is more likely to have been due 
to the method of calculating peak area (by dropping a vertical to the 
baseline). This would have resulted in a higher value since the MTX peak 
was not completely resolved from the previous peak. The peak height 
method was therefore used to determine the release of free MTX as for the 
non-enzymatically degraded samples. The change in MW of the dimer/monomer 
was not observed in the absence of trypsin, the only alteration in the 
chromatogram being a drop in the percentage of each which was due to the 
release of free MTX.
The degradation of MTX-HSA conjugates appeared to proceed via an 
intermediate molecular weight fraction of approximately 20,000 Daltons 
which formed fairly rapidly and then slowly disappeared as more lower 
molecular weight material was formed. This suggests that the molecule was 
cleaved to form primary degradation products and then cleaved again, as 
opposed to the small peptides being cleaved off the macromolecule 
directly. The latter would be unlikely due to the globular nature of the 
protein.
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The addition of trypsin at the lower pH brought about the breakdown of the 
conjugate in a similar manner (ie the same molecular weight fractions 
appeared) to that observed at the higher pH but the rate of degradation 
was much slower ie following 24 hours at 37°C (Figure 3.5), 61% of the HSA 
peak remained at pH5.6 whereas only 35% remained at pH7.4. The molecular 
weight of the HSA peak was also found to have reduced from 59,000 to
52,000. The amount of low molecular weight material was significantly 
less at the low pH (2% as opposed to 17% at pH7.4) however the percentage 
at around 23,000 was approximately the same (2T and 24%). This difference 
in activity was expected since the pH optimum for trypsin is between 7 and 
9. The decreased release of free MTX at reduced pH was confirmed in the 
experiment where only 1% of free. MTX was released after 24 hours at pH5.6 
whereas 3.4% were released at the higher pH (using MTXio-HSA). This may 
have been due to the different buffer systems (ionic strengths were the 
same) used however earlier experiments employed all phosphate buffer 
systems and showed similar results.
The degradation of MTX-HSA conjugates using tritosomes was performed with 
enzymes extracted from rat liver. The tritosomes used were from two 
production batches as described in Appendix A3 and were stored at ~I8°C 
prior to use. Tritosomes were tested for activity (Appendix A3) using a 
standard method. The surfactant selected (Synperonic OP10) to solubilise 
the lysosomal membrane was similar to Triton X-100 routinely used by other 
workers and was used since it was least likely to interfere with the assay 
(ref. Appendix A3). Reduced glutathione was added to the digestion 
mixture to activate thiol proteases and EDTA was present in order to 
chelate any metal ions that would interfere with enzyme activity. The
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tritosome blank was run on the column (detection at 300nm) and the 
resulting chromatogram showed two peaks, one eluting with the void volume 
and the other corresponding to an apparent molecular weight of around
18,000. The first peak was thought to be due to particulate surfactant or 
membrane components and the second was due to the dissolved components in 
the buffer. The blank chromatograms analysed were subtracted from the 
degraded conjugate chromatograms in order to produce results for the 
degraded MTX-HSA alone (manual subtraction was occasionally necessary due 
to the unexplained variability in the area of the second peak of the 
blank).
The effect of tritosomes on HSA alone was not investigated due to the high 
level of absorbance of the tritosomes at 280nm which would probably have 
had the effect of masking any degradation of the macromolecule (even using 
the subtraction programme). Degradation experiments were performed using 
conjugates by analysing the eluant at 300nm which minimised the absorbance 
of materials other than MTX (the tritosome system contributing to about 
25% of the total area).
The release of free MTX from the conjugate (MCR = 9) in the tritosomal 
sample (at pH5.6) was found to be less than 1% after 32 hours at 37°C, in 
contrast the blank sample (B) (ie. no tritosomes) was found only to 
release 0.1%, which was much lower than previously demonstrated at this 
pH. It is thought that this may have been due to the presence of 
surfactant. Analysis of the molecular weight distribution (Table 3.6) 
over an incubation period of 32 hours at 37°C reveals that there was a 
reduction in both the amount and the molecular weight of the dimer and 
monomer peaks of the conjugate from 66% to 24% in the case of the monomer
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(MW 69,000 to 64,000). The initial sample was found to contain some other 
low MW material at 27,000 and 6,000 which would have been caused by 
digestion of the conjugate prior to freezing and also upon thawing before 
analysis; the initial thus is in fact an intermediate time between 0 and 
1 hour. The incubated samples developed peaks corresponding to around 
20,000 and 6,000 Daltons which slowly increased to levels of 15 and 10% 
respectively. After 32 hours incubation the majority of the material was
found to be below MW 1,500 (39%) some of which eluted at the retention
time of MTX and some having a longer retention time, presumably due to
interaction with the column. The blank sample showed only a slight drop
in the levels of dimer and monomer (86 to 78% overall) with very little 
change in the molecular weight (especially up to 16 hours). The samples 
did however demonstrate the presence of peaks at around 20,000 and 6,000; 
these were present at a constant level throughout and may have been due to 
the buffer or additives to the conjugate solution. There was also some 
material present at longer retention times ie. 1.2 - 6.4% showing no 
definite increase in peak area.
The effect of tritosomes was further investigated using duplicate samples 
(MCR = 10) fractionated in pH5.6 and pH7.4 buffer (Figure 3.8). The 
release of free MTX was found to be lower at the more acidic condition 
(1.1% release in 24 hours at pH5.6, 2.6% at pH7.4) the relatively low 
level of release in buffer at pH7.4 was probably due to the method of 
preparation. The incorporation of surfactant with the buffer reduced the 
release of MTX to 0.4% and 0.8% at pH5.6 and 7.4 respectively. The 
addition of tritosomes had no effect on the release of drug at the 
elevated pH but brought about a quite substantial increase at the lower pH 
(2.6% in 24 hours).
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The addition of tritosomes had a significant effect on the MW distribution 
at pH5.6 with a reduction in the main peak to 40% after 24 hours and a 
drop in MW from 58,000 to 50,000, this was associated with 29% of the 
material being below about 1,500 and 16% at around 18,000. In contrast 
the only effect on the conjugate peak in buffer pH5.6 alone was a slight 
reduction to 97% over 24 hours with the appearance of 1% free MTX. The 24 
hour digestion with tritosomes at pH7.4 exhibited much reduced activity 
with 80% of the main peak remaining (with no significant change in the 
molecular weight) and only abut 10% appearing below MW 1,500.
The effect of pH on the activity of the enzymes is further exemplified by 
the comparison of the overall molecular weight distributions (Table 3.9) 
and polydispersity indeces. The increasing level of trypsin (24 hour at 
pH7.4) resulted in a decrease in the MW with the polydispersity index 
being of the same order of magnitude. This implies that the higher level 
of trypsin resulted in a more extensive dismantling of the conjugate. A —  
reduction in the pH to 5.6 also caused reduced efficiency. The control 
samples in buffer alone show little change in the molecular weight and 
polydispersity index; the slight increase occurring at pH7.4 may have 
been due to the free MTX peak. The tritosome samples exhibited a large 
difference between pH conditions with virtually no change in MW or index 
at pH7.4 inferring that the enzyme system was inhibited in alkaline 
conditions (as is the case when NH4CI is added to in vitro systems). The 
change in polydispersity index was however marked at pH5.6 where it 
increased from its initial value of 2.3 to 60.0 after 24 hours at 37°C 
with an associated drop in MW. This infers that the distribution is far 
from being monodispersed and reflects the situation where little material
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of intermediate molecular weight is formed) it being of either the high 
molecular weight of the conjugate or below 1,500.
The high degree of polydispersity with the tritosome samples was due to 
the panoply of enzymes capable of hydrolysing a variety of bonds and thus 
able to break the conjugate down into a series ofoligopeptides with only 
a few amino acids. This may also account for the increased release of 
free MTX in the presence of tritosomes due to carboxypeptidases. The 
trypsin on the other hand is specific for lysine/arginine bonds and 
although there is a fairly random distribution throughout HSA some bonds 
will be more susceptible than other leading to certain high molecular 
weight fragments. Trypsin may not be able to degrade lysine with MTX 
attached since the amino group will be unprotonated and will have the 
bulky drug molecule instead.
The partial thiol dependent nature of the tritosomal degradation of 
MTX-HSA was demonstrated by the omission of reduced glutathione (section 
3.8) which showed a slower rate of degradation of the monomer peak than 
the sample with reduced GSH present. In the latter case the MTX-HSA had 
been completely degraded following 7 days at 37°C whilst 22% was still — 
present as the high molecular weight conjugate in the absence of GSH.
This experiment exhibited greater activity than previous runs (eg section 
3.6) which may have been due to the fact that a lower pH buffer was used 
in this case or that a different batch of enzymeswere used which had 
lower activity. Unfortunately the activity of the first batch of 
tritosomes was not determined. Some of the fragments produced may not have 
had MTX attached to them and thus would not have been detected readily 
(due to a lower extinction coefficient) causing a distorted distribution.
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However the most important aspect with respect to the practical use of 
such prodrugs, is whether or not the MTX was released linked to 
oligopeptides of a low molecular weight which would be able to leave the 
lysosome and would be capable of binding to DHFR and exerting cytotoxic 
action. The results of the above experiments suggest that such low 
molecular weight oligopeptide derivatives of MTX are extensively released 
in the presence of lysosomal enzymes.




Synthetic peptides were originally produced in order to evaluate their 
chemical and physical properties as model proteins; they were also used as 
substrates to evaluate enzyme function and specificity. Synthetic 
polypeptides have proven useful-in the analysis of the molecular 
conformation of proteins (Fasman, 1967). The synthesis, chemical and 
biological properties have been reviewed previously (Katchalski and Sela,
1958, Sela and Katchalski, 1959). In latter years polyamino acids have been used 
as carrier systems for cytotoxic drugs whereas smaller peptides have been 
synthesized to produce pharmacologically active compounds.
The copolymers produced in this study were synthesized using Leuchs 
anhydrides of the appropriate amino acids (lysine and glutamic acid). The 
methods used were adapted from Bergmann et al (1935), Hanby et al (1950) 
and Katchalski (1957). The e-amino groups of L-lysine were protected by 
the benzoxycarbonyl group and the 7-oarboxyl groups of the L-glutamic 
acid were protected using the benzyl ester, to prevent the occurrence of 
side reactions. The N-carbobenzoxy anhydride (NCA) derivatives were 
prepared by reaction of the N-carbobenzoxyl derivative (of the respective 
a'amino group) with phosphorus pentachloride; the cyclic anhydrides being 
formed via the acyl chloride intermediate. The polymerisation of the 
NCA’s in DMF was initiated using a secondary amine (the mechanism is shown 
in Figures 4.3 and 4.4 (from Katchalski and Sela, 1958)) and subsequently 
deprotection of the product was achieved using hydrogen bromide in glacial 
acetic acid. This method has been reported to yield poly(amino acid)s 
retaining the L-configuration.
179
4.2 Synthesis of poly(amino acid)s
4.2.1 Preparation of N,N*-Dicarbobenzoxy-L-lysine
Lysine hydrochloride (10.Og; 0.055m) (I) was dissolved in 2N NaOH (82ml) 
in a 250ml reaction vessel and chilled on an ice bath. 25ml of chilled 
benzyl chloroformate (30g; 0.173m) and 4N NaOH (68.5ml) were added 
dropwise from two dropping funnels, with vigorous stirring, over a 30 
minute period maintaining the temperature below 10°C and alkaline 
conditions. The mixture was then left stirring for a further 20 minutes 
before extraction with ether and then acidified with 5N HC1, maintaining 
the temperature below 10°C. The resulting oil was extracted into ethyl 
acetate which was dried over anhydrous magnesium sulphate then filtered, 
washed with 50ml of distilled water, separated and redried over anhydrous 
magnesium sulphate. The filtrate was distilled under vacuum (30 - 40°C; 
20-25mm Hg) then 10ml of ether were added and evaporated off leaving a 
straw coloured syrup.- The syrup was saturated with petroleum ether and 
left for 60 hours at room temperature; the resulting white solid 
N,N*-dicarbobenzoxy-L-lysine (II) was then filtered and dried under 
vacuum (12.56g; 55%) mp 77-79°C. (Ref. Scheme 4.1).
*H NMR. 9.6(s)lH, 7.3(s)10H, 6.4(d)lH, 5.8(s)lH, 5.1(s)4H, 4.5(br s)lH,
3.1(s)2H, 1.7(m)2H, 1.4(m)4H. On deuteration peaks at 9.6, 6.4 and 5.8 
ppm disappeared.
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4.2.2 Preparation of €,N-carbobenzoxy- ,N-carboxy-L-lysine anhydride
All glassware was dried before use at 105°C.
NjN’-dicarbobenzoxy-L-lysine (9.6g; 0.023m) (II) was dissolved in 100ml of 
dry ether and 20ml dry ethyl acetate with stirring on an acetone/ice bath. 
Phosphorus pentachloride (9.2g; 0.030m) was added and stirred vigorously 
for 10 minutes until most of the solid phosphorus pentachloride had gone 
into solution. The solution was quickly filtered and left at room 
temperature for 75 mins to precipitate. Dry petroleum ether was added to 
complete precipitation and the suspension was sealed and cooled in a 
refrigerator for 2 hours. The white precipitate was filtered and dried 
under vacuum over phosphorous pentoxide for 2-3 hours. The product was 
recrystallised eight times from warm dry ethyl acetate and dry petroleum 
ether. The pure white crystalline anhydride, «,N-carbobenzoxy- a 
,N-carboxy-L-lysine anhydride, (III), that resulted was dried under 
vacuum over phosphorus pentoxide (2.2g; 31%), mp 97-98°C with 
decomposition (Ref. Scheme 4.1).
1E NMR 8.7{s)lH, 7.3(s)5H, 6.0(s)lH, 5.1(s)2H, 4.2(t)lH, 3.2(d)2H,
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4.2.3 Preparation of 7-benzyl-L-glutamate
Glutamic acid (30.0g; 0.204m) (IV) was dissolved in a mixture of 200ml 
benzyl alcohol (209.2g; 1.937m) and 50ml of hydriodic acid (85.Og; 0.382m) 
and left at 25°C with occasional stirring. The product was precipitated 
by adding 400ml of absolute alcohol and 60ml of pyridine, this was then 
filtered and washed with absolute alcohol. The resulting white solid was 
dried at 35°C over silica gel then cooled over phosphorus pentoxide under 
vacuum.
The percentage of glutamic acid remaining in the precipitate was 
determined as 34% (by titrating an aqueous solution with 0.02N NaOH using 
bromothymol blue indicator) consequently the material was recrystallised 
from 400ml of hot water containing 6.8g of sodium bicarbonate (CO2 
evolved). The suspension was brought up to 90°C and sufficient water 
added to produce a solution which was then filtered through a warm sinter. 
Crystallisation was initiated by cooling; the temperature was reduced to 
10°C then the product was filtered and rinsed with chilled water and dried 
over phosphorus pentoxide under vacuum. The product 
7-benzyl-L-glutamate (V) was in the form of white crystalline plates 
(18.4g; 80%) mp 169°C (Ref. Scheme 4.2).
*H NMR 7.5(s)5H, 5.2(s)2H, 3.8(t)lH, 2.6(t)2H, 2.1(q)2H.
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4.2.4 Preparation of 7-benzyl N-carbobenzoxy-L-glutamate
7-benzyl-L-glutamate (V) (17.8g; 0.075m) and sodium bicarbonate (15.Og; 
0.179m) were added to 750ml of distilled water and heated to 70°C to form 
a solution (with stirring). 15ml of benzyl chloroformate (18.0g; 0.104m) 
were added with vigorous stirring (CO2 evolved), the reaction was allowed 
to proceed for 45 mins (temperature dropped to 50°C) then it was cooled on 
ice. The mixture was then extracted with ether and acidified with 5N HCL 
to pH<3 and the resulting oil extracted into ether; this was then washed 
with 500ml of water containing 5.4ml of 1.4N potassium bicarbonate and 
then with 350ml of water. The ethereal solution was dried over anhydrous 
magnesium sulphate, filtered and then distilled under vacuum at 40°C. 
Cooling precipitated a white solid from the yellow syrup. 900ml of carbon 
tetrachloride were added, warmed to 50°C and distilled under vacuum to a 
volume of 100-150ml and left under ambient conditions overnight; islands 
of monoclinic crystals were formed. The volume was reduced by 10-20ml and 
then the mixture was refrigerated prior to filtration and washing with 
chilled carbon tetrachloride. The product 7-benzyl — 
N-carbobenzoxy-L-glutamate (VI) was dried under vacuum over phosphorus 
pentachloride (13.9g ; 50%)mp 75-76°C (Ref. Scheme 4.2).
NMR. 10.5(s)lh, 7.3(s)10H, 5.1(s)4H, 4.4(d)lH, 2.5(m)2H, 2.0(2m)2H.
On deuteration peaks at 10.5 and 6.7 ppm disappeared.
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Scheme 4 2 Preparation of 7-benzyl N-carboxy-L-glutamate anhydride
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4.2.5 Preparation of 7-benzyl N-carboxy-L-glutamate anhydride 
All glassware was dried at 105°C and cooled over silica gel
7-benzyl N-carbobenzoxy-L-glutamate (14.0g; 0.038m) (VI) were dissolved 
in 85ml dry ether and then cooled on an acetone/ice bath. Phosphorous 
pentachloride (9.4g; 0.045m) were added and stirred at room temperature 
for 10 minutes until most of the solid had gone into solution when it was 
quickly filtered and chilled to 0°C to complete the precipitation. The 
product was recrystallised three times from dry ethyl acetate and dry 
petroleum ether, with the careful exclusion of moisture, then dried at 
35°C under vacuum and cooled under vacuum over phosphorus pentoxide. The 
pure 7-benzyl N-carboxy-L-glutamate anhydride (VII) was in the form of 
white needle-like crystals (3.8g; 38%) mp 93-95°C (sealed) with 
decomposition (96-97°C reported) (Ref. Scheme 4.2).
NMR. 8.3(s)1H, 7.3(s)5H, 5.1(s)2H, 4.4(t)lH, 2.6(t)2H, 2.1(m)2H.
On deuteration peak at 8.3 ppm disappeared.
4.2.6 Preparation of *,N-carbobenzoxy-L-lysine- 7-benzyl-L-glutamate
copolymer
€,N-carbobenzoxy- 7 -N-carboxy-L-lysine anhydride (CLA) (III) (999.2mg; 
3.26 x 10'3m) and 7 -benzyl N-carboxy-L-glutamate anhydride (BGA) (VII) 
(863.5mg; 3.28 x 10'3m) were dissolved in redistilled dry 
dimethylformamide (35ml) to form a 5.3% w/v solution. The reaction was 
initiated by adding 77.5ul of a solution (4.34%v/v) of diethylamine in DMF
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Scheme 4.3
Polymerisation of N-carboxyanhydrides with primary and secondary aaines 
Initiation
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The amine reacts with the 2-carbonyl to form a ureido acid which is a less 
common reaction with a high activation energy (important at high 
temperature or high base concentration)
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(3.17 x 10"5m) giving an anhydride to initiator ratio (A/I) of 206:1. The 
flask was sealed and left in the dark under ambient conditions for 72 
hours and then transferred to a 30°C oven until termination. A sample was 
removed after 142 hours, diluted with DMF and the intrinsic viscosity 
determined (to give an indication of the degree of polymerisation). The 
reaction was terminated after about 145 hours by the addition of lOOul 
0.05N HC1. The white precipitate was left at ambient overnight then 
filtered and recrystallised from chloroform and petroleum ether before 
drying under vacuum over phosphorus pentoxide. The 
*,N-carbobenzoxy-L-lysine- 7-benzyl-L-glutamate copolymer (VIII) was 
isolated as a white solid (1.33g; 72%). (Repeat 85%) (Ref. Scheme 4.5).
4.2.7 Preparation of L-lysine-L-glutamate copolymer
e,N-carbobenzoxy-L-lysine- 7-benzyl-L-glutamate copolymer (VIII) (0.21g) 
was placed in a conical flask with a silica gel side arm and 5ml of a 
33%w/w solution of hydrogen bromide in glacial acetic acid were added; a 
clear yellow solution was formed accompanied by the evolution of gas. 
Precipitation started to occur and then the solution was warmed to 50°C, 
then cooled and precipitation completed by the addition of anhydrous 
ether. The material was then extracted several times with anhydrous ether 
until the supernatant was clear. The residue was then dried under 
vacuum. — The residue was then dissolved in a few drops of distilled water 
and then sufficient absolute alcohol was added to form a clear solution, 
the polymer was then precipitated as a white plastic material by the 
addition of ether. The supernatant was decanted off and the product dried 
under vacuum over silica gel. The yield of L-lysine-L-glutamate copolymer 
(IX) was O.llg (73%) (Ref. Scheme 4.5)»
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4.2.8 Polymerisation of CLA and BGA in DMF using diethylamine as 
initiator
The polymerisation reaction obviously should produce an increase in 
molecular weight which would result in an increased solution viscosity.
The viscosity of the reaction mix was determined using a suspended level 
viscometer (PSL Nol) which had been soaked in chromic acid then washed and 
rinsed with acetone and dried. The viscometer was immersed in a 
viscometer bath at 25°C + 0.1°C and flow times determined by stopwatch.
The solvent used was redistilled DMF which was stored over a molecular 
sieve; all solutions were filtered (0.5um PTFE) into the viscometer and 
allowed to equilibrate before measurement.
Viscosity Calculations
Kinematic viscosity = viscometer constant (k) x flow time (sec)
V0= viscosity of pure solvent 
V = viscosity of solution
V rel ~ relative viscosity = ^o
= t / to
= flow time solution/solvent 
V sp = ^rel - 1 = specific increase in viscosity
*1 sp/c = reduced specific viscosity, where c = concentration
[V ] = ^sp/c at infinite dilution = intrinsic viscosity
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Table 4.1:
The approximate molecular weight of a protected copolymer 
of lysine and glutamic acid as determined by viscosity 
measurements in DMF (25°C)
Anhydride concentration = 1.008% w/v 
Anhydride/Initiator (DEA) = 102:1
Time
(Hours)
[ V 1 
dL/g
Approx DP* Approx MW
1.5 0.0500 66 15,900
12 0.0711 88 21,200
18 0.0819 98 23,600
20 0.0866 103 24,750
24 0.0929 109 26,200
36 0.1108 125 30,100
39 0.1146 129 30,950
42 0.1180 132 31,700
44 0.1212 135 32,350
48 0.1244 137 33,050
61 0.1351 147 35,300
87 0.1477 158 37,900
94 0.1501 160 38,400
106 0.1537 163 39,100
109 0.1543 163 39,250
112 0.1559 165 39,550
120 0.1569 165 39,750
143 0.1616 169 40,700













Fig.4.1 The approximate molecular weight of protected 
lysine-glutamic acid copolymer during polymerisation 
as determined by viscosity measurements in DMF
(DEA as initiator)
42000-rAnhydr ide concentrat ion = l. 008% w/v
40000--A/I ratio 102: 1
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The intrinsic viscosity can be derived from one point determinations using 
the Simon-Cuita equation shown below (Rabek, 1980):
[ *7 ] = ( 2(77sp - ln^rel)1/2 )/c , usual units dL/g
CLA (64.4mg; 2.10 x 10"4 m) and BGA (56.2mg; 2.14 x 10"4m) were dissolved 
in DMF and 4.17 x 10’6m of diethylamine (DEA) in DMF were added to produce 
a total volume of 12ml (A/I = 102:1, concentration = 1.008% w/v). A 
magnetic flea was added to the bowl of the viscometer to stir the solution 
(switched off while viscosity determination were being performed) and the 
tubes were sealed between determinations. The flow times were determined 
over a seven day period, two determinations were routinely performed 
within twenty minutes of each other and from these the intrinsic 
viscosities and apparent molecular weights were calculated (Table 4.1).
The approximate DPs (degrees of polymerisation) were determined from 
viscosity determinations on polycarbobenzoxylysine in DMF (Yaron and 
Berger, 1963). The material from this experiment was recovered by 
precipitation with 0.1N HC1; the precipitate was then dried over 
phosphorus pentoxide under vacuum and then redissolved in DMF and its 
viscosity determined in a cleaned viscometer [ =  0.1699 dl/g (DP =
176, MW = 42,350).
The results of three further experimental runs are summarised in Table 
4.2.
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Table 4.2 Viscometric analysis of the copolymers
Sample BGA/CLA A/I Reaction 
time (hours)
DP MW Theoretical 
deprotected MW
COP 1 206 142 189 45,400 31,950
CPM 1 200 241 212 50,950 35,800
CPI 1 102 156 173 41,675 29,250
4.3 Amino acid analysis of poly(amino acid)s
The samples for analysis were dissolved in methanol then added to Pyrex 
tubes and evaporated to dryness over night under vacuum. 200ul of 6N HC1 
were added to the sample, the neck of the tube heated and drawn out then 
the liquid was frozen on dry ice/ethanol. The tube was then evacuated and 
the neck sealed-(whilst under vacuum) followed by incubation at 105°C for 
24 hours. The tube was then opened and the contents dried under vacuum 
overnight. The samples were reconstituted in acid and determined using 
standard methods; a pH gradient.on an ion-exchange column (norleucine as 
internal standard). The samples were derivatised (post-column) with 
ninhydrin and then assayed colourimetrically. Standards of all 20 amino 
acids (50 nanomolar) were run before and after the test samples; sample 
concentration could thus be calculated from the areas under the curve 
(integrator).
Samples of two batches of copolymer (COP and CPM) were analysed using the 
above method. At low levels (ie. 5-10ug of polymer) both were determined
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to contain 50% of each amino acid.
4.4 Synthesis of MTX-poly(amino acid) conjugates
The methods and reaction used in this experiment were essentially the same 
as for the HSA conjugation detailed in section 2.2.5.
20.1mg of copolymer were dissolved in 3.2ml of PBS pH7.4; 0.5ml of this 
solution (3.125mg = 1.25 x 10"7m) were placed in a vial and the 
appropriate volume of MTX solution (20mg/ml), ECDI solution (42.2mg/ml) 
and PBS were added to yield the required reaction mix (total volume = 
1.25ml). The mixes were stored at 25°C for 24 hours and then 1ml aliquots 
were separated on a Sephadex G15 column using PBS pH7.4 as the mobile 
phase, the conjugate peak being collected in 20ml volumetric flasks and 
analysed by UV spectrophotometry at 376nm. The MCR’s were then calculated 
from these results (Table 4.3)
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Fig.4.2 Effect of ECDI concentration on the MCR of 
MTX-L-copolymer conjugates (25°C, PBS pH7.4) 
Molar Ratio COP: MTX: ECDI = 1: 88: x











20 4 0 6 0 8 0 1 0 0  1 2 0  1 4 0  1 6 0 1 8 0
ECDI ratio (x)
197
Fig.4.3 Effect of concentration of MTX and ECDI 
on the MCR of MTX-L-copolymer conjugates 
(25°C, PBS pH7 . 35)
(Molar Ratio COP: MTX: ECDI-1: x: x)
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Table 4.3 Details of MTX-L-copolymer conjugates produced
Sample Polymer : MTX ; ECDI ratio MCR
A 1 : 88 ; 44 3.0
B1 1 : 88
0000 7.4
B2 1 : 176 : 176 17.4
B3 1 : 352 : 352 27.0
C 1 : 88 : 132 10.4
D 1 : 88 : 176 12.2
4.5 The effect of trypsin on the molecular weight distribution of 
MTX-L-copolymer conjugates
The copolymer samples used were those produced in section 4.4. The samples 
were sterile filtered ( 0.2um Aero) and 250 ul aliquots placed in vials 
(0.13mg/ml). A trypsin solution was prepared in PBS pH7.4 (1.244mg/ml) and 
filtered; 25ul samples were then added to the copolymer solution resulting 
in a molar ratio of 1:1. The vials were then sealed and mixed by 
vortexing followed by incubation at 37°C after which the samples were 
frozen prior to assay on the TSK system. A sample of D-copolymer, 
obtained from Sigma, (at the same concentration) was prepared in a similar 
manner. Assay results for trypsin degradation experiments are shown in 
Table 4.4
A further experiment was performed using MTX-copolymer sample B1 (see 
section 4.4). A 500ul sample of B1 solution (in PBS pH7.4) was placed in
Table 4.4:The molecular weight distributions of MTX-L-copolymers 
following incubation with trypsin in buffer pH 7.4 at 37°C for 24 hours
Trypsin:copolymer molar ratio - 1:1 
Copolymer concentration - 0.13 mg/ml
Molecular Weight x 10^
Sample 70-65 55-50 35-30 30-25 15 8 3.5 2 <1.5
A - - - 9.5 8.7 11.8 19.4 4.8 46.0
B1 - - - 10.3 10.8 15.5 21.7 4.5 37.3
B2 75.9 - - 8.6 9.6 - 5.9
B3 97.6 - - - - - - - -
C 28.5 10.2 16.2 21.4 - 23.9
D - - 56.3 - - 11.6 15.5 - 16.6
D-copolymer - 100.0 - - - - - - -
Results expressed as % of total area
j
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a vial, a 50ul aliquot of trypsin solution (0.124mg/ml) was added and the 
solutions mixed by vortexing. The resulting molar ratio of copolymer : 
trypsin was 10 : 1.
lOOul portions were dispensed into 500ul vials and stored at 37°C prior to 
assay. Samples were assayed on the TSK column at 0, 2, 6, 16 and 24 
hours. A blank solution was prepared by replacing the trypsin solution 
with PBS buffer pH7.4; these samples were also stored at 37°C and assayed 
at 0,2,6 and 24 hours. Data are shown in Table A8.4.1 and plotted in 
Figure 4.4. The blank samples exhibited little alteration in peak shape 
over the period of analysis with the bulk of the peak 94-99% having a 
molecular weight around 46,000. The molecular weight distribution 
following 24 hours at 37°C is displayed graphically in Figure 4.5. The 
overall molecular weight distributions were analysed using the molecular 









Fig.4.4 Effect of trypsin on the molecular weight 
distribution of MTX-L-copolymer conjugates 
(37°C, PBS pH7 . 4)
Copolymer cone.=4.73x10‘6 M, MW=25000. Try: COP= 1: 10
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Table 4.5:
The overall molecular weight distributions of MTX-L-copolymer 
conjugates using a fixed baseline, in the presence and absence of 
trypsin in buffer (pH 7.4) at 37°C
Sample AUC Mw x 10^ Mw/Mn
BLA-OH 12.2 42.6 5.8
BLA-2H 12.5 39.6 4.6
BLA-6H 16.5 37.2 6.6
BLA-24H 23.1 35.5 8.4
TRY-OH 37.8 36.4 8.8
TRY-2H 41.9 9.6 8.2
TRY-6H 45.8 8.0 8.7
TRY-16H 45.2 7.4 7.3
TRY-24H 45.0 6.7 7.8
BLA - Blank
TRY - Trypsinised sample
(molar ratio = Try:copolymer - 1:10) 
-xH - incubation time in hours 
Copolymer Concentration - 4.73 x 10"°M 
MW - 25,000
Fig.4.5 Effect of trypsin on the molecular weight 
distribution of MTX-L-copolymer (37°C. 24 hours)
(Try: COP-1: 10)
COP concentration-4.73x10"6 M, MW-25000 (PBS pH7.4)
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4.6 The preparation and stability of MTX-D-copolymer conjugates
Conjugates were prepared using a copolymer obtained from Sigma Chemical Co 
Ltd comprising D-glutamic acid and D-lysine (60:40, MW 24,000); the MTX 
being linked to the copolymer using the ECDI mediated reaction.
The reaction mixture comprised D-copolymer (19.7mg), ECDI solution 
(25mg/ml) and MTX solution (20mg/ml) in a total volume of 2.0ml; the molar 
ratio was 1:64:43. The medium was PBS pH7.4 however the pH of the 
reaction mixture was measured as 6.0. The reaction was allowed to proceed 
at 25°C for 26 hours before separation on a Sephadex G15 column. 1.04ml 
were applied to the column and collected in 46ml, diluted to 100ml with 
PBS prior to filtration (0.2um) and assay by UV spectrophotometry; the MCR - 
was found to be 8.73.
The conjugate solution was assayed using the Superose 12 system (300nm) by 
repeated sampling from a 50ml vial at 37°C. The chromatogram showed the 
main peak (conjugate) eluting at 19 minutes, which corresponded to a ~
molecular weight in excess of 200,000, and a small amount of free MTX 
(initially 0.33%) eluting after 50 minutes. The level of free MTX had 
increased to 0.5% after 12 hours and 0.75% after 89 hours at 37°C. There 
was no apparent alteration in the molecular weight distribution with the 
retention time being constant at 19 minutes and the peak width at half 
height remaining constant at 5.75 mm.
A further experiment was performed using an identical reaction mix. The 
conjugate solution was incubated at 37°C and then assayed on the TSK 
system at various time points. The chromatograms comprised one broad peak
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Table 4.6:
The effect of storage on the molecular weight distribution of 
MTX-D-copolymer conjugates (PBS, pH 7.4, 37°C)















Initial - - - - - 0.00
1 hr 20 min 83.6 6.5 - - 10.6 0.30
2 hr 40 min 91.4 - 3.0 80.8 10.6 0.33
3 hr 55 min 85.1 6.5 2.5 85.5 10.2 0.37
5 hr 10 min 85.6 6.9 2.3 87.3 9.7 0.48
6 hr 25 min 85.7 6.9 2.1 89.2 9.5 0.59
7 hr 40 min 85.9 7.0 2.6 91.8 9.1 -
8 hr 55 min 85.5 7.1 2.5 91.8 9.8 -
26 hr 45 min 84.4 7.0 2.9 93.7 11.1 1.03
38 hr - - - - - 1.10
47 hr 18 min 88.2 4.6 4.1 - - 1.18
50 hr 39 min 86.5 6.0 2.6 - - 1.14
51 hr 54 min - - - - - 1.13
53 hr 9 min - - - - - 1.18
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with a slight shoulder at a MW of approximately 7000 and a small peak at 
3,000. The chromatogram was also analysed for overall molecular weight 
distribution. The level of free MTX was determined from peak height 
measurements. Data is shown in Table 4.6
4.7 The effect of tritosomes on the molecular weight distribution and 
release of free MTX from MTX-D-copolymer conjugates
The production of the conjugate has been outlined in Section 4.6.
A sample of the conjugate was thawed and filtered (0.45um), the pH of the 





MTX-copolymer (0.102mg/ml) 3.33 3.33
10% surfactant 0.1 0.1
EDTA solution (17.4mM) 0.288 0.288
Reduced Glutathione (86.4mM) 0.288 0.288
H2O 0.034 - 0.034
Tritosomes 1.0
Sucrose 20% - 1.0
Total volume 5.04ml 5.04ml
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Table 4.7:
The effect of tritsomes on the molecular weight distribution of 
MTX-D-Copolymer conjugates (buffer pH 6, 37°C)
Copolyer Concentration - 0.102 mg/ml 
MW - 24,000
Sample/Storage 








Mw/Mn % Free 
MTX
Initial - T 97.5 93.9 3.1 0.30
1H - T 96.6 100.2 3.1 0.61
2H - T 96.4 89.7 3.0 0.51
4H - T 96.7 95.2 3.1 0.53
16H - T 96.1 97.4 2.9 0.68
25H - T 96.2 93.6 3.0 0.63
49H - T 95.4 85.4 2.7 0.85
16H - B 98.9 103.4 2.1 0.53
25H - B 97.8 112.3 2.9 1.04
49H - B 98.9 98.4 2.7 0.61
* Results expressed as % total area under curve
T = with tritosomes 
B - Blank
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The samples were then placed in vials and incubated at 37°C prior to assay 
on the Superose 12 system. The chromatograms showed a broad main peak 
with a second peak after about 34 minutes which was due to the 
enzyme/buffer system. A further blank containing enzyme etc. but no 
copolymer was run and the chromatogram subtracted from the copolymer and 
enzyme samples; the overall molecular weight was then calculated from 
these chromatograms. The level of free MTX was also calculated from peak 
heights by comparison with an MTX standard. Data is shown in Table 4.7.
4.8 The effect of tritosomes on the molecular weight distribution of 
MTX-L-copolymer conjugates
Conjugate was produced as for the D-copolymer (Section 4.6) yielding a 
final copolymer concentration of 0.2mg/ml with a molecular weight 
distribution of approximately 100,000. The conjugate was fractionated in 
buffer at pH 5 and the digestion mixtures produced according to that 
described in Section 4.7. Three solutions were produced ie. without 
tritosomes, with tritosomes but without reduced GSH and with tritosomes 
and reduced GSH. These were incubated at 37°C for up to 7 days prior to 
analysis on the Superose system. The results are presented in Table 4.8 
as the areas under the curve for the main conjugate peak and for low 
molecular weight material (with retention greater or equal to that of 
MTX).
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Table 4.8: The tritosomal degradation of MTX-L-Copolymer conjugates 
in buffer (pH 5, 37°C)
No tritosomes Tritosomes No 
GSH
Tritosomes + GSH
Peak No 1 4 1 4 1 4
Incubation
Time
MTX-COP low MW 
MTX 
derivs.
MTX-COP low MW 
MTX 
derivs.






































Results expressed as % of total area
MW = molecular weight x 1000 (in parentheses) 














Fig.4.6 The tritosomal degradation of MTX-L-Cop&ymer 
conjugates in the presence and absence of reduced 
glutathione (in buffer pH5, 37°C)
3 0 - r
s - -
200 4 0 6 0 8 0 100 1 4 0120 160 180
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— 0-—  Tritosomes No GSH 
— □—  Tritosomes + GSH
211
4.9 Discussion
The L-copolymersof lysine and glutamic acid were prepared from NCA’s of 
the parent amino acids. This was achieved by protection of both amino 
groups in the case of lysine by forming the dicarbobenzoxy derivative; 
the anhydride being formed via the acyl chloride using phosphorus 
pentachloride. The NCA of glutamic acid was produced by forming the 
benzyl derivative of the 7-carboxylic acid and the carbobenzoxy derivative 
of the amine group; the anhydride once again being formed by using PCls. 
The composition of these intermediate compounds was confirmed by XH NMR 
and 13C NMR as well as melting point determinations.
Copolymerisation of the NCA’s was performed in DMF with initiation using a 
secondary amine; the structure of these polymers could not be determined 
by NMR due to the breadth of the peaks however the presence of benzylic 
protons was obvious (7.3 ppm). The copolymer was deprotected using 
hydrogen bromide in glacial acetic acid thus forming the hydrobromide salt 
of the lysine. The absence of benzyl groups were confirmed by UV and NMR 
(as well as the increase in aqueous solubility). The polymerisation 
reaction was followed by viscometry to determine the optimum time to allow 
the reaction to proceed before termination; this showed that the reaction 
slowed after about 150 hours and that any time in excess of this should 
yield a polymer of suitable molecular weight (ie. approximately 25,000 
Daltons).
The intrinsic viscosity was determined using a one point determination of
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the viscosity. To determine the viscosity at a series of concentrations 
would have proved impractical at each time point although this would have 
yielded a more accurate value upon termination. The accurate 
determination of the intrinsic viscosity was considered inappropriate 
since the molecular weight/degree of polymerisation was determined from 
published values for poly-L-lysine and would thus only give an estimate of 
molecular weight for the copolymer. The viscosity experiment did prove 
useful since it showed that the reaction resulted in an increase in 
viscosity (and thus molecular weight) and gave an indication of the 
required reaction time.
The molecular weight of the deprotected copolymer was determined from the 
degree of polymerisation for the protected copolymer. This assumes (as 
has previously been demonstrated with polylysine) that treatment with HBr 
does not affect the integrity of the polymer backbone. The copolymers 
produced had theoretical molecular weights of 30-35,000; analysis on the 
TSK column showed the weight av. MW to be of the order of 37,600.
Amino acid analysis confirmed that the only amino acids present in 
copolymer samples were glutamic acid and lysine at the input levels of 
50mole% of each.
It has been reported previously that this method of preparation does not 
alter the configuration of the amino acids such that the resulting 
copolymer will also contain residues with the L-configuration. The 
configuration of the input amino acids and protected derivatives was 
confirmed by optical rotation measurements (compared to literature 
values); it was further confirmed by the ability of trypsin to degrade
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samples conjugated with MTX and the inability of the enzyme to degrade a 
MTX conjugated derivative of the D-copolymer.
The conjugation of MTX to copolymer was achieved using the same 
carbodiimide-mediated reaction employed when HSA was used as the carrier 
macromolecule. The MCR was calculated in a similar manner using the 
quoted molecular weight of 24,000 for the D-copolymer and a nominal value 
of 25,000 for the L-copolymer. The results showed an increasing MCR with 
increasing level of ECDI (for a copolymer:MTX molar ratio of 1:88) 
reaction efficiency increasing from 3 to 15% (ECDI = 44 to 176). The MCR 
also increased with increasing molar ratio of MTX and ECDI (at a fixed 
ratio of 1:1) reaction efficiency peaking at 10% at 176. The use of ECDI 
in addition to linking MTX to the copolymer also brought about an increase 
in the molecular weights of the conjugates the effect being more 
noticeable at the higher levels of ECDI. This was probably as a result of 
amide bond formation between the carboxylic acid residues of the glutamic 
acid and the amine of lysine mediated by the carbodiimide causing further 
polymerisation and/or cross linking with an associated increase in 
molecular weight.
The addition of equimolar proportions of trypsin to the solutions and 
incubation at 37°C for 24 hours in some cases brought a major change in 
the molecular weight distribution and in other cases had no effect at all. 
The chromatograms were all analysed without subtraction since the 
alteration in peak area due to the trypsin was minimal.
As expected the MTX-D-copolymer sample was not degraded at all by trypsin 
due to the fact that it was not composed of naturally occurring amino
214
acids. The L-copolymers, with the exception of B3 (see section 4.4), all 
exhibited some degree of breakdown although the amount of material below 
MW 1,500 was found to decrease with increasing MCR. This effect also 
corresponded to increasing levels of ECDI thus the enzymatic resistance 
may thus be explained by an increase in cross linking. However an 
examination of incubated samples of B2 and Dreveals that more extensive 
degradation of the latter sample occurred, which had the lower MCR, 
although the levels of ECDI in the reaction mixture were equivalent. This 
implies that the tryptic hydrolysis of the lysine peptide bond was impeded 
by the presence of conjugated MTX, which may be explained since the lysine 
amino group will not be protonated as it is derivatised which may prevent 
enzymatic hydrolysis. The MW bands that resulted from the degradation of 
the conjugates are fairly consistent although B2 and D exhibited a reduced 
number of peaks, with the main peak being fairly broad. A repeat of this 
experiment employed conjugate B1 only and trypsin at the lower level of 
10:1 molar ratio (copolymer : trypsin). The initial predominant peak was 
at 46,000 although other peaks existed at lower molecular weights, this 
was thought to be due to the time between addition of the enzyme and 
assay. The high molecular weight peak rapidly disappeared and was 
replaced by a peak at 30,000 which subsequently diminished (Figure-4.4). 
The peaks appearing in the other molecular weight bandi remained at a 
fairly constant level after 2 hours. The amount of low molecular weight 
(below 1,500) material rose rapidly to achieve a level of 38% after 24 
hours (Figure 4.5), the observed distribution was in fact not 
significantly different from that with the higher level of trypsin.
The overall molecular weight distribution of the blank samples showed a 
slight decrease from 43,000 to 36,000 and a slight change in the
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polydispersity index (Table 4.5). The trypsinised sample on the other 
hand exhibited a large drop from 36,000 to 7,000 over the same 24 hour 
incubation period with no change in the polydispersity index. The latter 
result was caused by the rapid change from material at high molecular 
weight to that at low molecular weight. The area contribution due to 
trypsin in these samples was relatively small and not subtracted from the
samples. However analysis of the areas under the curve revealed a large
discrepancy between the trypsinised samples and the controls (about 3 
fold). As yet this phenomenon cannot be explained.
The results of the tritosomal degradation experiment (Section 4.8, Figure 
4.6) demonstrated that the conjugate was broken down by the enzymes and 
that as previously shown for HSA conjugates this was dependent on the 
presence of reduced GSH. The data displayed in Table 4.8 only shows the 
high molecular weight conjugate peak and low molecular weight material 
being retained for times equal to or in excess of MTX. The main
intermediate peak was observed at 3-5kD but was subject to variability due
to interference in the chromatogram with the tritosomal solution.
CHAPTER FIVE: GENERAL DISCUSSION AND CONCLUSIONS
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CHAPTER FIVE: GENERAL DISCUSSION AND CONCLUSIONS
The use of macromolecules to alter drug distribution, uptake and 
selectivity has great potential in cancer chemotherapy. This study has 
investigated the linking of a cytotoxic agent to soluble carrier systems 
as well as their solution stability and enzymatic degradability in order 
to help to explain their modes of action at a cellular level. The 
macromolecular carriers used were the naturally occurring human serum 
albumin and synthetic polypeptides.
HSA was used as a carrier for investigation since it possesses a variety 
of functional groups for the attachment of drug molecules/targeting agents 
and would be able to remain soluble. The molecule itself is large enough 
to escape glomerular filtration and small enough to be extravasated which 
are important features of macromolecular carriers. Serum albumin is known 
to be taken up by pinocytosis and its uptake increased by modification eg. 
formaldehyde treatment (Moore et al, 1977). HSA has also been shown to be 
degraded by lysosomal enzymes which is a prerequisite for prodrug action. 
The modification of HSA however may lead to increased immunogenicity.
The linking of MTX to HSA is likely to occur via pendant amino groups 
since both the carbodiimide and NHS ester mediated reactions are via 
nucleophilic attack. The amino acid residues that may be involved in this 
are histidine, arginine and lysine. Histidine is unlikely to react due to 
its ring structure; arginine has a high pKa (>12) and would be charged 
under the reaction conditions, the lone pair would also be delocalised 
into the double bond. Lysine ( C-NH2) is thus the only residue that could 
form an amide bond with the carboxylic acid residue of MTX, evidence for
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this is the ease of conjugation of M TX to poly-L-lysine and copoly-L- 
lysine-L-glutamic acid. The ECDI reaction may also give rise to ester links 
eg with hydroxyl groups present on serine or threonine residues which 
would account for the increased release of ECDI-linked M TX  over that 
released from the NHS-mediated product which will only react with amine 
residues. Further evidence for the ester formation is supplied by the fact 
that the release is base catalysed and that M TX  can actually be linked at 
a low level to polyvinylalcohol which contains only hydroxyl groups. The 
similar levels of release observed from NHS linked M TX-HSA, refraction­
ated ECDI linked MTX-HSA and ECDI linked MTX-copolymer indicates 
that the amide bond itself is hydrolysed, since the free M TX  is not 
derived from protein bound material. A ’stable’ carbodiimide produced 
conjugate of M TX-HSA was produced by briefly exposing it to elevated 
pH prior to fractionation. A low level of M TX was also observed follow­
ing incubation at pH 11 once again pointing to amide hydrolysis since the 
elevated pH should rapidly hydrolyse any ester bonds. The conjugation 
reaction in this case was performed in water however this gave rise to an 
increased level of protein cross linking (ie higher molecular weight deriva­
tives). It would thus be preferable to perform the conjugation reaction in 
a buffer solution prior to increasing the pH of the system.
The release of free drug by simple hydrolysis extracellularly from a conju­
gate is undesirable as in cell culture it may lead to distorted results, since 
part of the cytotoxicity would be due to free drug as opposed to 
lysosomally degraded endocytosed conjugate (Chu and Whiteley, 1979).
The results presented in this paper show that 10'4M MTX-BSA was as 
effective in vitro against L1210 cells as 10_6M  M TX following 1 hour
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exposure at 37°C. The conjugation reaction time (ECDI mediated) was only 
4 hours followed by dialysis/lyophilisation; the results presented in this 
thesis suggest that 1% free M TX could be released from the conjugate 
following 1 hour at 37°C. The cytotoxicity reported by Chu & Whiteley 
(1979) is thus probably due to M TX  hydrolysed from the conjugate result­
ing in 10_6M free M TX  from 1(HM MTX-BSA
The tissue culture experiments of Halbert (1987) demonstrate a similar 
relationship in that a higher concentration of bound drug was required to
achieve the same level of inhibition as free drug. It is likely that the 
majority of this activity could once again be accounted for by the 
hydrolytic release of M TX  as opposed to the cytotoxicity being caused 
solely via an intracellularly mediated mechanism.
The release of free drug could also affect the selectivity of conjugates
linked to ' antibodies when tested in cell culture experiments since hydrolysis
of the drug would reduce the selectivity ie a targeted conjugate may be 
more specific than the data suggest. The work of Garnett et al (1983) 
demonstrates that there is a 1000 fold difference between the activity of
free drug and MTX-HSA; the activity of the conjugate could once again 
be caused solely by the release of free M TX.
The simple extracellular hydrolysis of drug-macromolecular conjugates can
have significant effects on the results of cell culture experiments. It is 
essential to produce a system that is completely stable in the extracellular
medium or at lease to quantify the release in order to explain the results
of in vitro cell experiments.
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The linkage of MTX to an amine could be via either the a  or 7 carboxylic 
acid residue although it is likely that the former may be more cytotoxic 
as has been demonstrated by Rosowsky et al (1984). This group found that 
MTX which is linked via the y carboxyl moiety to PLL was more active in
terms of DHFR inhibition and in cytotoxicity than the corresponding
a carboxyl derivative.
The method of choice for linking MTX to carrier is debrt hi-. -Unce both 
ECDI and NHS have advantages and disadvantages: the former can be used in 
a one step aqueous reaction but can also cause side reactions (ester 
formation and cross-linking) and is relatively inefficient. The NHS 
reaction is more efficient and results in a more stable product however it 
is a two step reaction and the presence of DMF may result in insolubility 
of the carrier and a reduced maximum molar conjugation ratio. It may be 
possible to improve the efficiency of the ECDI reaction by the addition of 
N-hydroxysuccinimide to the reaction mixture (which may also result in 
reduced cross-linking and other side reactions). This would be an 
interesting line of future research. Cross-linking or polymerisation 
would lead to an increase in molecular weight with consequent effects on 
the biodistribution caused by changes in the ability of the molecule to 
leave the vasculature (Halbert et al, 1989).
An improvement of the NHS method would be to form a water soluble salt of
the ester eg. the sodium sulphonate salt of NHS-MTX.
HSA has limited potential as a carrier for MTX since at high MCR’s the 
solubility at low pH is compromised. This is important since it is 
intended as a lysosomotropic agent and the insolubility could result in
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reduced degradability. The presence of the dimer may also cause problems 
in biodistribution studies since the higher molecular weight dimer would 
have a different distribution to the monomer. The potential restriction 
on the MCR coupled with the limited toxicity of MTX would require a large 
number of conjugate molecules to achieve a cytotoxic concentration 
intracellularly, if these were linked to a vectoring agent then the 
molecular weight may prove to be too great to achieve extravasation.
The use of a homopolymer of lysine as a carrier system has the potential 
advantage of maximising the number of sites for the formation of amide 
bonds (ie linking MTX) whilst keeping the molecular weight to a minimum 
and maintaining solubility. The use of poly-L-lysine is however 
restricted due to its inherent cytotoxicity since its cationic nature 
causes it to adsorb onto cells non selectively. The net charge of the 
polypeptide can be reduced by the incorporation of an anionic residue, eg. 
glutamic acid, however polymerisation of equimolar proportions of the 
NCA’s of lysine and glutamic acid will not produce a sequential copolymer 
due to the reaction mechanism. The result is close to a random copolymer, 
however the different rates of reaction (Shalitin and Katchalski, 1959) of 
NCA polymerisation are expected to result in regions of highly positive 
and negative charge density which may still result in non-selective 
binding. The loading of MTX onto the copolymer may once again be limited 
at lower pH due to solubility problems; this may be improved in future 
work by incorporation of amino acids bearing free hydroxyl groups eg 
serine.
The link between MTX and lysine may once again be effected using ECDI 
however this can also bring about an increase in molecular weight due to
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cross linking of polymer chains. This would also cause problems of 
esterification were serine to be included. The use of a water soluble NHS 
derivative is thus desirable in future work since the presence of DMF 
caused solubility problems (of the copolymer) which precluded the use of 
the NHS mediated reaction. The MTX-copolymer conjugates were found to be 
more stable in buffer solutions than MTX-HSA however a low level of free 
MTX was still released.
The release of drug from the conjugates in this study was determined in 
isotonic buffer, it may be that the release profile would be different in 
plasma due to the presence of low levels of enzymes and also other 
proteins (which would bind any free drug). This analysis, while possible 
to monitor using UV (at 370nm), would be more easily facilitated by 
employing radio labelled drug. Thus the use of a flow-through 
radiodetector coupled to the FPLC system would be a powerful tool for 
future work.
The enzymatic degradation of the conjugates was initially tested with 
trypsin as a model enzyme to check and develop the FPLC/molecular weight 
analysis programmes (this also has some application to the in vivo 
situation since acrosin , present in lysosomal enzymes, has a similar 
specificity to trypsin). The incubation of both conjugate systems with 
trypsin (at pH7.4) brought about a reduction in molecular weight but MTX 
was not released in the free form. The digestion of MTX-HSA with 
tritosomes brought about a dramatic change in the molecular weight with a 
large proportion of low MW material which is due to the presence of 
enzymes with different specificities. However thiol dependent proteases 
clearly have the most important role to play in the digestion process.
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The need for the MTX-L-polypeptide conjugate has been demonstrated 
since MTX-poly-D-lysine was found to be inactive in cell culture
experiments (Shen and Ryser, 1979); its lack of degradability has been
demonstrated in this study when incubated with trypsin and tritosomes. In 
contrast MTX-poly-L-lysine conjugates were broken down to low molecular 
weight derivatives by lysosomal enzymes or trypsin.
This study has shown th ,^. ^ poiypeptide-based macromolecular prodrugs of 
M TX  are lysosomotropic agents they are likely to be processed within the 
cell by lysosomal enzymes and that the enzymes likely to be involved are
pH dependent, thiol proteases.
It is unlikely that M TX  needs to be released in the free form to bind
with DHFR since the polyglutamated derivative is active and retained in
the cell longer (Jolivet et al, 1982). The pteridine moiety actually inserts 
into the cleft of the enzyme with the glutamate residue, particularly the
Y carboxyl, being less involved in the binding (Champness et ai, 1986).
Thus oligopeptides of M TX  may still be active and it has been shown 
that macromolecule-MTX conjugates still retain the ability to bind DHFR
(Shen and Ryser, 1981a). However, free M TX  is likely to be driven out
of the lysosome due to the pH gradient (low pH leading to more 
unionised drug and increased lypophilicity). It is uncertain whether the 
derivatives would be able to leave the lysosome, since it has been reported
that only molecules of molecular weight less than 200 Daltons can permeate 
the membrane (Forster and Lloyd, 1988), although it seems likely that they 
do since the conjugates are active in cell culture. This could possibly be 
explained by exocytosis followed by active uptake via the M TX  active 
transport system however this seems an unlikely mechanism (Garnett ei al,
1984). The nature of the low molecular weight fragments following 
tritosomal degradation should now be further investigated by ion exchange
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chromatography and isoelectric focussing. The ’low MW material’ could 
conceivably be large fragments with a high degree of column interaction 
(eg if they contained a large number of hydrophobic groups) or low MW 
derivatives due to the random distribution of residues in the 
macromolecule. Future work should be aimed at the isolation of 
degradation products and the assessment of their ability to inhibit DHFR 
activity.
The use of MTX itself may be restricted by its low toxicity necessitating 
high intracellular levels for cytotoxic effect. However the fact that MTX 
derivatives may be more active than free drug mean that it may not require 
a spacer to be active. An.advantage of MTX is that normal, non-target 
cells may be rescued using leucovorin.
In order to transform the aforementioned passive carrier systems into site 
specific delivery system a vectoring moiety needs to be added, eg an 
antibody, to improve the selectivity. The drug delivery system needs to 
be small enough to be extravasated in order to access the desired site 
whilst retaining selectivity and having sufficient drug loading to be 
active intracellularly following degradation. A further constraint on the
molecular size is that it should not be too large enough so that it may
escape uptake by the reticuloendothelial system. The preferred system 
would be the drug (possibly more than one type with different modes of 
action) linked to a polypeptide with the Fab portion (or better still the 
active site) of a monoclonal antibody as the site directing agent.
It is envisaged that such systems would be used primarily to mop up
metastases following excision of the tumour mass, consequently it is essen­
tial that the system can leave the circulation in order to attach to the 
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Appendix Al Materials
The following materials were used:
human serum albumin
Cohn Fraction V, crystallised and lyophilised 
obtained from Sigma (catalogue number A9511)
poly(D-glu-D-lys.HBr)
60 mole% glutamic acid, 40 mole% lysine, DP=151, MW=24,000 
obtained from Sigma (catalogue number P7568)
methotrexate
disodium salt, lyophilised 
donated by Cyanamid (GB) Ltd.
trypsin
from bovine pancreas, dialysed and lyophilised 
obtained from Sigma (catalogue number T8253)
All other materials and reagents were analytical grade and were used as
received.
APPENDIX A2: CALIBRATION AND CHARACTERISATION OF FPLC COLUMNS
Appendix A2 Calibration of FPLC columns
A2.1 Calibration and characterisation of the Superose 12 column 
A2.1.1 Molecular weight calibration
The column (Superose 12 HR 10/30) was supplied pre-packed by Pharmacia and 
had a claimed separation range of 1000 - 100,000 Daltons. Calibration was 
performed using Pharmacia protein standards. The conditions for a typical 
calibration run were as follows:
Flow rate: 0.48ml/min
Mobile phase: Phosphate buffered saline pH7.4
Column Temp: 25°C _
Typical calibration data are shown in Table A2.1. Regression analysis of 
Kav against log MW yielded the following, indicating a good linear fit:
Sample preparation: protein conc. 5mg/ml, blue dextran lmg/ml
in mobile phase (filtered 0.2um)
Sample volume: 200ul
Detection: 280nm
Column length: 28.5ml (Vt = 22.4ml, Vo = 6.4ml)
Slope = -0.245 + 0.014 (p= 0.05) 
Intercept = 1.521 + 0.062 (p = 0.05) 
R2 = 99.9% r = 0.9995
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Table A2.1:
Molecular weight calibration of the Superose 12 column 








Bovine serum albumin 67,000 4.826 11.8 0.338
Ovalbumin 43,000 4.634 12.6 0.388
Chymotrypsinogen A 25,000 4.398 13.6 0.450
Ribonuclease 13,700 4.137 14.5 0.506
Aprotinin 6,500 3.813 15.8 0.588
Table A2.2:
Molecular weight calibration of the Superose 12 column using protein 
standards (including HSA-dimer) (PBS, pH 7.4, 25°C, 0.48 ml/min)
Sample Molecular
Weight
log MW Mean Kav (sd) [n]
1. HSA-dimer 134,000 5.127 0.269 (±0.007) [5]
2. HSA-monomer 67,000 4.826 0.350 (±0.004) [6]
3. Ovalbumin 43,000 4.633 0.408 (±0.005) [6]
4. Chymotrypsinogen A 25,000 4.398 0.511 (±0.006) [6]
5. Ribonuclease A 13,700 4.137 0.554 (±0.006) [5]




Fig.A2.1 Molecular weight calibration of the 
Superose 12 column using protein standards 
(including BSA-dimer) (PBS, pH7.4, 25°C, 0.48ml/min)
0 . 7 5 - r
0 . 6 0 "
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The calibration could also be performed using HSA and the dimer of HSA as 
data points (Table A2.2). Figure 2.1 shows an example calibration which 
yielded the following parameters.
points 1-6 points 2-6
slope -0.327 (± 0.052) -0.341 (± 0.083)




Molecular weight calibration was sensitive to changes in the 
chromatographic variables and the condition of the- column. Therefore 
molecular weight calibration was-performed routinely during assays.
A2.1.2. Calibration with MTX
A series of solutions of MTX were produced from a 20mg/ml stock solution 
in PBS (pH 7.4). The following concentrations were produced: 0.001,
0.002, 0.0025, 0.004 and 0.005mg/ml. 200 ul samples were injected;
detection being at 300nm. All samples were repeated and all injections 
duplicated. The output from the detector was quantified by the following 
methods:-
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1. Measurement of peak height from the chart recorder
2. Integration and peak height using an LDC Cl10 integrator
3. Integration using the BBC microcomputer
Table A2.3 lists data obtained for calibration of Superose with MTX.
Figure A2/2 shows the plot of a representative set of data. A further 
repeat was conducted by measurement of peak height of the same samples 
after overnight storage at 4°C (Table A2.4). The regression analysis 
(Figure A2.3) yielded the following data:
slope (ml/mg), 300nm = 29.3xl03
intercept = -0.6
r = 0.99992
The mean retention time of MTX during this experiment was 49.27 min (+ 
0.14min, 0.29%) which represented a Kav valued in excess of 1 (c.1.2 - 
actual value not calculated since the void volume had not been 
determined). —
The calibration experiment was repeated at 280nm and 370nm using a 
concentration range of 0.02 - O.lg/ml MTX and injecting 50 ul samples.
The results obtained are shown in Table A2.4. The reproducibility of the 
Superose system was investigated by assaying the same MTX sample 
(O.Olmg/ml) repeatedly with the following result (detection at 300nm)
Mean peak height = 121mm
sd = 1.11 (n = 23)
RSD = 0.91%
ITable A2.3:





height [mm] Peak area Peak height [mm]
BBC microcomputer 
Area under curve
0.001 30 (±0) 171.3 (±1.0) 1095 (±9.4) 3.354 (±0.067)
0.002 60 (±0) 355.0 (±4.7) 2229 (±12.5) 7.038 (±0.080)
0.0025 75 (±0.2) 447.0 (±1.0) 2794 (±18.6) 8.879 (±0.173)
0.004 119 (±1.0) 713.1 (±4.7) 4415 (±47.4) 14.316 (±0.067)
0.005 147 (±1.9) 898.3 (±4.6) 5564 (±64.0) 18.086 (±0.414)
Slope [ml/mg] 29.3 x 103 
{±6.9 x 103}
181.1 x 103 
{±2.6 x 103)
1111.4 x 103 
{±22.0 x 103}
3.674 x 103 „ 
{±0.041 x 103)
Intercept 1.30 ±2.22 -8.2 ±8.3 -3.8 ±71.2 -0.319 ±0.134
Correlation [r] 0,99991 0.99997 0.99994 0.99998
(sd)











Fig.A2.2 Calibration of the Superose 12 column 
with MTX (300nm. PBS pH7.4. 25°C, 0.5ml/min.)
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Table A2.4:
Calibration of the Superose 12 column with MTX (at 370 and 280 nm) (PBS, pH 7.4, 25°C, 0.5 ml /min)
WAVELENGTH
Sample 370 nm 280 nm
concentration
mg/ml Run 1 Run 2 Run 1 Run 2
Peak height/mm
0.02 35.0 36.0 70.5 74.0
0.03 54.0 54.0 109.0 108.0
0.04 63.5 71.0 138.5 144.0
0.06 92.5 105.0 187.0 213.0
0.07 120.0 121.5 240.0 247.0
0.08 138.0 138.5 276.0 280.0
0.09 155.0 155.5 309.5 314.0
0.10 172.0 172.0 343.5 346.0
Slope/mm 1726.1 (±147.7) 1693.2 (±14.5) 3395.8 (±256.5) 3412.7 (±43.3)
Intercept -1.98 (±9.89) 2.92 (±0.97) 1.26 (±17.18) 6.72 (±2.90)











Fig.A2.3 Calibration of the Superose 12 column 
with MTX (370nm. PBS pH7.4. B50C, 0.5ml/min.)
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A2.1.3. Calibration with HSA
a) A series of sample solutions were produced by dilution of a 
lOmg/ml stock solution. The following concentrations were 
produced in PBS pH 7.4: 0.1, 0.2, 0.3, 0.4, 0.5 and l.Omg/ml. 
These gave a linear Beer-Lambert plot for peak height at 279nm 
with the following linear regression analysis:
slope (sd) = 5.37x10"1 (2.36xl0“3) ml/mg
intercept (sd) = 1.69xl0"3 (1.20xl0"3)
r = 0.99996
Peak area calibration was carried out by injecting 200ul samples onto the 
column the eluant being monitored at 280nm. Peaks were integrated using 
an LDC CI10 integrator. The results,_means of repeat injections, are
shown in Table A2.5. The plot of peak area against concentration yielded-
a straight line with the following regression analysis:—
slope (sd) = 1.890x10® (5xl04 )
intercept (sd) = -80.1xl03 (24.9xl03) ___
r = 0.99963
mean peak retention time (n=12) = 24.04 (0.03) min
b) The column was calibrated on a another,occasion using 50ul 
samples and a Pye Unicam detector (280nm). The following peak 
heights were measured and corrected to 0.16 AUFS; all results 
were means of four injections (Table A2.6 and Figure A2.4).
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Table A2.5:
Calibration of the Superose 12 column with HSA (at 279 nm) 














Calibration of the Superose 12 column with HSA (at 280 nm) 















Slope - 16.78 [±0.53] 












Fig.A2.4 Calibration of the Superose 12 column 
with HSA (280nm. PBS pH7.4. 25°C. 0.5ml/min.)
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The results of these calibrations indicated that the Superose 12 system 
was suitable for assaying human serum albumin since the retention time was 
found to be repeatable (and separate from the void volume) and linear 
calibration plots were obtained across the ranges 0.1 to lmg/ml and 0.2 to 
lOmg/ml.
The chromatogram revealed a peak eluting prior to the main HSA peak 
(21.55min + 0.28) which was due to the dimer of HSA and was present at a 
level of 11.3% (±0.6) of the monomer peak (by peak height). The dimer 
peak was also found to exhibit linearity when detected at 280nm (r = 
0.9995).
A2.1.4 Effect of dilution on assay of MTX-HSA
A conjugate of MCR 21 was produced and degraded at 37°C for twelve hours 
after-which time the level of free MTX present was 3.7%. The solution 
was removed from the high temperature environment and diluted with PBS pH 
7.4 and assayed using the Superose column at 300nm to determine MTX-HSA by 
peak area and peak height. Data is presented in Table A2.7.
A2.2 Calibration of ^ the TSK G3000 PWxl column 
A2.2.1 Molecular weight calibration
The calibration was performed using a variety of protein standards under 
the following conditions:
Table A2.7:






Dimer peak area 
x 105





0.171 (33.3) 13.2 (27.7) 41.8 (31.2) 13.0 (31.9) 25.0 (34.3)
0.257 (50.0) 21.3 (44.7) 63.6 (47.5) 20.3 (49.8) 37.0 (50.7)
0.342 (66.67) 29.4 (61.6) 85.9 (64.1) 27.4 (67.2) 48.5 (66.4)
0.428 (83.3) 38.5 (80.7) 110.2 (82.2) 33.5 (82.1) 59.5 (81.5)
0.513 (100.0) 47.7 (100.0) 134.0 (100.0) 40.8 (100.0) 73.0 (100.0)
Retention time/min 22.58 [±0.04] 25.46 [±0.06] 50.93 [±0.08]
Regression A -4.48 -5.35 -0.54 1.17
B 100.8 270.2 80.5 138.6
r 0.9995 0.9997 0.9996 0.9994
(expressed as % of maximum value)
249
Flow rate: 0.78ml/min
Mobile phase: Phosphate buffered saline pH7.4
Column Temperature: 25°C + 0.5°C
Detection: 280nm, Gilson 113
Sample preparation: dissolved in mobile phase and filtered 0.2um
Sample volume: 20ul
Column volume: 3.31ml (pre column) + 14.33ml (main)
Vt = 17.64ml, Vo = 7.02ml
Representative data for calibration are shown in Table A2.8 and Figure 
A2.5. The results from calibration 2 were the mean values (+sd) from six 
different chromatograms run over a three day period.
The regression analysis was as follows:
When the BSA dimer (134,000), Kav = 0.099, was included in the calibration 
the plot exhibited the classical sigmoid curve suggesting that the TSK 
G3000PWxl column had a useful separation range between about 5,000 and 
50,000 Daltons. The regression line (excluding the dimer) (Figure A2.5) 
gave a reasonable fit (r = 0.986). It was thought that the TSK G3000 
column could be used for molecular weight estimation within the range 
1,500 - 70,000 Daltons (correlation for 6,500 - 43,000 = 0.997). However 
it was noted that the performance of the Superose column was superior over 
this range.
Slope = - 0.419 ( 0.081) (95% confidence limits)
Intercept = 2.140 (0.342)
R2 = 97.3%, r = - 0.986
Table A2.8:
Molecular weight calibration of the TSK column using protein standards 














n - 6 (±sd)
BSA 67,000 4.826 8.52 0.143 0.144 (±0.003)
Ovalbumin 43,000 4.634 8.79 0.168 0.162 (±0.004)
Chymotrypsinogen A 25,000 4.398 9.82 0.267 0.264 (±0.003)
Trypsin 23,800 4.377 10.08 0.291 -
Ribonuclease 13,700 4.137 11.31 0.408 0.414 (±0.008)
Aprotinin 6,500 3.813 13.52 0.619 0.613 (±0.003)




Fig.A2.5 Molecular weight calibration of the 
TSK G3000PWx1 column using protein standards 
(280nm. PBS pH7 . 4, 25°C, 0.78ml/min.)
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A2.2.2. Calibration with MTX
A series of concentrations of MTX were produced in PBS pH7.4 from a stock 
solution (20mg/ml) and 20ul samples assayed using the TSK column.
Mobile phase = PBS pH7.4
Flow = 0.749ml/min (0.75ml/min in run 2). ~
The output was monitored at 303nm and also logged by computer to determine
the peak areas. Sample *2’ represented a second run with samples produced
from a fresh stock solution; each data point was the mean of 2 samples 
(Table A2.9). The mean retention times of MTX were:
Sample 1: 24.76 min (+0.06) (n = 5)
Sample 2: 24.86 min (+0.03) (n = 8)
This equated to a Kav of approximately 1.09 indicating that MTX was also 
adsorbed to the TSK column. The results (the mean values of which are 
represented graphically in Figure A2.6) showed that the TSK system 
provided both a repeatable and a reproducible assay for MTX across the 
range studied and that the peak height and peak area methods of analysis 
were equally valid.
A2.2.3 Calibration with HSA
A stock solution was prepared by dissolving HSA in PBS pH 7.4 to give a 
final concentration of 5.0mg/ml. Aliquots from this solution were diluted
Table A2.9:
Calibration of the TSK column with MTX (at 303 nm) (PBS pH 7.4, 25°C, 0.75 ml/min)




Mean peak height 
(mm) corrected 
to 0.02 aufs
Mean peak area 
corrected to 
0.02 aufs
Mean peak height 
(mm) corrected 
to 0.02 aufs
Mean peak area 
corrected to 
0.02 aufs
0.0005 12.8 1.2744 11.3 1.2034
0.001 23.4 2.3865 21.4 2.1904
0.002 46.8 4.8702 45.0 4.7853
0.004 95.3 9.8470 90.0 9.5445
0.008 188.0 19.2514 177.5 18.6755
0.01 235.0 23.3176 221.0 22.9562
0.02 467.5 - 465.0 47.8065
0.05 1200.0 118.7430 1143.8 116.6913
0.1 2440.0 244.1540 2330.0 233.4560
Regression analysis
Slope 24373 (±220) 2432.7 (±30.8) 23277 (±191) 2334.3 (±11.2)
Intercept -6.2 (±7.9) -0.4 (±1.2) -5.1 (±7.3) 0.1 (±0.4)
R2 100.0% 100.0% 100.0% 100.0%











Fig.A2.6 Calibration of the TSK G3000PWxl column 
with MTX (303nm, PBS pH7 . 4, 25°C, 0 . 75ml/min .)
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to give a range of concentrations, 20ul samples of which were assayed at 
279nm after being chromatographed on the TSK column using the following 
conditions:
Mobile phase: PBS pH 7.4
Flow rate: 0.745ml/min
The results, shown in Table A2.10, gave the regression analysis below:
Slope = 172.9 (±4.4)
Intercept = 1.80 (±10.93)
R2 = 100.OX, r = 1.000
Representative results are shown graphically in Figure A2.7.
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Table A2.10:
Calibration of the TSK column with HSA (at 279 nm)
(PBS, pH 7.4, 25°C, 0.75 ml/min)
HSA Concentration 
mg/ml
Mean peak height (mm) 
corrected to 0.04 auf 















Fig.A2.7 Calibration of the TSK G3000PWxl column 
with HSA (280nm, PBS pH7 . 4, 25°C, 0 . 75ml/min .)
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APPENDIX A3: ISOLATION AND CHARACTERISATION OF LYSOSOMAL ENZYMES
FROM THE RAT LIVER
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Appendix A3 The extraction and characterisation of lysosomal enzymes from 
rat liver
Lysosomal enzymes were extracted from rat liver using the principles 
described by Trouet (1974). Male Wistar rats (280-320g) were injected 
intraperitoneally with 3ml 20%w/v Tyloxapol solution in Milli Q water.
The rats were killed after 4 days, their livers removed and homogenised at 
4°C in 0.25M sucrose. The homogenate was centrifuged at 2000 rpm for 15 
minutes, the supernatant removed and recentrifuged at 12,000 rpm for 30 
minutes. The pellet was suspended in 45%w/v sucrose solution and then 
centrifuged at 25,000 rpm for 2 hours on a sucrose gradient composed of 
equal parts of 45%, 35.5% and 14.5% sucrose solutions. A distinct band of 
lysosomal material was present at the interface of the 14.5% and 35.5% 
sucrose layers. This fraction was removed using a Pasteur pipette, its 
volume noted, and stored at -18°C.
The enzyme activity was monitored using Bz-Phe-Val-Arg-NAp as substrate 
and the reaction monitored by change in UV absorbance at 410nm in citrate 
-phosphate buffers at 35°C. The following formula was used in activity 
experiments.
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tritosome suspension 0.10 ml
l%w/v Synperonic OPIO 0.02 ml
EDTA 50mM 0.02 ml
GSH 250mM 0.02 ml





Typical data generated using the above formula is shown in the table 
below.
Incubation time (mirn) 
at pH 5.0, 35°C












The effect of pH on the activity of the same batch of tritosomes was 
studied after 10 weeks storage of the enzyme preparation at -18°C. Data 
obtained is shown in the following table.
pH
mean change (sd) in absorbance at 410nm 









This indicated that the enzyme preparation had substantial activity 
between pH 4 and 7 but lower activity at pH 8. Storage of the enzyme 
preparation for 10 weeks had no adverse effect on its activity. A blank 
system containing no tritosomes but replacing their volume by 20% sucrose 
demonstrated no change in absorbance at 410nm over the 20 min incubation 
period.
The effect of reduced glutathione on the degradation of Bz-Phe-Val-Arg-NAp 
was investigated using a lower substrate concentration (as before but 





change in absorbance at 410nm 





The above data showed that degradation of the substrate at pH 5 was thiol 
dependent and that there was no substantial change in degradation rate 
within a concentration range of 5-50 mM GSH. A concentration of 5mM GSH 
was adopted for degradation experiments described in Chapters 3 and 4.
The effect of surfactant concentration on enzyme activity was also 
investigated (see below).
volume 1% Synperonic OP10 change in absorbance at 410nm
added to incubation mixture after 20 min at 35°C, pH 5.0
0.02 ml 0.084
0.20 ml 0.060
There was no advantage to be gained by increasing the surfactant 
concentration above 0.02 ml therefore the lower surfactant concentration 
was adopted as standard. The surfactant was present to allow 
solubilisation of the lysosomal membranes and release of enzymes. It was 
not clear what was the effect of freeze-thawing on the enzyme preparation
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but the turbidity of the suspension was thought to be lower after 
freeze-thawing. The enzymes may have been present in solution after 
freeze-thawing making the addition of extra surfactant unnecessary.
Assay of surfactants used in the isolation of tritosomal enzymes and 
screening of those employed in the lysosomal experiments
The surfactant which has been used in the isolation of lysosomal enzymes 
was a cross-linked octylphenol ethoxylate, Triton WR1339 (Trouet, 1974).
A surfactant with a similar composition ie Tyloxapol (obtained from Sigma) 
was employed in this assay. Triton X-100 has been used for tritosomal 
degradation studies since it is necessary to solubilise the lysosomal 
vesicle to release the enzymes. In this study surfactants with similar 
structures and HLBs to Triton X-100 were selected and assayed in order to 
discover which one would interfere least with the FPLC assay.
The surfactant solutions were produced by dissolving sufficient surfactant 
in pH5.6 buffer to produce at 10% w/v solution (all of which were found to 
be clear). A 1 in 50 dilution was then produced (ie 0.2%w/v) and 20ul 
samples applied to the Superose 12 column (mobile phase pH7.4, detection 














33 + 34.5 
33 + 34.5 
33 + 34.5 
33 + 35
Synperonic OPIO was selected as the solubilizing surfactant since it only 
exhibited peaks at around 34 minutes which were probably due to the buffer 
system used. Other surfactants gave a peak eluting with the void volume 
of the column which may have been due to micellar material.
APPENDIX A4: EXPERIMENT TO CONFIRM THAT MICROBIOLOGICAL SPOILAGE WAS
NEGLIGABLE DURING IN VITRO DEGRADATION STUDIES
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Appendix A4 Experiment to confirm that microbiological spoilage of 
MTX-HSA conjugates was negligible during in vitro 
degradation studies
The experimental procedure employed in the formation of the conjugate 
involved the use of clean/sterile glassware (dry heat, 160°C for a minimum 
of two hours) wherever possible. Solutions were filtered through a sterile
0.2um (or 0.45um) membrane filter into the sterile glass containers/vials. 
However it was clear that microbial contamination of HSA or MTX-HSA 
solutions resulted in rapid degradation of the HSA. Microbial growth was 
observed in non-sterile HSA solutions stored under ambient conditions for 
24 hours. Assay of such a system showed that considerable quantities of 
free MTX were released from MTX-HSA in the presence of bacteria. Thus to 
confirm the sterility of the samples use for in vitro degradation studies, 
an experiment was set up which included sterility checks on the actual 
samples which were analysed by FPLC.
The conjugation reaction was performed under the normal conditions used 
for the active ester method and separated on a Sephadex column (5.13ml 
injected, 100ml collected) in pH7.4 buffer then sterile filtered into 
sterile 2ml vials. The MCR was found to be 19.4 (MTX concn. = 68.4 x 
10“3 mg/ml).
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Sterility checks were performed, at various times over a 48 hour 
incubation period (at 37°C), in the following manner using aseptic 
technique:-
1. The rubber cap of the vial was swabbed with 70% alcohol and
then a 1ml sample withdrawn using a sterile syringe/hypodermic
needle.
2. The sample was emptied on to a sterile 0.2um filter contained
in a Millipore filtration unit (vacuum on), the filter had
previously been rinsed with a few millilitres of sterile water. 
The sample/filter were then rinsed with about 100ml of sterile 
water.
3. The filter was then transferred aseptically to an overdried 
nutrient agar plate.
4. The plate was incubated at 37°C for 48 hours before any
colonies were counted. The plate was then stored at 25°C for 
72 hours to check for the presence of moulds.
The samples were then analysed on the Superose 12 column following 
incubation at 37°C, sterility tested samples were assayed within 30 
minutes of testing. The samples were analysed for molecular weight 
distribution using the integration programme and for release of free MTX 






peak 1 (dimer) peak 2 (HSA) % free 
MTXarea(%) MW(xlO"3) area(%) MW(xlO'3)
0 NG 15.1 134 73.6 68.9 _
lhr 10m - 16.5 141 73.5 69.7 0.06
2hr 49m NG 16.9 140 73.1 69.3 0.13
4hr 29m - 16.4 139 73.5 68.7 0.20
6hr 14m - 16.5 140 73.7 69.2 0.24
7hr 24m - 16.8 135 74.2 67.6 0.29
19hr 44m NG 16.8 140 72.9 68.8 0.55
24hr 44m NG - - - - 0.64
31hr 26m - 15.9 - 73.2 - 0.73
47hr 44m NG - - - - 0.88
51hr 54m - - - - - 0.91
66hr 09m - - - - - 0.98
(NG, no growth; not tested)
The reaction mixture was also sterility tested after 3 days at 25°C with 
the result that no growth occurred.
A further sterility experiment was conducted using an ECDI produced 
conjugate.
All glassware was heated at 160°C for at least 2 hours prior to use to 
ensure sterility. The MTX, ECDI and HSA were weighed into the appropriate 
volumetric flasks, as were the buffer salts to which sterile water was 
added aseptically. The buffer solutions were then filtered (0.2um
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sterile) into the MTX, ECDI and HSA volumetric flasks in a laminar flow 
cabinet. The required volumes of each solution were mixed and then 
filtered (0.2um) into two vessels (HSA:MTX:ECDI = 1:116.2:172.5). One of 
the mixtures was then inoculated with a colony of Pseudomonas (a potential 
contaminant). The reaction mixtures were then incubated at 25°C 
overnight.
The inoculated sample (RM21 INN) was filtered on to a Sephadex G50 column 
(1.04ml sample) after incubation for 13.5 hours and the resulting 25ml 
sample sample filtered and analysed as normal.
The sterile sample (RM21) was desalted after storage for 36 hours (5.13ml 
fractionated and collected in 100ml) then sterile filtered and analysed on 
the Superose 12 column. The MCR was found to be 20.0 (reaction mixture 
HSA:ECDI:MTX = 1:116.2:172.5)
RM21INN RM21 — •
time post- % free time post- %free
f ractionation MTX fractionation MTX
lhr 00m 0.15 lhr 30m" 0.21
9hr 45m 1.99 3hr 40m* 0.27
17hr 10m* 3.33 9hr 10m 0.90
21hr 55m* 3.93 13hr 50m* 1.30
45hr 55m 5.91 31hr 10m 3.24
47hr 00m 5.99 32hr 14m 3.45
34hr 14m 3.61
(* - sterility tested all showing no growth)
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The conjugation mix from RM21INN was also tested and found to be heavily 
contaminated. All filtered samples were found to be sterile.
The release of MTX from the conjugates was as expected and could not be 
explained by microbial spoilage of the MTX-HSA since all the samples 
tested were sterile. The addition of microorganisms to the reaction 
mixture did not affect the integrity of the conjugate although the release 
of MTX was higher from the inoculated sample. This was thought to be due 
to the shorter reaction time used in the latter case.
APPENDIX A5: THE EFFECT OF SODIUM AZIDE ON THE ENZYMATIC DEGRADATION
OF MTX-HSA AND MTX-COPOLY(AMINO ACID) CONJUGATES
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Appendix A5 The effect of sodium azide on the enzymatic degradation of 
copolymer and HSA-MTX conjugates
The purpose of this experiment was to determine whether the addition of 
sodium azide (0.02% w/v) to the mobile phase resulted in any alteration of 
the degradation profile of the conjugates. Sodium azide had been 
incorporated into the phosphate buffer in order to minimize the risk of 
microbial spoilage of either the samples or the column employed for 
separation and analysis.
i) L-copolymer
The sample of L-copolymer-MTX conjugate used in this experiment was that 
described in section 4.5; this was in solution (0.125mg/ml) in PBS (pH 
7.4) containing azide. 7.5ml of this solution was freeze dried and then 
reconstituted with 1.2ml water and 1ml separated on a Sephadex G15 column, 
using PBS-(pH7.4 no azide) as the mobile phase, the sample being collected 
in a volume of 10ml (0.078mg/ml). The solution was then sterile filtered 
and 250ul samples placed in vials to which were added 25ul aliquots of two 
of the following:- trypsin solution lmg/ml, PBS pH7.4 or sodium azide in 
PBS (2.4mg/ml) in order to produce the following solutions.
RM35A - copolymer/MTX, no trypsin, no azide
RM35B - copolymer/MTX, no trypsin + azide 0.02%
RM35C - copolymer/MTX, trypsin, no azide (Cop:try = 0.78:1)
RM35D - copolymer/MTX, trypsin + azide 0.02% (Cop:try = 0.78:1)
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The samples were then sealed, mixed and incubated at 37°C for 10 and 24 
hours prior to assay on the TSK system.
The results for the samples without trypsin ie RM35 A and B showed that 
there was no alteration in the molecular weight of the main peak (36,000) 
but the sample containing azide exhibited a few low molecular weight peaks 
causing the proportion of the main peak to drop from 99% without azide to 
92% in its presence.
The incorporation of trypsin brought about the characteristic dismantling 
of the conjugate molecule into various molecular weight fractions. A 
slight reduction in activity was evident in the presence of sodium azide.
Sample Molecular weight (xl0~ 3)
27 15 8 3.5 <1.5
RM35C-10H 15.6 13.3 18.9 24.3 27.8
RM35D-10H 17.4 15.3 20.1 22.0 25.2
RM35C-24H 13.5 15.1 18.1 24.5 28.8
RM35D-24H 15.5 15.1 19.0 24.3 26.2 j
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ii) HSA
The conjugate reaction mixture, which had been previously frozen, was 
separated on a Sephadex column (1.04ml fractionated and collected in 25ml) 
using PBS pH7.4 (no azide) as mobile phase. The sample (MCR = 9.9) was 
then sterile filtered and 0.5ml aliquots mixed with 50ml trypsin solution 
(4mg/mi) or 50ui PBS or 50ul PBS + azide (2.4mg/ml) to produce the 
following samples:-
RM36A - HSA/MTX no trypsin, no azide
RM36B - HSA/MTX no trypsin + azide 0.02% w/v
RM36C - HSA/MTX trypsin, no azide molar HSA: Try = 1:2.7
RM36D - HSA/MTX trypsin + azide 0.02%w/v molar HSA: Try = 1:2.7
The vials were sealed, mixed and incubated at 37°C for 10 and 24 hours and 
frozen before assay on the TSK system
Sample in the absence of trypsin
Sample Molecular weight xl0“3 %free MTX
'
70 50 Mix by peak height
RM36A-10H 7.0 87.5 1.5 2.0
RM36B-10H 6.7 86.8 1.5 2.0
RM36A-24H 6.2 87.2 2.2 3.1
RM36B-24H 6.0 88.4 1.9 3.0
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Sample in the presence of trypsin
Sample Molecular weight xl0~3
48 24 12 7.5 4.5 <1.5
RM36C-10H 25.5 28.7 11.3 6.7 10.2 15.8
RM36D-10H 28.5 27.5 10.4 6.5 10.4 15.2
RM36C-24H 23.2 27.1 10.9 7.1 9.9 19.9
RM36D-24H 21.1 28.3 11.8 6.3 10.2 20.5
A comparison of the overall molecular weight distribution was determined 
with a fixed baseline:-





The results showed that the addition of sodium azide had very little 
effect on either release of free MTX in buffer solution or the degradation 
of the samples in the presence of trypsin.
APPENDIX A6: PHYSICAL AND SPECTROSCOPIC PROPERTIES OF METHOTREXATE
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Appendix A6 Physical and spectroscopic properties of MTX
The chemical structure of MTX is shown in section 1.4.2







Molecular weight = 454.4






Absorption coefficients were determined in phosphate buffered saline pH 
7.4 using a range of concentrations (0.001-0.lmg/ml) (Beer-Lambert linear 
r = 1.000, El%/lcra = 162.4, molar absorption coefficient = 7380,370nm)
The UV spectrum for MTX2 0-HSA is displayed with that for HSA at an 






w a v e l e n g t h
APPENDIX A7: COMPUTER PROGRAMMES FOR COLLECTION AND ANALYSIS OF DATA
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LI.
10 REM * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
20 REM * PROGRAM FOR SAVING CHROMATOGRAPHIC *
30 REM * DATA ON DISC *
40 REM * *
50 REM * R J MARRIOTT AND C W POUTQN *




100 PRINT’HAVE YOU RENAMED PREVIOUS FILES?”
110 PRINT
120 PRINT"IF NOT BY CONTINUING WITH THIS"




170 VDU 15 
180 DT=100
190 INPUT "ENTER DATA COLLECTION TIME (min) "DT 
200 ST%=DT*6000/1000
210 INPUT"ENTER THE NUMBER OF INJECTIONS (1-20)"NC









310 DEF PROCDATACOL 
320 FOR I%=1 TO 1000 
330 CT%=TIME 
340 AV=0





400 PRINT 1%;" ";DS(IX);" ";K%
410 PRINT£X,I%,DS(I%)





















































920 PRINT"TO START CHROMATOGRAPHIC RVS PRESS G
930 STARTS=GET





20 REM * PROGRAM TO RETRIEVE AND ANALYSE *
30 REM * SIZE EXCLUSION CHROMATOGRAPHIC DATA *
40 REM * *





100 DIM DS(1000),STY(20),STX(20),SP%( 10),EP%(10),PH%(10),CUT%(6),P(6)
110 DIM peak$(5):peak$(l)="FIRST":peak$(2)="SECOND":peak$(3)="THIRD"
120 peak$(4)="FOURTH":peakS(5)="FIFTH"
130 DIM cut$(6):cut$(1 )="FIRST":cut$(2) = "SECOND":cut$(3) = "THIRD"
140 cut$(4 )="FOURTH" : cuts ( 5 )="FIFTH": cuts (6) = "SLXTH"
150 VDU15 
160 SP=0.5
170 SP%(1) = 250:SP%(2)=250:SP%(3)=250:SP%( 4)=250:SP%(5)=250:SP%(6)=250
180 EP%(1) = 750:EP%(2)=750:EP%(3)=750: EP%( 4) = 750:EP%(5)=750:EP%(6) = 750
1 9 0  P H % ( 1) =  1 0 0 : P H % ( 2) = 1 0 0 : P H % { 3 ) = 1 0 0 : P H % (  4 ) =  1 0 0 :P H % ( 5 ) = 1 0 0
























440 PRINT "DO YOU WISH TO ANALYSE THE SAME DATA AGAIN?Y/N";: INPUT Y$
450 IF YS="Y" OR Y$="v" THEN 370 ELSE GOTO 460
460 print"havt: YOU FINISHED ? Y/N"
470IF GET=78 THEN 330
480 END
490:
500 DEF PROCINF 
510 CLS 
520 FLAG%=0
530 PRINT"OPTIONS AVAILABLE AT THIS STAGE"’
540 PRINT"f2 - CARRY OUT CALIBRATION"’
550 PRINT"f 3 - CONTINUE WITH RUN" *
560 PROCKEY
570 IF FLAG%=0 THEN 560
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580 IF FLAG%< >1 THEN 510 
590 ENDPROC 
600:
610 DEF PROCKEY 
620 *FX15,1
630 IF INKEY(—115)=—1 THEN PROCCALIB 





690 INPUT"ENTER F L O W  RATE (ml/min) "SP
700 INPUT"ENTER DEXTRAN (MW=2,000,000) ELUTION TIME (min) "TN 
710 INPUT"ENTER TOTAL VOLUME OF COLUMN (ml) "VT 
720 INPUT"ENTER NO. OF CALIB. POINTS "N%
730 FOR I%=1 TO NX 
740 PRINT"MOL. WT. "IX 
750 INPUT MLW 
760 STY(IX)=LOG(MLW)
770 PRINT"ELUT. TIME (min) "IX 
780 INPUT SIX(IX)
790 NEXT
800 FOR IX=1 TO NX




850 PRINT"PRESS SPACE TO CONTINUE"




900 INPUT"ENTER A NAME .AND/OR SHORT DESCRIPTION OF YOUR SAMPLE "D$
910 PRINT D$" IS THIS OK ? Y/N"
920 ZX=GET
930 IF ZX>90 THEN ZX=ZX-32
940 IF ZX<>78 AND ZX<>89 THEN 920
950 IF ZX=78 THEN 900
960 INPUT"DATE OF ANALYSIS "DATES
970 ENDPROC
980:





1040 PRINT’TF YOU WANT TO PRINT YOUR CHROMATOGRAM YOU WILL NEED MDUMP"
1050 PRINT"DO TOU WANT TO PRINT YOUR CHROMATOGRAM? (Y/N?)"
1060 *FX15,1
1070 IF GET-89 PR%=1 ELSE PR%=0
1080 PRINT"TO PLOT THE CHROMATOGRAM ON SCALE THE DIGITAL VALUE OF THE INPUT IS Ml 
FACTOR (MULTF)"
1090 PRINT
1100 PRINT "THE CURRENT VALUE OF MULTF =" MULTF 
1110 PRINT
1120 PRINT'DO YOU WANT TO CHANGE THE VALUE OF MULTF? (Y/N?)";: INPUT Y2S 
1130 IF Y2$="Y" OR Y2$="y" THEN 1140 ELSE 1150
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1260 PRINT'DO YOU WANT TO REPLOT? (Y/N)"
1270 *FX15,1





1330POR PEAK%=1 TO 5
1340 CLS
1350 *FX15,1
1360PRINT"RETENTION TIME - PEAK ";STR$PEAK%
1370 PRINT"A/S -INC.TIME Z/X -DEC.TIME"
1380 PRINT"SPACE - NO FURTHER CHANGE"
1390 *FX15,1 
14 OOPROCRT(PEAK%)




1450 PRINT"A/S-INC.PEAK START Z/X-DEC.PEAK START"
1460 PRINT"J/K-INC.PEAK END N/M-DEC.PEAK END"
1470 PRINT"SPACE - NO FURTHER CHANGE"
1480 *FX15,1 
14 90PROCKEY3(PEAK%)




1540PRINT"DO YOU WANT TO ANALYSE A ";peaks(PEAK%+1);" PEAK? (Y/N?)" 
1550 *FX15,1
1560 IF GET$="N" THEN P(PEAK%+1)=0 





1620 A=0 : B=0 : BARX=0 : BARY=0 : R=0
1630 SUMXY=0.0 : XSUM=0.0 : YSUM=0.0
1640 X2SUM=0.0 : Y2SUM=0.0












1760 R= (NX*SUMXY-XSUM*YSUM) / (SQR( (NX*X2SUM-XSUM~2) * (NX*Y2SUM-YSUM~2) ) )




1810 PRINT"CURRENT SLOPE OF CALIB. - "A 
1820 PRINT "CURRENT Y-INTERCEPT = "B 
1830 PRINT"CURRENT VOID VOL. TIME = "TN 
1840 PRINT’CURRENT TOTAL VOL. COLUMN = "\T 
1850 PRINT"CURRENT FLOW RATE = "SP" ml/min"
1860 PRINT"DO YOU WISH TO ENTER CALIB VALUES ? Y/N "
1870 Z%=GET
1880 IF Z%>90 THEN Z%=ZX-32
1890 IF Z%<>78 .AND Z%<>89 THEN 1870
1900 IF Z%=78 THEN 2000
1910 INPUT"ENTER VOID VOL. TIME (min) "TN
1920 INPUT"TOTAL VOLUME OF COLUMN (ml) "VT
1930 INPUT "ENTER SLOPE OF CALIB "A
1940 INPUT”ENTER Y-INTERCEPT "B
1950 INPUT "ENTER FLOW RATE (ml/min) "SP
1960 PRINT"THE CURRENT CHROMATOGRAPHIC RUN TIME IS "DT" mins"
1970 PRINT"DO YOU WISH TO ENTER A NEW RUN TIME? (Y/N?)"
1980 ZZX=GET
1990 IF ZZX="Y" THEN 2000 ELSE 2010 











2110 PRINT"DATE OF ANALYSIS :- "DATES
2120 PRINT"SAMPLE: - "DS
2130PRINT"EXPTL.CODE:- "ECS
2140 PRINT"FLOW:- "SP
2150 PRINT"DATA COLL TIME:- "DT" min"
2160 ENDPROC 
2170:
2180 DEF PROCRETRIEVE 
2190INPUT"FILENAME ".FILES 
22OOX%=OPENIN FILES 
2210 FOR IX=1 TO 1000 
2220 INPUT£X%,1%,DS(1%)






2280 DEF PROCANAL 
2290 CLS
2300PRINT"OPTIONS AVAILABLE AT THIS STAGE"
2310 PRINT 
2320PRINT
2330 PRINT"A - UP TO FIVE WELL-SEPARATED PEAKS: AUC ONLY" 
2340 PRINT
2350 PRINT"B - UP TO FIVE WELL-SEPARATED PEAKS: AUC AND MW" 
2360 PRINT
2370 PRINT"C - UP TO SIX OVERLAPPING PEAKS: AUC ONLY"
2380 PRINT
2390 PRINT"D - UP TO SLX OVERLAPPING PEAKS: AUC AND MW"
2400 *R15,1 
2410 K$=GET$
2420IF K$="A" THEN PROCanal(l)
2430IF K$="B" THEN PROCanal(2)
2440IF K$="C" THEN PROCanal(3)






2510 IF NX=1 OR N%=2 PR0CALTER1 ELSE PROCALTER2





2570IF N%=1 PROCPROCESS1:PROCPRINT1 
2580IF N%=2 PROCPROCESS2:PROCPRINT2 
2590 IF N%=3 THEN PRCESS=3 
2600IF N%=3 PROCPROCESS4:PROCPRINT4 
2610 IF N%=4 THEN PRCESS=4 






2680 IF INKEY(-99)=-l THEN FX=1
2690 IF INKEY(-66)=-l THEN F%=2
2700 IF INKEY(-98)=-1 THEN F%=3




2730 IF INKEY(-82)=-l THEN F%=6
2740 IF INKEY(-67)=-l THEN F%=7
2750 IF INKEY(—71)=—1 THEN F%=8
2760 IF INKEY(-102)=-l THEN F%=9 
2770 IF F%=0 THEN ENDPROC
2780 PROCX(SP%(N%)+100,(DS(SP%(N%) )*MULTF)+100)
2790PROCN(EP%(N%)+100,(DS(EP%(N%) )*MULTF)+100)
2800 IF F%=2 THENSP%(N%)=SP%(N%) + 1
2810 IF F%=3 THENSP%(N%)=SP%(N%)-1
2820 IF F%=4 THENEP%( N%)=EP%(N%)+1
2830 IF F%=5 THENEP%(N%)=EE%(N%)-1
2840 IF F%=6 THENSP%(N%)=SP%(N%)+10
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2850 IF F%=7 THENSP%(N%)=SP%(N%)-10
2860 IF F%=8 ™ENEP%(N%)=EP%(N%)+10
2870 IF F%=9 THENEP%( N%)=EP%(N%)-10
2880 IF SP%(N%)<1 THEN SP%(N%)=1
2890 IF EP%(N%)>1000 THEN EP%(N%)=1000
2900 PROCX(SP%(N%)+100,(DS(SP%(N%))*MULTF)+100)
2910PROCX(EP%(N%)+100,(DS(EP%(N%) )*MULTF)+100)
2920 PRINT"START POINT = " ;SP%( N%); ” END POINT = *’;EPX(NX)
2930 PRINT"A/S-INC.PEAK START Z/X-DEC.PEAK START"
2940 PRINT"J/K-INC.PEAK END N/M-DEC.PEAK END"












3070 FOR I%=SP%(1) TO EP%(1)
3080 CEXP1=DS(IX)-DS(SP%(1))
3090 CEXPl=CEXPl-(((DS(EP%(1))-DS(SP%(1)))/( EP%( 1)-SP%(1)))*(IX-SF%(1))) 
3100 F11=F11+CEXP1 
3110 NEXT
3120 IF P(2)=0 THEN ENDPROC 
3130 FOR IX=SP%(2) TO EPX(2)
3140 CEXP2=DS(1%)-DS(SP%(2))
3150 CEXP2=CEXP2-(((DS(EP%(2))-DS(SP%(2)))/(EPX( 2)-SP%(2)))*(I%-SP%(2))) 
3160 F12=F12+CEXP2 
3170 NEXT
3180 IF P(3)=0 THEN ENDPROC 





3240 IF P(4)=0 THEN ENDPROC 





3300 IF P(5)=0 THEN ENDPROC 








3390 PRINT"DO YOU WANT TO PRINT YOUR DATA ON PAPER? (Y/N?)"
3400 *FX15,1
3410 IF GET=89 THEN PR%=1 ELSE PR%=0
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3420 CLS










3530 PRINT" 1 ft DT*PH%( 1)/1000,Fll
3540 IF P(2)=0 THEN 3620
3550 PRINT" 2 f DT*PH%(2 )/1000,F12
3560 IF P(3 )=0 THEN 3620
3570 PRINT" 3 DT*PH%(3)/1000,F13
3580 IF P(4)=0 THEN 3620
3590 PRINT" 4 M DT*PH%(4)/1000,F14
3600 IF P(5)=0 THEN 3620




3650 PRINT "PRESS SPACE BAR TO CONTINUE"
3660 *FX15,1 
3670 L=GET






3740 IF INKEY(-99)=-l THEN FX=1 
3750 IF INKEY(-66)=-l THEN F%=2 
3760 IF INKEY(-98)=-l THEN F%=3 
3770 IF INKEY(-82)=-l THEN F*=4 
3780 IF INKEY(-67)=-l THEN F%=5 
3790 IF F%=0 THEN ENDPROC
3800 PROCX(PH%(N%)+100,(DS(PH%(NX))*MULTF)+100)
3810 IF F%=2 THEN PH%(NX)=PHX(N%)+1
3820 IF F%=3 THEN PH%(N%)=PH%(N%)-1
3830 IF F%=4 THEN PH%(N%)=PH%(N%)+10
3840 IF F%=5 THEN PH%(N%)=PH%(N%)-10
3850 PROCX(PH%(N%)+100,(DS(PH%(N%))*MULTF)+100)
3860 PRINT"RETENTION TIME - PEAK ";STR$PEAK%
3870 PRINT”A/S -INC.TIME Z/X -DEC.TIME"
3880 PRINT"SPACE - NO FURTHER CHANGE"









3980 FOR I%=SP%(1) TO EP%(1)
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3990 F0=10~(A*( (ST%*I%/6000)*SP-TN*SP)/(VT-TN*SP)+B)
4000 CEXP1=DS(I%)-DS( SP%( 1))





4060 IF P( 2 )=0 THEN ENDPROC 
4070 FOR I%=SP%(2) TO EP%(2)
4080 F0=10~(A*( (ST%*I%/6000)*SP-TN*SP)/(VT-TN*SP)+B)
4090 CEXP2=DS (1%) -DS(SP%( 2))





4150 IF P(3)=0 THEN ENDPROC 
4160 FOR I%=SP%(3) TO EP%(3)
4170 F0=10~(A*( (ST%* 1%/6000) *SP-TN*SP)/(VT-TN*SP) +B)
4180 CEXP3=DS(I%)-DS(SP%(3) )





4240 IF P( 4 ) =0 THEN ENDPROC 








4330 IF P(5)=0 THEN ENDPROC 











4450 PRINT”DO YOU WANT TO PRINT YOUR DATA ON PAPER? (Y/N?)"
4460 *FX15,1
4470 IF GET=89 THEN PR%=1 ELSE PR%=0 
4480 CLS






4550 PRINT"PEAK RETN.TIME (min) AUC"
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4 5 6 0  P R I N T " - - -
4 5 7 0  P R I N T  
4 5 8 0  @ % = & 2 0 4 0 8
4 5 9 0 P R I N T "  1 •f ;D T * P H % ( 1 ) / 1 0 0 0 , F I  1
4 6 0 0 I F  P ( 2 ) = 0 THEN- 4 6 8 0
4 6 1 0 P R I N T "  2 *1 ; D T * P H % ( 2 ) / 1 0 0 0 , F 1 2
4 6 2 0 I F  P ( 3 ) = 0 T H E N 4 6 8 0
4 6 3 0 P R I N T "  3 ft ; D T * P H % ( 3 ) / 1 0 0 0 , F I  3
4 6 4 0 I F  P ( 4 ) = 0 T H E N 4 6 8 0
4 6 5 0 P R I N T "  4 ; D T * P H % ( 4 ) / 1 0 0 0 ,F 1 4
4 6 6 0 I F  P ( 5 ) = 0 T H E N 4 6 8 0
4 6 7 0 P R I N T "  5 ; D T 3t'PH%( 5 ) / 1 0 0 0 , F I  5
4 6 8 0 P R I N T
4 6 9 0 P R I N T
4 7 0 0 P R I N T
4 7 1 0 @ % = & 1 0 5 0 7
4720 PRINT"PEAK NUH.AVE.MW WT.AVE.MW Mw/Mn"
4730 PRINT"------------------------------------ "
4740 PRINT
4750 PRINT" 1 ";F11/F31,F21/F11,(F21*F31/(Fll~2))
4760 IF P(2)=0 THEN 4840
4770 PRINT" 2 ";F12/F32,F22/F12,(F22*F32/(F12~2))
4780 IF P(3)=0 THEN 4840
4790 PRINT" 3 ";F13/F33,F23/F13,(F23*F33/(F13~2))
4800 IF P(4)=0 THEN 4840
4810 PRINT" 4 ";F14/F34,F24/F14,(F24*F34/(F14~2))
4820 IF P(5)=0 THEN 4840




4870 PRINT"PRESS SPACE BAR TO CONTINUE"
4880 *FX15,1 
4890 L=GET








4980 PRINT"BASELINE OF WHOLE CHROMATOGRAM"
4990 PRINT"A/S-INC.PEAK START Z/X-DEC.PEAK START"
5000 PRINT"J/K-INC.PEAK END N/M-DEC.PEAK END"
5010 PRINT"SPACE - NO FURTHER CHANGE"
5020 *FX15,1 
5030 PROCKEY3(6)




5080 FOR C%=1 TO 6
5090 PRINT"MARK PEAK CUT ";STR$C%
5100 PRINT"A/S- INC. TIME Z/X- DEC. TIME"









5190 IF C%=6 THEN 5240
5200 PRINT"DO YOL: WANT TO MAKE A ";cut$(C%+l);M CUT? (Y/N?)”
5210 *FX15,1
5220 IF GET$="N” THEN P(C%+1)=0 







5300 IF INKEY(-99)=-l THEN F%=1
5310 IF INKEY(-66)=-l THEN F&=2
5320 IF INKEY(-98)=-l THEN F%=3
5330 IF INKEY'( -82) =-1 THEN F%=4
5340 IF INKEY(-67)=-l THEN F%=5
5350 IF F%=0 THEN ENDPROC
5360 PROCX(CUT%(N%) + 100,(DS(CUT%(N%) )*MULTF)+100)
5370 IF F%=2 THEN CUT%(N%)=CUT%(N%)+1
5380 IF F%=3 THEN CUTX(N%)=CUT%(N%)-1
5390 IF F*=4 THEN CUT%(N%)=CUT%(N%)+10
5400 IF F%=5 THEN CUT%(N%)=CUT*(N%)-10
5410 PROCX(CUTX(N%)+100,(DS(CUT%(N%) )*MULTF)+100)
5420 PRINT"MARK PEAK CUT ";STR$C%
5430 PRINT”A/S- INC. TIME Z/X- DEC. TIME"
5440 PRINT"SPACE - NO FURTHER CHANGE"
















5600 FOR I%=SPX(6) TO EPX(6)










5700 FOR IX=SP%(6) TO CIT%(1)
5710 IF PRCESS=3 THEN 5730 ELSE 5720
5720 F0=10~(A*( (ST%*I%/6000)*SP-TN*SP)/(VT-TN*SP)+B>
5730 CEXP2=DS(I%)-DS(SP%(6))
5740 CEXP2=CEXP2-(((DS( EP%( 6) )-DS( SPX( 6)))/(EPX( 6)-SP%( 6)) )*( I%-SP%( 6) )) 
5750 F12=F12+CEXP2




5800 IF P(2)=0 THEN 5810 ELSE 5920 
5810 FOR I%=(CUT%(1)+1) TO EP%(6)
5820 IF PRCESS=3 THEN 5840 ELSE 5830
5830 F0=10 * (A* ( (ST%*I%/6000} *SP-TN*SP) / (VT-TN*SP) +B)
5840 CEXP7=DS(1%)-DS(SP%(6))
5850 CEXP7=CEXP7-( ((DS( EP%( 6 )) -DS ( SP%( 6)) )/(EPX(6)-SP%(6) ) )*(I%-SP%(6) ) ) 
5860 F17=F17+CEXP7




5910 IF P( 2 )=0 THEN ENDPROC 
5920 FOR I%=(CUT%( 1 ) + l) TO CUT%( 2)
5930 IF PRCESS=3 THEN 5950 ELSE 5940
5940 F0=10*(A*( (ST%*I%/6000)*SP-TN*SP)/(VT-TN*SP) +B)
5950 CEXP3=DS( I%)-DS( SP%( 6) )
5960 CEXP3=CEXP3-( ( (DS(EP%(6) )-DS(SP%(6) ))/( EP%( 6)-SP%( 6) ) )*( I%-SP%(6) )) 
5970 F13=F13K:EXP3




6020 IF P( 3)=0 THEN 6030 ELSE 6140 
6030 FOR I%=(CUT%(2) + 1) TO EP%(6)
6040 IF PRCESS=3 THEN 6060 EIjSE 6050
6050 F0= 10* (A* ((ST%*I%/6000} *SP-TN*SP) / (VT-TN ; SP) +B)
6060 CEXP8=DS(1%)-DS(SP%(6))
6070 CEXP8=CEXP8-(((DS(EP%(6))-DS(SP%(6)))/(EP%(6)-SP%(6))) * ( I%-SP%(6)J) 
6080 F18=F18+CEXP8




6130 IF P(3)=0 THEN ENDPROC 
6140 FOR I%=(CUT%( 2) + l) TO CUT%(3)
6150 IF PRCESS=3 THEN 6170 ELSE 6160
6160 F0=10*(A* ((ST%*I%/6000)*SP-TN*SP)/(VT-TN*SP)+B)
6170 CEXP4=DS(1%)-DS(SP%(6 ) )
6180 CEXP4=CEXP4-( ( (DS(EP%(6) )-DS(SP%(6) ))/(EP%( 6 )-SP%( 6)) ) * ( I%-SP%( 6) )) 
6190 F14=F14+CEXP4




6240 IF P(4)=0 THEN 6250 ELSE 6360 
6250 FOR I%=(CUT%(3)+1) TO EP%(6)
6260 IF PRCESS=3 THEN 6280 ELSE 6270
6270 F0=10~(A*( (ST%*I%/6000)*SP-TN*SP)/(VT-TN*SP)+B)
6280 CEXP9=DS(1%)-DS(SP%(6))
6290 CEXP9-CEXP9-( ( (DS( EP%( 6) }-DS( SPX( 6)) )/(EP%( 6 )-SP%(6)) )*( I%-SP%( 6 »))
6300 F19=F19+CEXP9




6350 IF P(4)=0 THEN ENDPROC 
6360 FOR I%=(CUTX(3) + 1) TO CUT%(4)
6370 IF PRCESS=3 THEN 6390 ELSE 6380
6380 F0= 10~ (A*((ST%*I%/6000) *SP-TN*SP) /(VT-TN*SP) +B)
6390 CEXP5=DS(1%)-DS(SP%(6))
6400 CEXP5=CEXP5-< ((DS(EP%(6) )-DS(SP%(6) ) )/(EP%(6)-SP%(6)) )*(I%-SP%(6)))
6410 F15=F15+CEXP5




6460 IF P(5)=0 THEN 6470 ELSE 6580 
6470 FOR I%=(CUTX(4)+1) TO EP%(6)
6480 IF PRC ESS=3 THEN 6500 ELSE 6490
6490 F0=10~(A*( (ST%*I%/6000)*SP-TN*SP)/(VT-TN*SP) +B)
6500 CEXP10=DS(I%)-DS(SP%( 6))
6510 CEXP10=CEXP10-( ( (DS(EP%(6) )-DS(SP%(6)) )/(EP%(6)-SP%(6>) )*( I%-SPX(6)))
6520 fiio=f h o -h:expio




6570 IF P(5)=0 THEN ENDPROC 
6580 FOR I%=(CUT%(4)+1) TO CUTX(5)
6590 IF PRCESS=3 THEN 6610 ELSE 6600
6600 F0=10~(A*((ST%*I%/6000)*SP-TN*SP)/(VT-TN*SP)+B)
6610 CEXP6=DS(I%)-DS(SP%(6))
6620 CEXP6=CEXP6-(((DS(EPX(6) )-DS(SP%(6) ))/( EP%( 6)-SP%(6) ) )*( I%-SP%(6)))
6630 F16-F16+CEXPS




6680 FOR I%=(CUT%(5)+l) TO EP%(6)
6690 IF PRCESS=3 THEN 6710 ELSE 6700
6700 F0=10"(A*( (ST%*IX/6000)*SP-TN*SP)/(VT-TO*SP) +B)
6710 CEXP11=DS(I%)-DS(SP%( 6))
6720 CEXP1 l=CEXPll-( ((DS(EP%(6) )-DS(SP%(6)) )/(EP%(6)-SP%(6)) )*( I%-SP%(6)))
6730 Fill=F111+CEXP11




6780 IF P(6)=0 THEN ENDPROC 
6790 FOR I%=(CUTX(5)+1) TO CLT%(6)
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6890 FOR I%=(CUTX(6)+1) TO EPX(6)
6900 IF PRCESS=3 THEN 6920 ELSE 6910




6950 IF PRCESS=3 THEN 6980 ELSE 6960
6960 F213=F213+CEXP13*F0
6970 F313=F313+CEXP13/FO





7030 PRINT"DO YOU WANT TO PRINT YOUR DATA? (Y/N?)M 
7040 *FX15,1
7050 IF GET=89 THEN PR%=1 ELSE PR%=0 
7060 CLS














7210 IF PC 
7220PRINT"
7230 IF PC 
7240PRINT"
7250 IF PC 
7260PRINT"















:0 THEN 7300 ELSE 7320
4 ";F19,;" ";F19*100/F11
=0 THEN- 7430
4 ** ;F15,;" ";F15*100/F11





7370 IF P(6)=0 THEN 7380 ELSE 7400
7380PRINT" 6 ";F111,;"
7390 IF P(6)=0 THEN 7430
7400 PRINT" 6 ";F112,;'
7410PRINT" 7 ";F113,;"











W T .A V E .M W Mw/Mn"
7 500PRINT" 1
7510 IF P(2)=0 THEN 7520
7520PRINT" 2
7530 IF P(2)=0 THEN 7720
7540PRINT" 2
7550 IF P(3)=0 THEN 7560
7560PRINT" 3
7570 IF P(3)=0 THEN 7720
7580PRINT" 3
7590 IF P(4)=0 THEN 7600
7600PRINT" 4
7610 IF P(4)=0 THEN 7720
7620PRINT" 4
7630 IF P(5)=0 THEN 7640
7640PRINT" 5
7650 IF P(5)=0 THEN 7720
7660PRINT" 5
7670 IF P(6)=0 THEN 7680
7680PRINT" 6
7690 IF P(6)=0 THEN 7720
7700PRINT" 6
FI2/F32,F22/F12,(F22*F32/(F12~2))
E L S E  7540
F17/F37,F27/F17,(F27*F37/(F17~2))
F13/F33,F23/F13,(F23*F33/(F13~2))
E L S E  7580
F18/F38,F28/F18,(F28*F38/(F18~2))
F14/F34,F24/F14,(F24*F34/(F14 ~2))
E L S E  7620
F19/F39,F29/F19,(F29*F39/(F19"2))
FI 5/F35,F25/F15,(F25*F35/(F15~2))
E L S E  7660
F110/F310.F210/F110,(F210*F310/(F110~2))
F16/F36.F26/F16, (F26=»'F36/(F16"2))







7750 PRINT"PRESS SPACE EAR TO CONTINUE" 
7760 *FX15,1 
7770 L=GET
7780 IF L=20 THEN 4910
7790 ENDPROC
7800:
APPENDIX A8: TABLES OF EXPERIMENTAL DATA
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Table A8.2.1:
The effect of reaction time on the MCR
of MTX-HSA conjugates (ambient temperature, PBS, pH 7.45) 










The effect of reaction time on the MCR 
of MTX-HSA conjugates (25°C, PBS, pH 7.35) 












The effect of the molar ratio of MTX on the MCR 
of MTX-HSA conjugates (25°C, PBS, pH 7.35)
















The effect of the molar ratio of ECDI on the MCR 
of MTX-HSA conjugates (25°C, PBS, pH 7.35)






1:58.3:21.6 2.90 (±0.08) [2]
1:58.3:43.2 5.08 (±0.03) [3]
1:58.3:86.5 8.62 (±0.14) [2]
1:58.3:173.0 13.59 (±0.07) [2]
Table A8.2.5:
The effect of increasing the molar ratio of MTX and ECDI 
(1:1.5) relative to HSA on the MCR of MTX-HSA conjugates 
(25°C, PBS pH 7.35)





1:29.2:43.2 2.88 (±0.29) [6]
1:58.3:86.5 8.62 (±0.14) [2]
1:87.5:129.7 14.39 (±0.21) [2]
1:116.5:173.0 19.43 (±0.44) [4]
1:145.8:216.2 23.55 (±0.44) [2]
Table A8.2.6:
The effect of pH on the MCR of MTX-HSA conjugates 
(HSA:MTX:ECDI - 1:58.3:86.4, 25°C)
HSA Concentration - 10 mg/ml











Conjugation of MTX to HSA via the active ester of MTX 
(DMF/PBS pH 7.4)















0.01 0.6 0.69 0.83
0.04 2.3 1.86 2.01
0.08 4.6 4.03 3.81
0.16 9.2 8.12 7.33
0.32 18.4 13.44 13.55




Release of free MTX from MTX-HSA conjugates of different MCR 
(37°C, PBS, pH 7.4)
HSA Concentration - 7.7 x 10'^M
Mean MCR - 4.7 (±0.9) Mean MCR - 19.5 (±0.8)
Time Mean % Time Mean %
Hours free MTX Hours free MTX
(± sd) (± sd)
0.3 0.13 (±0.13) 0.3 0.05
1.6 0.42 (±0.01) 1.3 0.33 (±0.04)
2.6 0.83 (±0.10) 2.4 0.67
- - 3.4 0.98 (±0.04)
4.1 1.12 (±0.18) 4.5 1.26 (±0.09)
5.4 1.39 (±0.09) 5.6 1.56 (±0.13)
6.6 1.64 (±0.07) 6.7 1.78 (±0.13)
7.9 1.89 (±0.05) 7.7 1.87 (±0.15)
9.1 2.12 (±0.07) 8.8 2.12 (±0.06)
10.3 2.30 (±0.09) 9.9 2.27
11.6 2.50 (±0.06) 10.9 2.40
12.9 2.69 (±0.09) 11.9 2.49 (±0.02)
14.1 2.88 (±0.11) - -
15.3 3.06 (±0.13) - -
16.7 3.24 18.1 3.09 (±0.10)
20.4 3.41 19.4 3.18 (±0.07)
25.1 3.85 (±0.39) 24.0 3.63 (±0.13)
Table A8.2.9:

























Time Mean % Time Mean % Time Mean %
Hours free MTX Hours free MTX Hours free MTX
(±sd) (±sd)
0.3 0.13 (±0.13) 0.2 0.27 (±0.07) 0.2 0.03
1.6 0.42 (±0.01) 1.3 1.63 (±0.13) 1.3 0.42
2.6 0.83 (±0.10) 2.3 2.59 (±0.10) 2.3 0.66
4.1 1.12 (±0.18) 4.3 3.84 (±0.19) 4.4 1.27
6.6 1.64 (±0.07) 6.3 4.70 (±0.25) 6.5 1.72
7.9 1.89 (±0.05) 8.4 5.33 (±0.23) 7.6 1.93
10.3 2.30 (±0.09) 10.5 5.74 (±0.15) 10.6 2.45
12.9 2.69 (±0.09) 12.6 6.15 (±0.40) 12.7 2.78
15.3 3.06 (±0.13) 16.0 6.53 (±0.30) 18.0 3.20
25.1 3.85 (±0.39) 25.1 7.18 (±0.16) 25.0 3.94
Table A8.2.10:












3.96 x 10-?M 









1.98 x 10-6M 
3.74 x 10-5m 
18.89
Time % free Time % free MTX Time % free Time % free MTX
Hours MTX Hours Hours MTX Hours
0.3 0.05 0.3 0.00 0.3 0.05 0.3 0.06
1.3 0.30 1.3 0.11 1.3 0.35 1.3 0.12
2.4 0.67 2.3 0.19 2.4 0.67 2.5 0.21
4.5 1.20 - - 4.8 1.32 4.6 0.28
7.7 1.88 8.2 0.37 8.2 2.05 - -
11.9 2.50 11.8 0.48 11.7 2.47 12.2 0.51
18.1 3.16 17.5 0.66 18.3 3.02 - -
24.0 3.72 24.6 0.84 23.2 3.45 - -
- - - - 35.9 4.47 - -
- - - - 47.6 4.91 - -
65.0 5.00 66.0 1.71 64.8 5.10 - -
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Table A8.2.11:
Effect of pH on the release of free MTX (%) from MTX-HSA conjugates 

















Buffer Type ---Citric Acid/phosphate--- ---Boric Acid/NaOH---
Time (Hours) 
Initial 0.66 0.49 0.41 0.37 0.33 4.09 8.27
2 0.74 0.66 0.74 1.23 1.72 4.59 8.19
4 1.15 1.10 1.43 1.72 2.46 5.32 7.94
8 1.47 1.97 1.88 2.54 3.44 6.55 8.19
24 2.54 3.11 3.93 4.34 5.32 7.61 8.19
Table A8.2.12:
Release of free MTX from MTX-HSA (ester conjugated)
(37°C, PBS, pH 7.4)
Sample No 1 2
Reaction Time 5.5 hours 5.5 hours










Initial - Initial 0.03
1.1 0.19 1.2 0.10
2.3 0.30 2.4 0.34
3.5 0.41 3.6 0.46
4.7 0.50 4.8 0.57
5.9 0.59 6.0 0.65
7.1 0.67 7.2 0.73
8.3 0.74 8.4 0.83
9.5 0.78 9.6 0.89
10.7 0.84 10.8 0.99
11.9 0.90 44.6 1.87
- - 60.5 2.10
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Table A8 .3.1:
The effect of trypsin on the release of free MTX from 














7.74 (±0.01) x 10-6M 
20.5 (±1.3)
Time % free MTX Time % free MTX
(Hours) (±sd) (Hours) (±sd)
0.5 0.07 (±0.01) 0.3 0.06 (±0.03)
1.8 0.66 (±0.18) 1.4 0.42 (±0.15)
4.3 1.53 (±0.12) 4.2 1.29 (±0.16)
8.1 2.35 (±0.16) 7.7 2.17 (±0.33)
11.9 3.02 11.9 2.76 (±0.38)
17.6 3.74 18.1 3.13 (±0.17)
24.0 3.87 (±0.28) 24.0 3.64 (±0.09)
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Table A8.3.2 :
The effect of different levels of trypsin on the release of free MTX 
from MTX-HSA conjugates (37°C, PBS, pH 7.4)
Sample A Sample B Sample C NT

















- - - - - - 0.2 0.01
1.6 - 2.7 0.62 4.0 1.12 5.2 0.89
7.4 1.79 - - - - - -
- - 21.0 2.84 22.3 2.94 23.5 3.04
- - 30.1 3.62 31.2 3.37 32.3 3.62
42.0 4.29 43.1 4.09 44.2 3.94 45.2 4.34
51.9 4.71 53.1 4.96 54.3 4.91 - -
* = molar ration of trypsin to HSA
NT = no trypsin
HSA Concentration Sample A = 7.75 x 10"°M
Sample B = 7.45 x 10“°M
Sample C = 7.72 x 10*°M
NT - 7.75 x 10‘6M
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Table A8.3.3:
The effect of trypsin on the molecular weight distribution of human 
serum albumin (37°C, PBS, pH 7.4)









40 31-27 21-15 12-9 <1.5
A-OH (S) 4.1 75.6 - 13.2 - - -
A-20H (S) 2.1 23.3 3.3 17.8 16.1 13.5 5.4
B-OH (S) 5.7 82.9 - 6.2 - - -
B-20H (S) 1.9 43.9 3.5 13.0 9.4 6.7 3.9
C-OH 10.2 85.0 - - - - -
C-20H 8.6 86.3 - 3.6 - - -
Results are expressed as % total area
A = Trypsin:HSA molar ratio - 2.82:1 
B = Trypsin:HSA molar ratio - 0.29:1 
C = HSA
OH = initial
20H - 20 hours at 37°C (S) - subtracted chromatogram
Table A8.3.4:
The molecular weight distribution of MTX-HSA conjugates in the presence and absence of trypsin in buffer 
















- - - - 1.0
(±0.2)

































Results expressed as % of total area
1 - MW - molecular weight
2 - expressed as % of total calculated from standard peak height 
HSA Concentration - 4.2 x 10"%
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Table A8.4.1:The molecular weight distribution of a MTX-L-copolymer 
conjugate incubated with trypsin in buffer (PBS, pH 7.4) at 37°C
Trypsin:copolymer molar ratio =1:10 
Coploymer Concentration = 4.7 x 10'°M
Molecular weight >i 103
Time at 
37°C/hours
>60 46 30 15 8 4 1.8 <1.5
0 17.7 33.4 - 28.6 - 7.3 3.7 9.4
2 - - 22.0 8.6 13.9 17.9 6.4 31.1
6 - - 13.5 12.6 13.9 19.7 5.9 34.6
16 - - 11.2 11.0 14.5 20.3 5.3 37.8
24 - - 10.6 11.4 13.8 20.8 5.4 38.1
results expressed as % of total area
